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1 ZUSAMMENFASSUNG 
Das zelluläre Genom ist fortwährend durch genotoxische Einflüsse und ebenso durch die 
DNA Duplikation in jedem Zellzyklus gefährdet. Folglich haben sich Signalwege entwickelt, 
die Schäden in der DNA erkennen und reparieren. Im Zentrum der DNA Schadensantwort 
stehen die Kinasen ATR und ATM, die Signale an Checkpoint-Kinasen und andere Ziel-
proteine weiterleiten. Antimetabolite wie Hydroxyurea werden häufig in der Krebstherapie 
eingesetzt und blockieren gezielt die DNA Replikation, um Krebszellen abzutöten. Obwohl 
bekannt ist, dass die Kombination mit Histondeacetylase (HDAC)-Inhibitoren das Ergebnis 
solcher Behandlungen verbessert, waren die molekularen Mechanismen dazu unklar. 
In der vorliegenden Arbeit wird zum ersten Mal gezeigt, dass die Aktivität von Klasse I HDACs 
notwendig für eine anhaltende DNA Schadensantwort nach Hydroxyurea- und 5-Fluorouracil 
induziertem Replikationsstress ist. Diese Beobachtungen wurden mit dem Klasse I HDAC-
Inhibitor (HDACi) MS-275 erzielt. Genauer führte der zeitgleiche Verlust von HDAC1 und 
HDAC2 Aktivität zu einer verringerten Phosphorylierung der Kinasen ATR/ATM und 
CHK1/CHK2. Dies ging mit einer schwächeren Aktivierung und Zielgenexpression von p53 
einher. Trotz einer verstärkten DNA-Schädigung konnten Zellen unter dem Einfluss des 
HDACi keinen stabilen Zellzyklusarrest in der S Phase ausbilden, was letztlich zu einer 
erhöhten Apoptoserate führte. Bei Experimenten mit selektiven Kinaseinhibitoren zeigte 
sich, dass die verringerte Aktivität nur einer Kinase nicht ausreichte, um die für MS-275 
beschriebenen Effekte zu imitieren. Die Ergebnisse legen nahe, dass der HDACi die Aktivität 
von sowohl ATR als auch ATM negativ reguliert.  
Diese Arbeit schlägt die unterdrückte Expression der PP2A B‘‘ regulatorischen Untereinheit 
PR130 als zugrunde liegenden Mechanismus vor, die durch HDAC1 und HDAC2 geregelt wird. 
MS-275 induzierte einen verzögerten Anstieg an PR130 auf transkriptioneller wie auch auf 
Proteinebene. Es wurde zudem gezeigt, dass PR130 mit phosphoryliertem ATM interagiert. 
Dies markiert die Kinase für die PP2A-vermittelte Dephosphorylierung, da ein  Knockdown 
von PR130 die ATM Phosphorylierung wiederherstellte.  
Die Studie beschreibt damit eine neue molekulare Verknüpfung zwischen den 
epigenetischen Regulatoren HDAC1/2 und einer Phosphatase-abhängigen Modulation der 
DNA Schadensantwort in Zellen unter Replikationsstress. Dabei wurde PR130 als potenzieller 
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Regler der DDR identifiziert, welcher der Kinaseaktivität entgegenwirkt und somit die 
normale zelluläre Physiologie wiederherstellen kann. 
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2 SUMMARY 
The integrity of the genome is constantly challenged by genotoxic factors and also DNA 
duplication during every cell cycle. Hence, signaling pathways have evolved to sense and 
repair sites of damage. At the center of the DNA damage response (DDR) are the apical 
kinases ATR and ATM, which delegate signaling to checkpoint kinases and various other 
downstream targets. Anti-metabolites like hydroxyurea are commonly used in cancer 
therapy and intentionally block replication to eliminate cancer cells. Although it was found 
that HDAC inhibitors favorably combine with these treatments, the molecular mechanisms 
were unknown.  
The present study shows for the first time that class I HDAC activity is necessary to keep up a 
sustained DDR after replication stress induced by hydroxyurea and 5-fluorouracil. These 
observations were made with the class I HDAC inhibitor (HDACi) MS-275. Specifically, 
simultaneous loss of HDAC1 and HDAC2 activity was required to diminish phosphorylation of 
the kinases ATR/ATM and CHK1/CHK2. This was accompanied by reduced p53 activation and 
target gene expression. Despite the higher incidence of DNA damage, cells were unable to 
establish a stable cell cycle arrest in S phase in the presence of the HDACi, which ultimately 
resulted in elevated rates of apoptosis. Experiments with selective kinase inhibitors revealed 
that the attenuated activity of only one apical or checkpoint kinase was insufficient to 
imitate all signaling and cellular effects of MS-275. They rather demonstrated that the HDACi 
negatively regulates both, ATR and ATM activity. 
This work proposes the suppressed expression of the PP2A B’’ regulatory subunit PR130 as 
the underlying molecular mechanism governed by HDAC1 and HDAC2. MS-275 induced a 
delayed increase in PR130 at the transcriptional and protein level. Furthermore, PR130 
protein was shown to physically associate with phosphorylated ATM. This targets the kinase 
for PP2A-mediated dephosphorylation, since PR130 knockdown restored ATM 
phosphorylation.  
Taken together, this study describes a novel molecular link between the epigenetic 
regulators HDAC1/2 and a phosphatase-dependent modulation of DDR signaling intensity in 
cells suffering from replication stress. PR130 was identified as a potential modulator of the 
DDR to terminate kinase activity and restore normal cellular physiology. 
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3 INTRODUCTION   
Genetic information needs to be preserved from one cell generation to the next and 
genomic stability is a prerequisite for the survival of proliferating cells, while genomic 
instability promotes and is a common feature of cancer 1. However, cells are constantly 
exposed to genotoxic stress originating from environmental sources as well as from within. 
Merely duplication of the DNA repeatedly generates unstable replication forks that are 
prone to breakage. Thus, a sophisticated and highly conserved network has evolved in 
eukaryotes to detect alterations in the DNA and ultimately coordinate their repair. It 
engages several signaling cascades, which are largely regulated by posttranslational 
modifications (PTMs), the most common of which is phosphorylation. These mechanisms are 
also known as the ‘safeguards of genome integrity’ 2. 
3.1 Genomic lesions induce DNA damage response signaling 
The term ‘DNA damage response’ (DDR) describes a network of numerous signaling 
pathways that is initiated in a cell after alterations of the genome and which regulates cell 
cycle transition, DNA replication, DNA repair, and apoptosis 3-6. These signaling cascades are 
specifically regulated by PTMs. They enable cells to cope with endogenous challenges like 
reactive oxygen species (ROS) or stalled replication forks, as well as with environmental 
threats like ionizing and ultraviolet radiation (IR and UV, respectively). DNA damage 
response signaling is organized in successive stages during which the signal is amplified: the 
damage is recognized by sensor proteins that transmit the message to transducers, which in 
turn activate effector proteins. The first line of transducer molecules belongs to the family of 
phosphatidylinositol 3-kinase (PI3K)-like kinases (PIKKs). In mammals, the family consists of 
six members who possess serine/threonine protein kinase activity except one. They include 
ATM (Ataxia telangiectasia mutated), ATR (ATM and Rad3-related), DNA-PKc (DNA-
dependent protein kinase catalytic subunit), mTOR (mammalian target of rapamycin), and 
SMG1 (suppressor of mutagenesis in genitalia 1). The last member is TRRAP 
(transformation/transcription associated protein) that lacks kinase activity. All of them share 
a PI3K-like, a FAT (FRAP-ATM-TRRAP), and a FATC (FAT C-terminal) domain but only three 
PIKKs play major roles in DDR signaling 7. 
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 Figure 3.1:  Induction of the DNA damage response – a simple overview.  
UV-induced DNA lesions, replication stress (e.g. by depletion of deoxyribonucleotides), or end resection of DNA 
DSBs lead to the exposure of single-stranded DNA stretches, which in turn induce ATR signaling with 
subsequent phosphorylation of CHK1 and p53. Double-strand breaks (DSB) of the DNA induced by ionizing 
radiation or chemotherapeutic substances stimulate ATM activation. Cross-activation of ATM by ATR is 
indicated with a black dashed arrow. ATM signaling activates CHK2 and p53. To a lesser extent, also CHK1 might 
be phosphorylated by ATM (grey dotted arrow). After 
8-11
. 
DNA-PK’s catalytic subunit forms an active heterotrimer with KU70-KU80 in response to DNA 
double-strand breaks (DSB) and is critically involved in coordinating DNA repair by non-
homologous end-joining (NHEJ) 12. The apical kinases ATM and ATR are at the center of the 
DNA damage response and initiate comprehensive phospho-protein cascades following their 
catalytic activation. They are both important for the maintenance of genomic stability. In 
humans, mutation of the ATM gene causes the disease ‘Ataxia telangiectasia’ associated 
with severe genomic instability 13. Mutations of ATR result in a rare and serious 
developmental disorder called ‘Seckel syndrome’ 14. However, ATR is essential for the 
sustained survival of replicating cells and a complete loss of ATR activity is embryonically 
lethal 15,16. ATM and ATR not only show sequence similarity, but also have a common SQ/TQ 
(a serine or threonine residue followed by glutamine) phospho-site consensus motif. That 
explains the considerable redundancy among their hundreds of substrates 3. The key 
difference between both kinases is their response to different kinds of genotoxic stress 
(Figure 3.1). Rarely occurring DSBs initiate DDR signaling through ATM with subsequent 
phosphorylation of its downstream kinase checkpoint kinase 2 (CHK2) and of the tumor 
suppressor p53. ATR on the other hand is activated in every cell cycle during DNA replication 
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or after UV radiation and phosphorylates checkpoint kinase 1 (CHK1) and p53 17. Yet, both 
signaling pathways are not strictly separated since processing of DSB sites and replication 
fork collapse may trigger activation of the other kinase. A direct cross-activation of ATM by 
ATR was also reported 9,18. In each case, the locally acting apical kinases delegate stress 
signaling to diffusing downstream molecules and thereby pave the way to a global cellular 
response 10. 
3.1.1 Initiation of the DNA damage response – ATR and ATM  
Activation of ATR 
The kinase activity of ATR is stimulated in response to many genomic insults like replication 
stress, base adducts, cross-links, or DSBs. All these damages ultimately create stretches of 
single stranded DNA (ssDNA), which seem to be the key structure for ATR activation in most 
cases 11,19. For example, stalled replication forks directly generate ssDNA when polymerases 
are stopped due to depleted dNTP pools or lesions in the DNA while the leading helicase 
complex proceeds to unwind DNA 6,17. Also, nuclease activity may form ssDNA stretches 
during end resection of DSBs. In any case, replication protein A (RPA) rapidly coats exposed 
DNA single strands and creates a complex  further referred to as ssDNA-RPA 20 (Figure 3.2 A). 
ssDNA-RPA is crucial for the recruitment of ATR to sites of DNA damage 19. Nevertheless, 
ATR alone is unable to recognize RPA and depends on ATR interacting protein (ATRIP). ATRIP 
is not only important for ATR localization as it directly binds RPA 21, but also for ATR 
stability 16. It has been shown that the assembly of ATRIP-ATR complexes on ssDNA-RPA 
alone already promotes ATR phosphorylation in trans at threonine 1989 (Thr1989) 22,23. This 
phosphorylation event is indispensable yet insufficient to activate ATR kinase function 
(Figure 3.2 B). In an independent cascade, the heterotrimer RAD9-RAD1-HUS1 (9-1-1) is 
brought to the site of DNA damage. The clamp loader RAD17-replication factor C (RAD17-
RFC) first recognizes a 5´-junction of dsDNA, which is adjacent to ssDNA-RPA 24. In a second 
step, it loads the ring shaped 9-1-1 onto the junction, which resembles a PCNA (proliferating 
cell nuclear antigen)-like sliding clamp 25. Importantly, the 9-1-1 element RAD9 is 
constitutively phosphorylated in its C-terminal tail at serine 397 (Ser397) 26. This creates a 
binding site for topoisomerase 2-binding protein 1 (TOPBP1), which recognizes the 
phosphorylation with its BRCT domains 27,28 (Figure 3.2 C). TOPBP1 additionally contains an 
ATR activation domain and binds to the phosphorylated Thr1989 residue of ATR via other 
BRCT domains. The close proximity of TOPBP1 to ATRIP-ATR is crucial to trigger full 
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activation of ATR, although the detailed mechanisms are poorly understood and remain to 
be defined 29,30. Prior to activation of downstream signaling, ATR phosphorylates a number 
of mediator molecules including RAD17 and Claspin 31. The mediator Claspin associates with 
RAD17 and serves as a platform for the recruitment and ATR-dependent phosphorylation of 
CHK1 32. Downstream activation of CHK1 is currently the best readout of ATR activity except 
for Thr1989 ATR auto-phosphorylation. Once phosphorylated, CHK1 is released from 
chromatin and targets its soluble substrates 33 (Figure 3.2 D). Moreover, ATR phosphorylates 
the histone variant H2A.X at Ser139 (H2A.X) in the chromatin flanking the damage site 34. 
H2A.X foci formation facilitates the recruitment of repair proteins or other DNA damage 
mediators and thereby participates in the orchestration of the DNA damage response 2.   
 
 
Figure 3.2:  Activation of ATR by DNA damage. 
(A) ATR is recruited to Replication protein A (RPA)-coated ssDNA through its interaction partner ATRIP. RPA also 
independently recruits the clamp loader complex RAD17-Replication factor C (RFC) to the ssDNA junction, 
where RAD17-RFC loads the RAD9-RAD1-HUS1 (9-1-1) clamp onto the DNA. (B) Congregation of ATRIP-ATR 
complexes on ssDNA-RPA enables trans-phosphorylation of ATR molecules. The independent loading of 9-1-1 
facilitates recruitment of the Topoisomerase-binding protein 1 (TOPBP1). (C) Subsequent binding of TOPBP1 
activates ATR (red shadow) and thereby triggers phosphorylation of histone 2A.X (H2A.X) and (D) ATR 
downstream targets like CHK1. Red bullets indicate phosphorylation. After 
1,22,35
. 
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Activation of ATM 
In contrast to ATR, ATM is primarily activated in response to DSBs of the DNA 36. Undamaged 
cells contain homodimerized ATM to hold the kinase inactive. Rapidly after the occurrence 
of DSBs, the molecules auto-phosphorylate each other at Ser1981 within the FAT domain 
and are released as monomers 37. This first step of activation can be used as a marker of 
ATM activity since it is essential to develop complete catalytic activity of ATM in humans 38 
(Figure 3.3 A). At least four additional phosphorylation sites of ATM were identified since 
then. Three of the residues (Ser367, Ser189, Ser2996) are auto-phosphorylated by ATM 39,40. 
In parallel to phosphorylation, the histone acetyltransferase (HAT) TIP60 acetylates ATM in a 
DNA damage-dependent manner on a single site at Lys3016 and thereby contributes to ATM 
activation 41. 
What exactly triggers ATM auto-phosphorylation is still a matter of debate. In addition to a 
conformational change in chromatin structure after DSBs, direct interaction with free linear 
DNA at sites of damage or simple association with chromatin were suggested 37,42,43. 
However, the need of the MRE11-RAD50-NBS1 (MRN) complex for complete catalytic 
activation of ATM is beyond question. Initially, the MRN sensor complex directly recognizes 
and binds to the site of damage where it recruits ATM monomers to achieve complete 
activation of the kinase 44,45. One of the earliest phosphorylation targets of ATM is H2A.X. 
This creates H2A.X foci that can extend over mega-base pairs around the DSB and set on an 
enormous positive feedback loop for ATM signaling 2,46 (Figure 3.3 B). In the beginning, 
H2A.X molecules next to the DNA lesion serve as anchor points for mediator of DNA 
damage checkpoint 1 (MDC1) 47,48 (Figure 3.3 C). This mediator protein is phosphorylated by 
ATM itself 7,38. Phosphorylated MDC1 now generates a binding site for NBS1 of the MRN 
complex 49. ATM is then indirectly tethered to H2A.X by MRN, which stimulates its catalytic 
activity 50. Moreover, direct binding of ATM to MDC1 increases the retention of the kinase at 
DNA damage sites 50. This amplifies H2A.X phosphorylation and facilitates further 
accumulation of DNA damage mediators, transducers, and repair proteins 7,51. 
Any of the multiple ATM substrates in the signaling cascade spatially and timely fine-tunes 
the DNA damage response. For example, 53BP1 was found to directly interact with MRN and 
ATM. This association not only optimizes the ATM-dependent phosphorylation of NBS1. It 
also promotes 53BP1 phosphorylation that in turn serves as a mediator of the DDR positive 
feedback loop 45,52. Besides NBS1, also MRE11 and RAD50 of the MRN complex are targeted 
INTRODUCTION  HDACs regulate phosphatase activity  
page | 9 
  
by ATM 7,38. Phosphorylation of MRE11 and RAD50 was found to affect their role in 
regulating DNA repair 53,54. The functional consequences for phosphorylated NBS1 are better 
known. As mentioned above, it firstly assembles ATM at sites of damage. Furthermore, it is 
evident that phospho-NBS1 facilitates DDR downstream signaling by serving as an adapter 
for ATM substrates 55,56. One of the best documented targets of ATM is the cell cycle 
regulator CHK2 1 (Figure 3.3 D). Initial phosphorylation of CHK2 at Thr68 by ATM results in 
transient homodimerization of the checkpoint kinase, followed by auto-phosphorylation to 
gain complete catalytic activity 57-59. 
 
 
Figure 3.3:  Activation of ATM by DNA double-strand breaks. 
(A) Occurrence of DSBs causes auto-phosphorylation of inactive ATM dimers in trans and independently 
recruits the MRN complex to sites of damage. (B) TIP60 acetylates ATM and the MRE11-RAD50-NBS1 (MRN) 
complex fully activates ATM monomers (red shadow). Subsequently, ATM phosphorylates adjacent H2A.X 
molecules which in turn recruit the mediator of DNA damage checkpoint 1 (MDC1) to H2A.X.  (C) Binding of 
MRN complexes and ATM to MDC1 amplify the DNA damage signaling at damage foci. (D) The downstream 
kinase CHK2 is phosphorylated by ATM at Thr68, which triggers homodimerization and trans-phosphorylation 
of CHK2 molecules. Red bullets indicate phosphorylation. Yellow bullets indicate acetylation. After 
5,35,37
. 
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3.1.2 Checkpoint kinases and cell cycle control 
Downstream of the apical kinases ATM and ATR phylogenetically conserved signaling 
cascades are activated.  Two major players in this process are the serine/threonine kinases 
checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2). Despite being structurally 
unrelated and activated upon diverse stressors, they show overlapping functions 60. CHK2 is 
primarily activated by ATM in response to DSB. ATM phosphorylates CHK2 at Thr68, which 
promotes homodimerization and subsequent intramolecular trans-phosphorylation of the 
checkpoint kinase molecules at Thr383 and Thr387 57,61,62 (Figure 3.3 D). CHK1, on the other 
hand, is phosphorylated by ATR (and to a lesser extent maybe also by ATM) at Ser317 and 
Ser345 6,63,64. This phosphorylation event is dependent on Claspin (see section 3.1.1) and 
directly triggers catalytic activity of CHK1. There are currently two mutually non-exclusive 
models for CHK1 kinase activation. Firstly, phosphorylation by ATR would block an inhibiting 
intramolecular interaction of CHK1 whereby the kinase domain becomes exposed 65. In a 
second model, phosphorylation rapidly releases CHK1 from chromatin and thereby enables 
the kinase to phosphorylate its soluble substrates 33. Once activated, CHK1 and CHK2 
phosphorylate specific as well as overlapping effectors implicated in DNA damage-induced 
transcription, replication fork stabilization, DNA repair, or apoptosis signaling. Especially 
CHK1 appears as a key regulator in the initiation and surveillance of cell cycle checkpoints in 
response to DNA damage 11,66. 
Cell cycle progression is a tightly regulated process and proceeds in an ordered sequence of 
cell cycle phases. It is governed by cyclin-dependent kinases (CDKs), which require binding of 
cyclins for their temporal activation. On a second layer of control, specific phosphorylation 
events act as positive or negative regulators of CDK activity. In the end, CDK/cyclin 
complexes rule progression from one cell cycle stage to the next and are an important part 
of cell cycle checkpoints (Figure 3.4). Activation of these checkpoints in response to DNA 
damage is generally mediated by two mechanisms. The ATM/ATR-CHK1/CHK2-CDC25 
pathways mediate a fast arrest of the cell cycle. Induction of the p53-dependent pathway, 
on the other hand, is much slower, yet indispensable to keep up sustained checkpoint 
control (see section 3.1.3).  
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Figure 3.4:  Regulation of the cell cycle by CDK/cyclin complexes. 
Cell division is controlled by the regulated progression through sequential cell cycle stages (indicated by grey 
arrows). Specific CDK/cyclin complexes govern the passage through these phases and the transitions between 
them. Cell cycle checkpoints are indicated in red. After 
11,67-69
. 
Activated CHK1 indirectly interferes with the formation of CDK/cyclin complexes as it 
stabilizes inhibitory phosphorylations of CDKs. In an undisturbed cell cycle, these 
phosphorylations are removed by the family of CDC25 phosphatases. Upon DNA damage, 
CDC25 phosphatase activity is impeded by CHK1 (Figure 3.5). Phosphorylation of CDC25A by 
CHK1 tags the phosphatase for proteasomal degradation. This inhibits formation of 
CDK2/cyclin E and CDK2/cyclin A complexes and consequently results in arrest at the G1/S 
transition or in S phase. In contrast, phosphorylation of the CDC25C isoform creates a 
binding site for 14-3-3 proteins, which sequester the phosphatase in the cytoplasm. The 
resulting lack of active CDK1/cyclin B dimers halts the cell cycle at the transition from G2 
phase to mitosis 67,70. Of note, CHK2 was also reported as a possible kinase for CDC25 
phosphatases 60. The checkpoint kinase CHK1 further contributes to CDK inactivation by 
targeting WEE1. Upon phosphorylation, the kinase WEE1 becomes stabilized and catalyzes 
inhibiting phosphorylation of CDK1 and CDK2 which prevents their interaction with cyclins 71. 
CHK1 further supports the arrest of cells in S phase by directly targeting members of the 
DNA replication machinery. CHK1 inactivates the cyclin-like protein ASK (also called DBF4), 
which normally complexes with CDC7 kinase to initiate DNA replication. CDC7-dependent 
phosphorylation of the MCM helicase complex is essential for the recruitment of CDC45 to 
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sites of replication origin. A loss of CDC7/ASK activity therefore stops replication origin firing 
and blocks S phase progression 72,73.  
Moreover, transcription of cell cycle-regulating genes is repressed by DNA damage-induced 
CHK1. A slight basal kinase activity enables chromatin-bound CHK1 to phosphorylate Thr11 
on histone H3, which in turn correlates with the expression of e.g. CCNB1 (cyclin B1) and 
CDK1. The dissociation of activated CHK1 from chromatin reduces expression of these genes 
and contributes to cell cycle arrest 74. 
 
 
Figure 3.5:  CHK1 signaling mediates cell cycle arrest. 
Upon activation, CHK1 phosphorylates several downstream effectors involved in cell cycle checkpoint 
regulation and thereby mediates cell cycle arrest. Phosphorylation of CDC25 phosphatases results in their 
degradation (in case of CDC25A) or sequestration in the cytosol by binding of 14-3-3 (in case of CDC25C). 
Hence, cyclin-CDK complexes cannot be established and the cell cycle stops. Phosphorylated WEE1 contributes 
to CDK inhibition by direct negative phosphorylation of CDK proteins.  CHK1 further phosphorylates ASK, which 
is, in complex with CDC7, an important factor for DNA replication initiation during S phase. In addition, 
activated CHK1 dissociates from chromatin. The resulting lack of basal histone H3 phosphorylation stops 
transcription of cell cycle regulatory genes like CCNB1 (cyclin B1) or CDK1. Dark red bullets indicate activating 
phosphorylation. Light red bullets indicate inhibitory phosphorylation. After 
6,67,69,71,73,74
. 
3.1.3 P53 as a downstream effector of the DNA damage response 
The tumor suppressor p53 is strongly engaged in DDR signaling as a downstream effector, 
whose activity as specific transcription factor is triggered in response to a variety of stresses. 
Actually, p53 was the first identified substrate of ATM 75-77. In order to keep its actions under 
control, p53 is subject to a number of positive and negative regulators. The level of p53 
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protein in unperturbed cells is kept low mainly by interaction of the tumor suppressor with 
its E3 ubiquitin ligase mouse double minute 2 (MDM2, in humans also ‘HDM2’). This 
association mediates constant proteasomal degradation of p53 78,79. Upon DNA damage, the 
protein p53 is rapidly stabilized by many PTMs. Phosphorylation in the N-terminal 
transactivation domain at Ser15 and Ser20 by ATM/ATR and CHK1/CHK2, respectively, 
reduces the affinity of HDM2 for p53 75,80-82 (Figure 3.6). In turn, these phosphorylation sites 
convey increased acetylation of lysines in the C-terminal regulatory domain excluding HDM2 
ubiquitination at the same residues 83,84. Furthermore, HDM2 activity is also directly 
regulated by ATM/CHK1/CHK2-dependent inhibiting phosphorylation at Ser395 85,86.  
 
 
Figure 3.6:  The effector p53 participates in the cellular response to DNA damage. 
Activated DDR kinases ATM/ATR and CHK1/CHK2 phosphorylate p53 at the residues Ser15 and Ser20, 
respectively. Furthermore, ATM and CHK1/CHK2 inhibit the p53 negative regulator HDM2 via phosphorylation. 
Transcriptionally active p53 induces expression of its target genes, including those depicted. They are 
implicated in DNA repair and cell cycle checkpoint activation (e.g. the CDK inhibitor p21), but also convey 
induction of apoptosis if damage is too severe. In a disabling feedback loop, p53 expresses its negative 
regulators HDM2 and WIP1. Red bullets indicate phosphorylation. After 
87-89
. 
Transcriptional activity of p53 originates from homotetramerization and enables the 
expression of its various target genes.  Among those, the cyclin-dependent kinase inhibitor 1 
(CDKN1 or p21) is critical to keep up sustained cell cycle arrest in G1 after DNA damage 90. 
P21 is a negative regulator of CDK2 activity and prevents the transition of cells from G1 to S 
phase. The proteins 14-3-3 and growth arrest and DNA damage 45 A (GADD45A) contribute 
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to G2/M cell cycle arrest by inhibition of CDC25C 87 (see also Figure 3.4). This allows cells to 
eliminate damage and p53 in parallel supports repair of DNA through expression of DDB2 91. 
Simultaneous induction of the negative regulators HDM2 and wild-type p53-induced 
phosphatase 1 (WIP1) tends to (i) prevent escalating and potentially fatal performance of 
p53 and (ii) to reduce and finally turn off p53 activity if cells recover from stress 92. In 
severely damaged cells, p53 initiates the intrinsic pathway of apoptosis by expression of e.g. 
p53 upregulated modulator of apoptosis (PUMA) and BCL2-associated X protein (BAX). They 
induce permeabilization of the outer mitochondrial membrane by inhibition of anti-
apoptotic proteins like B-cell lymphoma 2 (BCL2) and formation of pore complexes, 
respectively 93,94. Also, cytosolic p53 takes action in this process as it can bind to and 
inactivate BCL2-like anti-apoptotic proteins at the mitochondrial membrane 95. Subsequent 
release of cytochrome c from mitochondria is the ultimate trigger of apoptotic cell death. 
For completion it should be noted that p53 also transactivates genes of extrinsic apoptosis 
factors (e.g. FAS) 87.  
 
3.2 Removing phosphorylation – the protein phosphatase 2A family 
Protein phosphorylation as posttranslational modification is a central regulator of cellular 
signaling. It occurs on about 30% of all proteins and regulates their stability, enzymatic 
activity, interaction with other proteins, or subcellular localization 96. In an enzymatic 
reaction catalyzed by kinases, a phosphate is mostly transferred to a hydroxyl group of the 
amino acid residues serine, threonine, or tyrosine (in order of frequency). The task of 
phosphatases is to hydrolytically remove phosphoryl groups in an opposing reaction, which 
makes phosphorylation a highly dynamic PTM. Based on their sequence, structure, and 
catalytic mechanism, phosphatases are classified into three families: protein 
serine/threonine phosphatases (PSP), protein tyrosine phosphatases (PTP), and aspartate-
based protein phosphatases. About 40 PSPs are encoded by the genome and they are 
further categorized in phospho-protein phosphatases (PPP) and metal-dependent 
phosphatases (PPM; including WIP1) 97. This rather small number of phosphatases faces a 
superiority of over 400 known Ser/Thr kinases 97. However, PSPs are not promiscuous in 
choosing their substrates, but convey target specificity via assembly of phosphatase 
subunits. The class of PP2A phosphatases from the PPP family is a good example of this 
mechanism 98,99.  
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PP2A accounts for the majority of dephosphorylation events at serine and threonine 
residues accomplished by soluble phosphatases 100. It regulates many biological processes 
like cell metabolism, G1/S transition, mitotic exit, DNA replication, transcription, translation, 
and predominantly displays pro-apoptotic function 101,102. Active forms of PP2A exist as 
trimeric complexes. The core enzyme is composed of a catalytic subunit C and a structural 
subunit A. They associate with a regulatory subunit B to build the functional holoenzyme 
(Figure 3.7). The structural and especially the catalytic subunits are very abundant and 
ubiquitously expressed. Together, all PP2A subunits account for up to 1% of cellular 
protein 100. Subunit A serves as a scaffolding base to bind the C-terminus of the catalytic and 
to facilitate the dynamic interaction with a regulatory subunit. Whilst subunit A and C have 
two conserved isoforms each, the structure of B subunits is far more diverse. Consequently, 
regulatory subunits were classified in four groups - B, B’, B’’, and B’’’. They are encoded by 
15 genes, which give rise to at least 20 B-type isoforms due to alternative splicing or 
translation 103. Combinatorial assembly of all isoforms yields at least 75 active variants of 
PP2A phosphatase 102. Among the three subunits, the regulatory B-type was described to act 
as a master regulator of PP2A. It is the B subunit that affects phosphatase activity, defines 
subcellular localization, and mediates target specificity 102,104. Moreover, some B subunits 
are specific for certain tissues or distinct developmental stages controlling the temporal and 
spatial availability of PP2A activity 100. Also, PTMs play a role in modulating the holoenzyme. 
The C subunit can be modified by methylation and phosphorylation, which controls catalytic 
efficiency 105,106. Phosphorylation of B subunits might additionally regulate PP2A 
activity 102,107.  
 
 
 Figure 3.7:  Composition of PP2A holoenzymes.  
Catalytically active PP2A represents a heterotrimer, consisting of a structural subunit (A), a catalytic subunit (C), 
and a regulatory subunit (B). B-type subunits can be divided into four unrelated families: B, B’, B’’, and B’’’. 
Each subunit (A, C) and family (B) comprises several isoforms (e.g. α, β) which are encoded by distinct genes 
and may give rise to several proteins (e.g. α1, α2). After 
100,102
.  
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3.3 Histone deacetylases and their inhibitors 
3.3.1 The family of histone deacetylases  
Protein acetylation is one of the most abundant posttranslational modifications found in 
eukaryotic cells. The highly dynamic state of protein acetylation is regulated by the interplay 
of histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs catalyze the 
covalent binding of an acetyl group from acetyl-CoA to the -amino group of lysine residues, 
while HDACs are able to remove this modification in an opposing hydrolytic reaction 108 
(Figure 3.8 A). Transfer of acetyl groups to the N-terminal tails of core histones, for example, 
is crucial for chromatin remodeling (Figure 3.9 B). Lysine acetylation lowers the positive 
charge of histone tails and hence reduces their interaction with the negatively charged DNA 
backbone. This loss of internucleosomal affinity yields an open chromatin structure and 
correlates with gene transcription 109. In contrast, a more condensed conformation of 
chromatin as caused by HDACs was reported to repress transcription 110. Next to histones, 
HATs and HDACs can also modify a continuously growing number of non-histone proteins 111-
113. This clearly extends the role of acetylation beyond altering gene expression. The 
modification of non-histone substrates may regulate protein stability, activity, interaction, or 
signaling and thereby affects many pivotal cellular processes 111. 
 
Figure 3.8:  The balance of protein acetylation. 
(A) Histone acetyltransferases (HATs) catalyze the addition of an acetyl group from acetyl-CoA to lysine 
residues. The opposing reaction is performed by HDACs, which remove acetyl groups by a hydrolytic reaction. 
Pharmacological inhibitors of HDACs (HDACi) impede deacetylation and hence stabilize protein acetylation. 
(B) N-terminal tails of core histones can be reversibly modified by HATs. Resulting acetylated histones create an 
open chromatin conformation. Deacetylation by HDACs conversely leads to a tightly packed chromatin state. 
Ac (black spot) – acetyl-group. Circles indicate histone octamers. Modified from 
108
 and after 
113
. 
In humans, 18 HDACs have been identified and are grouped into two separate families based 
on their enzymatic activity and homology to yeast deacetylases. So called ‘classical’ HDACs 
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are zinc-dependent enzymes 114 while the second family of sirtuins (SIRT) depends on NAD+ 
for catalytic activity 115 (Figure 3.9). Classical HDACs are further divided into three classes. 
Class I HDACs share sequence homology with the yeast deacetylase Rpd3. Included HDAC1, 
HDAC2, HDAC3, and HDAC8 enzymes are ubiquitously expressed and mainly localize in the 
nucleus 116. The yeast Hda1 orthologues of class II HDACs are grouped into two subclasses, 
class IIa (HDAC4, HDAC5, HDAC7, HDAC9) and class IIb (HDAC6, HDAC10). These isoforms 
show tissue-specific expression and are able to shuttle between the cytoplasm and nucleus. 
Class IIb HDACs though predominantly localize in the cytoplasm 117. Since HDAC11 shares 
sequence homology with both, Rpd3 and Hda1 yeast deacetylases, it has been grouped into 
a distinct class IV 118. Finally, sirtuins represent class III of human HDACs. The seven members 
(SIRT1-SIRT7) show homology to the yeast silent information regulator 2 (Sir2) 119. 
 
 
Figure 3.9:  The histone deacetylase superfamily.  
The human histone deacetylase (HDAC) family is divided into four classes based on their sequence homology to 
yeast proteins. HDACs class I, IIa/b and IV are Zn
2+
-dependent enzymes and are also referred to as “classical” 
HDACs. The NAD
+
-dependent class III of sirtuins includes seven members.  Modified from 
120
. 
3.3.2 Histone deacetylases 1, 2, and 3 in focus 
Aberrant expression of individual HDACs has been found in a wide range of human cancers 
and expanded the ‘classical’ causes of carcinogenesis as gene mutations or deletions by 
epigenetic alterations. It was shown that modifications of  the histone acetylation pattern 
alter the cellular gene expression profile as they influence chromatin conformation and 
affect the accessibility of transcription factors and other effector proteins to DNA 121,122. For 
example, HDAC1 overexpression was demonstrated in gastric, prostate, breast, and colon 
cancer; HDAC2 is overexpressed in gastric and colorectal cancer, while increased levels of 
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HDAC3 are frequently observed in chronic lymphoblastic leukemia (CLL), ovarian, or 
colorectal cancer 113,120,123. In many cases, the elevated amount of HDAC1, HDAC2, or HDAC3 
in tumor tissue correlates with a poor patient prognosis and lower survival rates 123,124. 
All three deacetylases are recruited to the transcriptional machinery with specific 
transcription factors and corepressors. As catalytic subunits, they form the core of multi-
protein complexes, which are involved in chromatin modification and mediate 
transcriptional repression. HDAC1-HDAC2 heterodimers are components of the corepressor 
of RE1-silencing transcription factor (CoREST), nucleosome remodeling deacetylase (NuRD), 
and mammalian Sin3 corepressor complexes 116. Both enzymes are highly related with 85% 
sequence identity and show redundant functions in cellular regulation 123. Loss of one HDAC 
variant can be compensated by the other during neuronal differentiation, cardiac 
development, and hematopoiesis 125-127. HDAC1 and HDAC2 further repress expression of 
the CDK inhibitor p21 and therefore play a pivotal role in cell cycle regulation 128,129. After 
exposure of cells to IR, HDAC 1 and HDAC 2 deacetylate histone H3 at lysine 56 (H3K56) at 
DNA damage sites and thereby promote DNA repair via NHEJ 130. Nevertheless, both 
deacetylases must also have specific functions, most likely dependent on developmental 
stage and tissue type. Knockout experiments in mice revealed that HDAC1 deprivation is 
embryonically lethal and HDAC2 knockout mice die soon after birth 125,128. 
HDAC3 is an essential element of nuclear receptor corepressor (N-CoR) and silencing 
mediator for retinoic acid/thyroid hormone receptor (SMRT) complexes 131,132. Several 
studies suggest an important impact of HDAC3 during mitosis and S phase. It was shown that 
HDAC3 complexes are localized with mitotic spindles and regulate sister chromatid 
adhesion as well as kinetochore-microtubule attachment 133,134. HDAC3 seems to deacetylate 
the N-terminal tail of histone H3, which in turn guides the mitotic kinase Aurora B to 
phosphorylate H3 on serine 10 and drives progression through mitosis 135. Moreover, 
conditional depletion of HDAC3 in mouse embryonic fibroblasts (MEFs) causes cell cycle 
delay in S phase and cells develop DSBs due to impaired DNA repair. This was also associated 
with reduced chromatin compaction, heterochromatin content, and apoptotic cell death 
showing that HDAC3 activity is required for cell viability 136,137. Accordingly, germline 
deletion of HDAC3 in knockout mice caused early embryonic lethality whereas sole cardiac-
specific deletion evoked severe defects in heart function 138. 
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3.3.3 Histone deacetylase inhibitors and their implication in cancer therapy 
When epigenetic changes caused by dysregulation of HDACs were found to correlate with 
the onset and progression of malignancies, it was a rational strategy to establish histone 
deacetylase inhibitors (HDACi) as anti-cancer drugs 108.  Nowadays, a large number of 
naturally derived and synthetic HDACi is known. They are compounds with various structure, 
specificity, and biological activity even though all of them target classical HDACs 113.  
HDACi are classified by their structure into hydroxamic acids, short fatty acids, benzamides 
and cyclic peptides. Hydroxamic acids like trichistatin A (TSA) or vorinostat (SAHA) are rather 
unspecific inhibitors affecting all classes of HDACs. Short fatty acid (e.g. valproic acid – VPA) 
and benzamide compounds (e.g. MS-275) exert their properties more specifically on class I 
and IIa HDACs or only class I HDACs, respectively. Cyclic peptides like depsipeptide are most 
selective and target only a subset of class I HDACs 108,113. All inhibitors share a comparable 
structure composed of three pharmacophore domains. A metal-binding moiety interacts 
with the catalytical Zn2+ of the active site, whereas a hydrophobic linker and surface 
recognition domain connect with the active side cavity and its periphery 139. Application of 
HDACi shows a multitude of biological effects, which origin from their ability to promote 
acetylation of histone and non-histone protein. This alters chromatin structure and affects 
expression of a variety of genes, in which about half of the genes are upregulated and the 
second half is suppressed 140. On the biological level, HDACi can induce DNA damage, ROS, 
cell cycle arrest, differentiation, and apoptosis and reduce angiogenesis or metastasis 141. 
Interestingly, they possess high tumor cell-directed toxicity whereas normal cells are 
relatively resistant to HDACi 142. Both were good prerequisites for their use in clinic (Table 
3.10). 
 
Table 3.10:  HDACi in clinical trials (partial list). 
143
 





Short fatty acids Valproic acid (VPA) 
Benzamides Entinostat (MS-275, SNDX-275) 
MGCD0103 
Cyclic peptides Romidepsin (Depsipeptide) 
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Many clinical studies demonstrated the potential of HDACi as efficient monotherapy for 
hematological malignancies and solid tumors 120,144. However, results often indicated a more 
favorable outcome of HDACi treatment in combination regimens with other antitumor 
agents or radiotherapy 145. So far, the inhibitors vorinostat (SAHA) and depsipeptide were 
approved by the Food and Drug Administration (FDA) for treatment of refractory cutaneous 
T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in the USA 146,147. Many trials 
with several other HDACi are still ongoing 113. One of the inhibitors in clinical development is 
the benzamidine MS-275 (also called Entinostat or SDNX-275), which specifically inhibits 
HDAC1, HDAC2, and HDAC3 148. It is currently applied in Phase 1 to Phase 3 studies. A benefit 
of MS-275 in co-treatment with aromatase inhibitors is tested in patients with recurrent or 
refractory breast cancer. Also, combination studies are conducted with tyrosine kinase 
inhibitors in non-small cell lung cancer (NSCLC) and breast cancer patients as well as with the 
nucleoside analogue 5-Azacytidine in patients with metastatic colorectal cancer 149. 
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4 AIMS OF THE WORK 
Chemotherapeutic drugs are a standardized regimen in the treatment of cancer. In order to 
increase the efficacy of the treatment and to reduce the likelihood for the development of 
resistances, these compounds are often administered in combination therapies. For 
example, several pharmacological inhibitors for histone deacetylases (HDACi) were shown to 
sensitize cancer cells for the DNA-damaging, cytotoxic effects of chemotherapeutics and to 
act highly tumor cell-specific.  
Histone deacetylases (HDACs) are key modulators of gene expression and intracellular 
signaling pathways as they target histones and non-histone proteins. However, it was largely 
unknown how the reduction of their catalytic activity by HDACi might regulate the cellular 
response to DNA stress. Among others, a previous study revealed that HDAC1 and HDAC2 
are involved in the DNA damage response (DDR) by promoting double-strand break repair. 
These studies mostly concentrated on the relevance of HDACs in the context of DNA double-
strand lesions. Whether and to what extent HDACi affected the S phase stress response 
upon drugs blocking DNA replication remained unclear. 
The aim of the present study was to investigate the consequences of HDAC inhibition for the 
replication stress-induced DDR. In the beginning, the potential impact of the HDAC class I-
specific inhibitor MS-275 on DDR signaling via ATR and ATM should be examined. The 
resulting extent of DNA damage and apoptosis as well as the implementation of cell cycle 
arrest should be additionally monitored as readouts for the final cellular outcome. If the 
results suggested that MS-275 modulated the DDR following perturbed DNA synthesis, the 
putative roles of HDAC1, HDAC2, and HDAC3 should be addressed by specific siRNA-
mediated knockdown. Furthermore, the molecular mechanism underlying modulation of the 
replication stress response via increased intracellular acetylation by HDACi should be 
elucidated. 
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Albumin Fraction V (BSA) Sigma-Aldrich 
Antipain Roth 
Ammonium persulfate (APS) AppliChem 
Aprotinin Roth 
Benzamidine Sigma-Aldrich 
Bromophenol blue Serva 
Calcium chloride (CaCl2) Roth 
Chloroform Roth 
Diethylpyrocarbonate (DEPC) Roth 
Dimethyl sulfoxide (DMSO) Roth 
Dithiothreitol (DTT) Roth 
ECL (Super Signal® West Pico Chemiluminescent Substrate) Pierce (Thermo Scientific) 
ECL (Immobilon Western Chemiluminescent HRP Substrate) Millipore 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Ethanol (MEK denatured) Mineralöle Albert 
Ethanol (≥ 99.5%) Roth 




Hydrogen chloride (HCl) Roth 
HEPES Roth 
Isopropyl alcohol Roth 
Leupeptin Roth 
Lipofectamine® 2000 Life Technologies 
-Mercaptoethanol Serva 
Nonidet P-40 (IGEPAL® CA-360) Sigma-Aldrich  
Okadaic acid (OA) Abcam 
Paraformaldehyde Sigma-Aldrich  
Phenylmethylsulfonyl fluoride (PMSF) Roth 
Potassium chloride (KCl) Roth 
Potassium dihydrogen phosphate (KH2PO4) Riedel-DeHaёn 
Propidium iodide Sigma-Aldrich 
Protein A SepharoseTM CL-4B Amersham (GE Healthcare) 
Protein G SepharoseTM 4 Fast Flow Amersham (GE Healthcare) 
Roti®-Nanoquant 5x Roth 
Rotiphorese® Gel 30 Roth 
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Skimmed milk powder Saliter 
Sodium azide (NaN3) Sigma-Aldrich 
Sodium chloride (NaCl) Roth 
Sodium dodecyl sulfate (SDS) Roth 
Disodium hydrogen phosphate dihydrate (Na2HPO4 x 2 H2O) Roth 
Sodium fluoride (NaF) Sigma-Aldrich 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich  
TEMED Roth 
Tris Roth 
TritonTM X-100 Sigma-Aldrich  
Tween® 20 Roth 
 
5.2 Enzymes, proteins and inhibitors 
Enzyme/protein/inhibitor company 
Accutase PAA (GE Healthcare) 
Annexin V FITC-conjugated Immunotools 
Cantharidin Sigma-Aldrich  
ETP-46464 from Z-Q Wang (FLI, Jena) 
5-Fluorouracil (5-FU) Enzo Life Sciences  
Hydroxyurea (HU) Sigma-Aldrich  
KU-55933 Selleck Chemicals 
MS-275 (Entinostat) Selleck Chemicals  
RNase A Serva 
Trypsin-EDTA 1x PAA (GE-Healthcare) 
UCN-01 from Z-Q Wang (FLI, Jena) 
 
5.3 Antibodies 
Primary antibody host company order number dilution 
anti Actin rabbit Sigma-Aldrich  A2066 1 : 10,000 
anti ATM rabbit abcam ab32420 1 : 1,000 
anti ATM  phospho-Ser1981 rabbit abcam ab81292 1 : 1,000  
anti CHK1 mouse Santa Cruz sc-8408 1 : 2,000 
anti CHK1  phospho-Ser317 rabbit Bethyl A300-163A 1 : 1,000 
anti CHK2 rabbit Santa Cruz sc-9064 1 : 1,000 
anti CHK2  phospho-Thr68 rabbit abcam ab32148 1 : 1,000 
anti CHK2  phospho-Thr68   rabbit Acris antibodies AP01556PU-N 1 : 500 
anti H2A.X  phospho-Ser139  
(H2A.X) 
mouse Millipore 05-636-K 1 : 5,000 
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5.4 Buffers and solutions 
Buffer  conc. ingredient 
Binding buffer 10x 0.1 M HEPES, pH 7.4 
 
 
 1.4 M NaCl 
  25 mM CaCl2 
Blocking buffer 1x 5% Skimmed milk powder 
   in PBS-T 
Co-IP lysis buffer 1x 50 mM Tris-HCl, pH 8 
  120 mM NaCl 
  0.5% Nonidet P-40 
Co-IP wash buffer 1x 20 mM Tris-HCl, pH 8 
  900 mM NaCl 
  1 mM EDTA, pH 8 
  0.5% Nonidet P-40 
anti HDAC1 mouse abcam ab46985 1 : 1,000 
anti HDAC2 rabbit Santa Cruz sc-7899 1 : 5,000 
anti HDAC3 rabbit abcam ab16047 1 : 1,000 
anti HDM2 mouse Santa Cruz sc-56154 1 : 5,000 
anti HSP90 mouse Santa Cruz sc-13119 1 : 400,000 
anti mSIN3A rabbit Santa Cruz sc-994 1 : 20,000 
anti p21 mouse Santa Cruz sc-6246 1 : 2,000 
anti p53 mouse Calbiochem OP03 1 : 1,000 
anti p53 mouse Santa Cruz sc-81168 1 : 50,000 
anti p53  phospho-Ser15 rabbit Cell Signaling 9284 1 : 5,000 
anti p53  phospho-Ser20 rabbit Cell Signaling 9287 1 : 2,000 
anti p53  phospho-Ser46 rabbit Cell Signaling 2521 1 : 1,000 
anti PARP-1  mouse BD Pharmingen 556362 1 : 1,000 
anti PARP-1 (cleaved) mouse BD Pharmingen 552596 1 : 5,000 
anti PPM1D (WIP1) rabbit Bethyl A300-664A 1 : 5,000 
anti PPP2R3A (PR72/PR130) rabbit Novus 
Biologicals 
NBP1-87233 1 : 5,000  
anti α-Tubulin mouse Sigma-Aldrich  T5168 1 : 50,000 
anti Vinculin mouse Biozol BZL-03106 1 : 5,000 
normal rabbit IgG (pre-immune)  Santa Cruz sc-2027 for IP 
Secondary antibody     
anti mouse IgG HRP-conjugated goat Pierce 32430 1 : 5,000 
anti rabbit IgG HRP-conjugated 
 
goat Pierce 32460 1 : 5,000 
anti mouse IgG Alexa Fluor® 488 goat Life 
technologies 
A11001 for IF 
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Co-IP final wash buffer 1x 10 mM Tris-HCl, pH 8 
  100 mM NaCl 
  1 Mm EDTA 
  0.5% Nonidet P-40 
Crosslink solution for Co-IP 1x 1% Formaldehyde 
   in 1x PBS 
Crosslink quencher for Co-
IP 
1x 1 M Glycine 
   in 1x PBS 
Hypotonic buffer 1x 20 mM HEPES, pH 7.9 
  10% Glycerol 
  0.2% Nonidet P-40 
  10 mM KCl 
  1 mM EDTA 
Laemmli sample buffer 6x 350 mM Tris-HCl, pH 6.8 
  4.3 M β-Mercaptoethanol 
  10% SDS 
  33% Glycerol 
NETN 1x 10 mM Tris-HCl, pH 7.4 
  100 mM NaCl 
  1 mM EDTA 
  10% Glycerol 
  0.5% Nonidet P-40 
PBS, pH 7.25 10x 1.37 M NaCl 
  27 mM KCl 
  65 mM Na2HPO4 x 2 H2O 
  14 mM KH2PO4 
PBS-T 1x 1x PBS 
  0.05% Tween® 20 
PIC 1x 1 mg/ml Leupeptin 
  2 mg/ml Antipain 
  100 mg/ml Benzamidin 




Protein A/G sepharose   Protein A/G sepharose (in equal parts) 
   NETN (same volume as beads) 
  0.1% BSA 
  0.01% NaN3 
Resolving gel buffer 1x 1 M Tris-HCl, pH 8.8 
Running buffer 10x 250 mM Tris 
  2.5 M Glycine 
  1% SDS 
Strip buffer 1x 62.5 mM Tris-HCl, pH 6.8 
  2% SDS 
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  100 mM β-Mercaptoethanol 
Stacking gel buffer 1x 1 M Tris-HCl, pH 6.8 
Towbin buffer, pH 8.9 10x 250 mM Tris 
  1.92 M Glycine 
 
5.5 Oligonucleotides 
5.5.1 Primer for qRT-PCR 
gene orientation sequence 
PPP2R3A fwd 5´- GCGGTCCAGAAGGATGTTGAGA-3´ 
 rev 5´- TCCTGGAATTGTGCTTGGGC-3´ 
GAPDH fwd 5´-TGCACCACCAACTGCTTAGC-3´ 
 rev 5´- GGCATGGACTGTGGTCATGAG-3´ 
HMBS fwd 5´-GGCAATGCGGCTGCAA-3´ 
 rev 5´- GGGTACCCACGCGAATCAC-3´ 
 
5.5.2 Small interfering RNAs (siRNAs) 
siRNA target sequence company 
Control 5'-AGGUAGUGUAAUCGCCUUGTT-3 Eurofins MWG Operon 
PR72/PR130 5´-GAAAGUUGCUGAAUAACCTT-3´ Life technologies (s10975) 
HDAC1 5´-CUAUGGUCUCUACCGAAAATT-3´ 
 
Life technologies (4390824) 
HDAC2  Santa Cruz (sc-29346) 
HDAC3 5´-GGAGCUUCCCUAUAGUGAATT-3´ 
 
Life technologies (s16878) 
 
5.6 Kits and marker 
PageRulerTM Plus Prestained Protein Ladder Thermo Scientific  
peqGOLD RNAPureTM Peqlab 






ProLong® Gold Antifade Reagent Life technologies 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific 
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5.7 Medium and serum 
DMEM (Dulbecco´s Modified Eagle Medium),  
high Glucose (4.5 g/l) 
PAA, now GE Healthcare 
FCS  (Fetal Calf Serum) PAA, now GE Healthcare 
Opti-MEM® I Life technologies 
  
5.8 Cell lines 
HCT116 
 
human colorectal carcinoma cell line (verified by DSMZ) 
HCT116 p53 -/- 
 
human p53-negative counterpart of HCT116 
RKO human colorectal carcinoma cell line 
MEF p53 +/+ 
 
murine Mouse embryonic fibroblasts, p53 positive; from Z.-Q. Wang (FLI,  
Jena) 
MEF p53 -/- 
 
murine Mouse embryonic fibroblasts, p53 negative; from Z.-Q. Wang (FLI, 
Jena) 
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6 METHODS 
6.1 Methods of cell culture and whole cell analysis 
6.1.1 Cultivation and long-term storage of adherent cells 
All eukaryotic cell lines were handled with sterile buffers, media and glass equipment.  Any 
handling, including passaging, seeding, freezing, and thawing was performed under sterile 
working benches in one separate room. Here, cells were stored in specific incubators 
ensuring stable conditions with humidified air containing 5% CO2 and a temperature of 37°C. 
The used cell lines were all adherent and maintained in DMEM (supplemented with 10% FCS) 
in cell culture flasks until they reached a critical confluence of nearly 100%. To passage them, 
old medium was removed, cells were washed with sterile PBS and incubated with 
Trypsin/EDTA until all cells detached from the bottom of the cell culture flask. Then, they 
were taken up and carefully resuspended in 5 ml fresh medium. For further cultivation, cell 
suspension was diluted 1:10 or 1:20 in a new flask or seeded in cell culture dishes at the 
desired dilution. The cell density per milliliter medium was determined with the help of a 
Neubauer chamber. 
Long-term storage was at -150°C. For this, cells were taken up in freezing medium, consisting 
of FCS and 10% DMSO. The cell suspension was distributed to cryo vials, which were then 
stored in a freezing box at -80°C. The isopropyl alcohol in the freezing container allowed a 
slow cooling of the cells over night, after which vials were transferred to -150°C.  
6.1.2 Transient transfection 
Transient transfection is defined as the temporary incorporation of exogenous DNA or RNA 
into a eukaryotic cell. In this study, LipofectaminTM2000 was used as transfection reagent to 
insert small interfering RNAs (siRNAs) into mammalian cells. The reagents cationic lipids 
spontaneously interact with the negatively charged backbone of DNA or RNA and form small 
vesicles. These can bind to and fuse with the cell´s plasma membrane and release the nucleic 
acid into the cytoplasm.  
The day before transfection, cells were seeded in 6 or 12 well plates (Greiner Bio-One) so 
that confluence would be about 30-40% at the time of transfection. Cells were transfected 
with 10-40 pmol or 20-60 pmol siRNA in 12 and 6 well plates, respectively. For transfection, 
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the appropriate amount of LipofectaminTM2000 was incubated in 100 µl Opti-MEM® I 
reduced serum medium for 5 min. In the meantime, siRNAs were diluted in 100 µl Opti-
MEM® I as well. Both dilutions were united and further incubated for 10 min. Afterwards, 
200 µl of siRNA-lipid complexes were added right into a well´s growth medium. Transfection 
reagent remained on the cells for up to 48 h without changing the medium.Flow cytometry 
Flow cytometry is a biophysical method to characterize cell populations in high speed on 
single cell level. For this, a constant stream of fluid with suspended cells runs through the 
capillary system of the FACS (Fluorescence activated cell sorter) and passes a laser. Thereby, 
the incident laser beam is refracted and scattered by the surface and nature of the passing 
cell, which directly correlates with cell size (forward light scatter) and granularity (side light 
scatter). Additional fluorescence labeling with antibodies or dyes allows investigation of 
further characteristics (see below).   
Quantification of apoptosis 
One of the early events of apoptosis is the loss of membrane asymmetry, which leads to the 
exposure of phosphatidylserine on the outer layer of the plasma membrane. Annexin V, a 
natural anticoagulant, binds phosphatidylserine with high affinity in a calcium-dependent 
manner. If conjugated with a fluorophore like Fluorescein isothiocyanate (FITC), it can be 
used to detect apoptotic cells by flow cytometry.  
Cells were seeded in 6 well plates and treated 24 h later as required for the experiment. The 
medium was collected; cells were washed with PBS, and detached from the dish with 300 µl 
Accutase. After incubation for about 5 min at room temperature (RT), cell suspension was 
taken up in 1 ml PBS and transferred to the medium. They were centrifuged at 700xg for 
5 min at RT and the supernatant was aspirated. The cell pellet was washed once with PBS 
and centrifuged as described. In the end, each sample was resuspended in 800 µl 1x binding 
buffer and 5 µl Annexin V-FITC were added. The following incubation for 15 min was carried 
out at RT and in the dark. Sampled were measured using the BD FACSCantoTM with the 
488 nm excitation laser and BD FACSDiva Software (both BD Biosciences). 
Cell cycle analysis 
The DNA content of a cell can be determined by staining with propidium iodide (PI). PI is an 
intercalating agent, which can be excited to fluoresce in its DNA or RNA bound form. The 
fluorescence intensity of a cell correlates linearly with its DNA amount. The DNA content, 
METHODS  HDACs regulate phosphatase activity  
page | 30 
  
however, varies during the cell cycle. While cells in G1 (gap 1) show a haploid set of 
chromosomes, G2 (gap 2) and mitotic cells contain diploid genomes. Therefore, comparison 
of the fluorescence signals within a cell population allows the assignment of cell cycle stages. 
For harvesting, the medium was collected. Cells were washed with PBS, and detached from 
the culture dish with 300 µl Accutase. After incubation for about 5 min at RT, cell suspension 
was taken up in 1 ml PBS and transferred to the medium. They were centrifuged at 700xg for 
5 min at RT and the supernatant was aspirated. The cell pellet was washed with 1 ml PBS and 
centrifuged as described above. For fixation and permeabilization the remaining cell pellet 
was resuspended in 1 ml of ice-cold 70% Ethanol (EtOH) in a dropwise manner while 
vortexing. Cells were then stored at 4°C at least overnight. For final preparation, the 
suspension was centrifuged at 700xg for 5 min and EtOH was aspirated. The cell pellet was 
washed twice with 1 ml cold PBS and each centrifuged. After the last washing step, cells 
were again resuspended in 1 ml PBS with the addition of 5 µl PI (final concentration: 
12.5 µg/ml) and 10 µl RNase A (final concentration: 100 µg/ml). To remove all double-
stranded (ds) RNA by RNase A, samples were incubated at 37°C for 30 min in the dark. 
Sampled were measured using the BD FACSCantoTM with the 488 nm excitation laser and BD 
FACSDiva Software (both BD Biosciences). Evaluation of data was also carried out with 
FlowJo 7.6.5 (TreeStar Inc.). 
6.1.4 Fluorescence microscopy 
HCT116 cells were grown on sterile coverslips in a 6 well plate. At the end of the treatment, 
medium was vacuumed and cells were fixed in 4% formaldehyde in PBS for 10 min. After 
washing they were stored at 4°C in PBS or subsequently permeabilized with 0.25% TritonX-
100 for 3 min at RT. After washing three times with PBS the coverslips were incubated with 
25 µl of primary antibody dilution (H2AX  1: 1,000) for 1 h in the dark. Then, coverslips were 
rinsed three times for 5 min each with PBS, covered with secondary anti-mouse IgG 
AlexaFluor®488 and stored in the dark at RT for 1 h followed by washing with PBS. All 
remaining PBS was removed and the coverslips were fixed on microscope slides with liquid 
mountant ProLong® Gold Antifade Reagent containing DAPI. Cell staining was analyzed with 
the confocal laser scanning microscope LSM710 (Carl Zeiss). 
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6.2 Methods of mRNA analysis  
6.2.1 Isolation of RNA 
Total cellular RNA was isolated by Trizol extraction with peqGOLD RNAPureTM according to 
the manufacturer´s protocol. The precipitated and washed RNA was dissolved in 50 µl 
RNase-free DEPC-H2O. 
6.2.2 Determination of concentration and purity for isolated RNA 
The amount and quality of the isolated RNA was analyzed with the help of a NanoDrop 1000 
spectrophotometer (Thermo Scientific) at a wavelength of 260 nm. One unit of OD260 is 
equivalent to a RNA concentration of 40 ng/µl. To assess the purity of the RNA, ratios of 
OD260/OD230 and OD260/OD280 were calculated. The samples were considered as not 
contaminated with proteins and phenol, if the ratios were OD260/OD280 ≥ 1.8 and 
OD260/OD230 ≥ 2.2. 
6.2.3 Reverse transcription 
 A total of 2 µg RNA was transcribed to cDNA by means of the RevertAid First Strand cDNA 
Synthesis Kit (Thermo Scientific), using random hexamer primers. Therefore, 2 µg of total 
RNA and 1 µl of random hexamer primer were filled up with DEPC-H2O to a final volume of 
11 µl and incubated at 70°C for 5 min. Then, 4 µl 5x reaction buffer, 1 µl RiboLockTM RNase 
Inhibitor, 2 µl dNTP Mix (10 mM) and , finally, 1 µl RevertAid Reverse transcriptase (M-MuLV 
RT) were added. After incubation at 25°C for 5 min the reverse transcription (RT) was carried 
out at 42°C for 60 min and terminated at 70°C for 10 min. 
6.2.4 Quantitative real-time PCR 
Quantitative or real-time polymerase chain reaction (qPCR) is a method based on 
conventional PCR. It is able to amplify specific DNA in a sample and at the same time detect 
and quantify the PCR products, which are displayed by software in real-time. Specific primers 
mediate the amplification of desired DNA sequences. One method to detect newly 
synthesized DNA is using non-specific fluorescent dyes like SYBR Green, which intercalate in 
dsDNA. If excited, their emitted fluorescence directly correlates with the DNA amount. 
Quantitative RT PCR was performed in triplicates with the SYBR® Green Real-Time PCR 
Master Mix on the StepOnePlusTM Real Time PCR System (both Applied Biosystems). The 
METHODS  HDACs regulate phosphatase activity  
page | 32 
  
mixture consisted of 7.5 µl SYBR® Green RT-PCR Master Mix, 200 nM of each specific 
forward and revers oligonucleotide primer and 1.5 µl of cDNA. The following program was 
used: activation of the polymerase for 10 min at 95°C was followed by 40 cycles of cDNA 
denaturation at 95°C for 15 sec, and annealing and elongation at 60°C for 1 min. In a last 
step, melting curves were created to define PCR products. Therefore, samples were heated 
gradually from 55°C to 95°C. A single peak at a specific melting temperature ensured 
amplification of a specific product. 
Obtained data for Ct values were analyzed with the Cq quantification model to determine 
the relative expression levels. The gene of interest (GOI) was then normalized to two 
reference genes, HMBS and GAPDH. Both housekeeping genes were verified as stably 
expressed genes with the geNorm program. 
6.3 Methods of protein analysis 
6.3.1 Preparation of whole cell extracts 
All steps during the preparation of whole cell extracts were performed on ice. For 
harvesting, medium was collected and cells were scraped off the plate bottom in 1 ml cold 
PBS. Cell suspension was transferred to the medium and the tubes were centrifuged at 
700xg and 4°C for 3 min. Supernatant was vacuumed and the cells were resuspended in 
NETN (supplemented with protease and phosphatase inhibitors) with 5 times the volume of 
the pellet. A complete lysis was achieved by incubation of the mixture for 15 min on ice and 
subsequent sonification with Branson sonifier (Danbury). Then, tubes were spinned at 
14,000 rpm at 4°C for 15 min to remove cell debris. The supernatant was transferred to a 
fresh tube and stored at -80°C. 
6.3.2 Preparation of cytosolic and nuclear extracts 
Like in preparation of whole cell lysates, all steps were performed on ice. First, medium was 
aspirated from 6 well plates and cells were washed and scraped off in 1 ml cold PBS. After 
centrifugation, the cell pellet was carefully resuspended in about 80 µl of hypotonic buffer. 
Its hypotonic conditions lead to swelling and bursting of cells. In order to prevent lysis of 
nuclei, cells were incubated for 5 min at the most and subsequently centrifuged at 
14,000 rpm and 4°C for 2 min. The supernatant which represents the cytosolic lysate was 
transferred to a fresh tube. Remaining nuclei were washed and resuspended in about 80 µl 
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hypotonic buffer. They were sonicated and nuclear as well as cytosolic lysates were stored at 
-80°C. 
6.3.3 Bradford assay 
The photometric determination of protein concentration by Bradford is based on the 
interaction of Coomassie Brilliant Blue G-250 with charged and hydrophobic amino acid 
residues of a protein. This interaction leads to a shifted absorbance maximum of the dye, 
which is measured as absorbance of the solution at 595 nm (A595).  
For the assay, lysates were diluted (1:10) and mixed with 1:5-diluted Roti®-Nanoquant in a 
96 well plate. After incubation for 5 min at RT, absorbance at 595 nm was measured with the 
plate reader FLUOstar Optima (BMG labtech). Simultaneously, a concentration series of 
bovine serum albumin (BSA: 25; 50; 100; 250; 500; 1,000 µg/ml) was measured to obtain a 
standard curve. 
6.3.4 Immunoprecipitation 
The method of immunoprecipiation is used to isolate and concentrate a protein of interest 
out of a cell lysate and, in extension, to study protein-protein interactions. Since some 
interactions are very transient, like those of a phospho-protein and its phosphatase, the 
contact needs to be stabilized by crosslinking for detection. 
For this, medium was removed from 10 cm culture dishes and cells were washed once with 
PBS. Then, cells were covered with crosslink solution and incubated for no longer than 
10 min at RT. Crosslinking was stopped by adding a quencher solution of 1 M glycine for 
5 min. Cells were washed with PBS and lysed in 1 ml Co-IP lysis buffer for 30 min on ice. Per 
sample, the lysates of two 10 cm dishes were united, sonicated for 5 seconds at 20% 
amplitude and centrifuged at 14,000 rpm for 10 min. The supernatant was transferred into a 
new tube. This lysate was used for Co-IP and for input control.   
For Immunoprecipitation, at least 500 µl of lysate were incubated with 0.6 µg of primary 
antibody (pATM, rabbit monoclonal ab81292). The same volume of lysate was incubated 
with 0.6 µg IgG from rabbit (pre-immune serum) or no antibody as negative controls. All 
mixtures were rocked at 4°C for 1-2 h. After addition of 50 µl protein A/G sepharose beads, 
rotation was continued overnight. While protein A and G bind Fc regions of mammalian 
antibodies with high specificity, the sepharose beads allow easy sedimentation and thereby 
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purification of antibody-protein complexes. The next day, beads were washed five times 
with Co-IP wash buffer and once with Co-IP final wash buffer. The beads were pelleted by 
centrifugation at 14,000 rpm for 1 min. After the last washing step, remaining buffer was 
removed with an insulin syringe and 60 µl of 2x Laemmli buffer were added. Samples were 
heated (95°C, 5 min) and directly loaded to SDS gels. 
6.3.5 SDS-PAGE by Laemmli 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) enables the 
separation of proteins according to their molecular weight in an electric field. The 
discontinuous, denaturing gels are composed of a resolving gel and a stacking gel poured on 
top 150. Acrylamide concentration of the resolving gel was chosen depending on the 
molecular weight of the proteins, which should be separated. Gels were casted with the help 
of the Mini-PROTEAN® 3 System (Bio-Rad) according to the following scheme. Casted gels 
could be stored for up to three weeks at 4°C wrapped in wet tissue. 
(for 3 gels) Stacking gel  Resolving gel 
   7% 8% 10% 12% 
Rotiphorese® Gel 30 1.64 ml  3.5 ml 4 ml 5 ml 6 ml 
Resolving gel buffer - 
 
 5.6 ml 5.6 ml 5.6 ml 5.6 ml 
Stacking gel buffer 1.25 ml  - - - - 
SDS 20% 50 µl  75 µl 75 µl 75 µl 75 µl 
H2O 6.98 ml  5.74 ml 5.24 ml 4.24 ml 3.24 ml 
APS 10% 50 µl  75 µl 75 µl 75 µl 75 µl 
TEMED 10 µl  10 µl 10 µl 10 µl 10 µl 
 
Prior to loading, protein samples were mixed with 6x Laemmli sample buffer and heated for 
5 min at 95°C for complete denaturation. Then, they were loaded into gel pockets with a 
microliter syringe. A pre-stained protein marker (PageRulerTM plus prestained protein ladder) 
was used to estimate molecular weights of separated proteins. SDS-PAGE´s were run in a 
Mini-PROTEAN® 3 system (Bio-Rad) with 1x running buffer at a constant current of 20 mA 
per gel and a maximum voltage of 120 V. 
6.3.6 Western blot and immunostaining 
Gel electrophoresis was followed by western blotting, to electrophoretically transfer the 
separated proteins from inside the gel onto a PVDF membrane (Roti®-PVDF).  The gels were 
blotted using a tank blot system (Mini-PROTEAN® 3 blotting chamber, Bio-Rad) and SDS-free 
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Towbin blot buffer. Transfer was performed either for 2 h at 150 mA per gel, or for 18 h 
overnight at a current of 20 mA per gel. Then, the PVDF membrane was placed in blocking 
buffer (5% skimmed milk powder in PBS-T) to block residual non-specific binding sites. After 
1 h, membranes were incubated in primary antibody solution (diluted in 5% non-fat milk in 
PBS-T) overnight at 4°C. The next day, they were washed three times in PBS-T and incubated 
for 1 h with secondary antibody coupled to horseradish peroxidase (HRP; diluted in 2% non-
fat milk in PBS-T). Afterwards, membranes were washed again three times for 10 min each in 
PBS-T and prepared for immunodetection. 
Protein-antibody complexes are indirectly detected by a chemiluminescence reaction of the 
HRP with ECL (enhanced chemiluminescence) solution. The enzyme catalyzes the oxidation 
of luminol and phenol additionally enhances the emission of light. Therefore, membranes 
were covered with ECL solution for 1 min (Super Signal® West Pico Chemiluminescent 
Substrate; Immobilon Western Chemiluminescent HRP Substrate). In a dark chamber they 
were exposed to X-ray films (Fuji Super RX, Fujifilm; Euromed EC-plus Grünfilm), which were 
developed using an automatic film processor (Optimax, PROTEC®). 
Detection of additional proteins required the removal of bound antibodies from the 
membrane. For this, membranes were incubated in strip buffer for 15 to 45 min on a role 
mixer. Afterwards, they were washed in ddH2O and PBS-T, until the smell of the denaturing 
agent β-Mercaptoethanol had completely vanished.  
6.4 Statistical analysis 
Dispersion around the mean of a data set is always given as standard derivation (s.d.). To 
evaluate the difference of two data sets, and thereby their mean values, two-tailed unpaired 
student´s t-test was applied. Samples were considered as significantly different if the 
respective P-value was below a threshold of 0.05.  The level of significance is represented by 
the number of added asterisks: * P<0.05; ** P<0.01; *** P<0.001. 
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7 RESULTS 
7.1 Histone deacetylases modulate the hydroxyurea-induced DNA damage 
response  
7.1.1 The histone deacetylase inhibitor MS-275 attenuates replication stress signaling  
During replication of the cellular genome in the synthesis phase (S phase) of the cell cycle, 
single stranded DNA is extremely susceptible to insults. One strategy in cancer therapy is the 
application of chemotherapeutic substances called anti-metabolites, which specifically 
interfere with the progression of DNA replication in S phase and generate DNA lesions in 
order to eliminate cancer cells. The drug hydroxyurea (HU) belongs to this family of anti-
metabolites and is commonly used in the treatment of leukemia 151,152 and various other 
malignant carcinomas 153,154. As an inhibitor for ribonucleotide reductase (RNR), HU cuts off 
the supply of deoxyribonucleotides for the synthesis of DNA 155. Thereby, HU treatment 
leads to stalled replication forks as well as ruptures in the DNA during S phase and ultimately 
causes death of damaged cells. Recently, it has been shown that this cytotoxic effect of HU 
treatment on cancer cells could be further enhanced by co-treatment with histone 
deacetylase inhibitors (HDACi) 156,157. 
The human colon carcinoma cell line HCT116 is a suitable model system for studying the 
DDR. HCT116 cells possess intact DNA damage-inducible cell cycle checkpoints and 
accomplish effective DNA repair by homologous recombination (HR) 158-160. The cells were 
treated with HU and the HDACi MS-275, either alone or in combination, to decipher single 
effects of both drugs as well as the impact of joint administration on cellular signaling. 
Phosphorylation levels of DDR kinases ATM, CHK1, and CHK2 were detected by western 
blotting as readout for DDR pathway activation (Figure 7.1 A). Treatment with 1 mM HU led 
to the activation of ATM (phosphorylation at Ser1981), CHK2 (phosphorylation at Thr68), 
and the ATR target CHK1 (phosphorylation at Ser317) of the DDR signaling cascade. 
Incubation with 2 µM MS-275 on the other hand did not trigger phosphorylation of these 
kinases. However, MS-275 had a time-dependent impact on the HU-induced DDR in co-
treated cells. After six hours, no differences were obtained in the phosphorylation of ATM, 
CHK1 and CHK2. A longer treatment period of 24 hours though resulted in diminished to 
nearly abrogated ATM/CHK2 and ATR/CHK1 signaling. This loss of phosphorylation could not 
be explained by reduced expression of the respective kinases.  
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Figure 7.1:  DNA damage response signaling after replication stress relies on HDAC activity. 
(A) HCT116 cells were treated with 1 mM hydroxyurea (HU) and 2 µM MS-275 for 6 and 24 hours, respectively. 
Whole cell lysates were blotted to two membranes for protein detection. HSP70 and mSIN3A were used as 
individual loading controls. (B) Cells were incubated with 2 µM MS-275 and/or 5 µM 5-FU and harvested after 
24 h of treatment. Protein phosphorylation and expression were assessed with specific antibodies by western 
blot. Experiment (B) was carried out by Maria Schreiber, former Master student of AG Krämer, FSU Jena. 
This experiment was repeated with 5-Fluorouracil (5-FU), which is another commonly used 
anti-metabolite and also applied in the treatment of colorectal cancer 161. It acts in a similar 
way like HU by reducing the pool of deoxyribonucleotides. More specifically, it inhibits the 
enzyme thymidylate synthase and finally depletes the amount of available deoxythymidine 
triphosphate (dTTP) and other deoxynucelotides 162,163. Treatment of HCT116 cells with 5-FU 
resulted in the activation of DDR signaling (Figure 7.1 B). Again, simultaneous application of 
MS-275 for 24 hours diminished the phosphorylation of apical and checkpoint kinases. These 
data point to the relevance of HDAC1-3 activity for a sustained DNA damage response in 
cells suffering from replicative stress.  
To further investigate whether this effect relies on p53, the same experimental setup was 
performed in p53-negative HCT116 and RKO cells, a second p53-positive colorectal 
carcinoma cell line. In this context, the treatment was also applied to wild-type and p53-/- 
mouse embryonic fibroblasts (MEFs). All studied cell lines showed reduced HU-induced 
phosphorylation of ATM when they were exposed to the HDACi at the same time 
(Figure 7.2). Moreover, this effect was visible independently of the cell´s p53 status 
(Figure 7.2 A).   
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Figure 7.2:  Activation of the DNA damage response in presence of MS-275 in several cell lines. 
(A) HCT116 and MEF cells (each p53 
+/+
 and p53 
-/-
) were incubated with 1 mM HU alone or together with 2 µM 
MS-275 for 24 h or were left untreated for control. Phosphorylation of ATM was determined by western blot 
analysis. Vinculin (MEFs) and mSIN3A (HCT´s) served as loading controls. (B) RKO cells were incubated with HU 
and MS-275 for 6 and 24 h. Single MS-275 treatment was carried out only for 24 h. ATM phosphorylation as 
well as mSIN3A expression were detected by western blot. 
 
7.1.2 DDR downstream activation of p53 and its target genes is impaired by MS-275 
The protein p53 acts as an important effector downstream of the DDR signaling pathway 164. 
Treatment with HU led to the phosphorylation of the residues serine 15 (Ser15) and 
serine 20 (Ser20) within the N-terminus of p53 by apical and checkpoint kinases, 
respectively 75,76,80,81 (Figure 7.3 A). At the same time, application of HU increased the 
amount of total p53 protein due to the role of these particular phosphorylations for p53 
stabilization 165. Single treatment with MS-275 had no effect on p53 
phosphorylation (Figure 7.3 A). If MS-275 was applied simultaneously with HU though, a 
dramatic decrease in p53 phosphorylation of Ser15 and Ser20 could be detected. However, 
phosphorylation of the residue serine 46 (Ser46) was increased compared to single HU 
treatment (Figure 7.3 A). Both kinases reported to target this residue, HIPK2 (homeodomain-
interacting protein kinase 2) and DYRK2 (dual specificity Y-phosphorylation-regulated 
kinase 2) can be activated upon exposure to genotoxic stress 166,167. Total p53 protein was 
still increased compared to the control, although the protein was less stabilized than in cells 
treated with HU alone. 
In a next step, the MS-275-related attenuation of p53 activation should be verified by 
densitometric analysis of western blots. Several blots of Ser15 phosphorylated and total p53 
were measured. One representative example is shown in the right part of Figure 7.3 B. The 
signal intensities for treatment with either MS-275 or HU+MS-275 treatment were 
determined and related to that of single HU treatment (Figure 7.3 B). A statistical analysis of 
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the values showed, that MS-275 significantly diminished the HU-induced Ser15 
phosphorylation of p53 and the increase in p53 protein itself. Although p53 Ser15 
phosphorylation is reduced by about 70%, there is only 40% less p53 protein present in co-
treated cells compared to the effects of HU alone. 
 
 
Figure 7.3:  Impact of HDAC activity on the activation of p53 after HU treatment. 
(A) Analysis of three serine phosphorylation sites within the N-terminus of p53, which are phosphorylated after 
DNA damage. HCT116 cells were treated for 24 h with 1 mM HU and/or 2 µM MS-275. Phosphorylation of the 
indicated serine residues as well as the expression of total p53 and mSIN3A was analyzed with specific 
antibodies. (B) Left panel: Densitometric evaluation of p53 phosphorylation on serine 15 and total p53 levels 
(after 24 h treatment) from western blots. For treatment, same concentrations were used as in (A). Data were 
normalized to the individual loading control being used. The respective amount of (phosphorylated) protein is 
compared to that of HU-treated cells. Error bars represent the standard derivation (s.d.) of three independent 
experiments (*** P<0.001). Right panel: Western blots show one representative experiment used for 
densitometric analysis. α-Tubulin (henceforth referred to only as Tubulin) was used as loading control. 
 
The phosphorylation of p53 is inseparably linked to its function as a transcription factor. 
S phase stress, such as dNTP reduction caused by HU, triggers the expression of p53 target 
genes 168,169. Transcription of the genes encoding for HDM2, p21 (also known as CIP1/WAF1), 
and WIP1 proteins is positively regulated by p53. While p21 is an important cell cycle 
regulator 170, both the E3 ubiquitin ligase HDM2 and the phosphatase WIP1 are engaged in a 
negative feedback loop to downregulate p53 171,172 (see also Figure 3.6). As shown in 
Figure 7.4, the expression of these proteins was induced upon HU treatment. However, this 
expression was sensitive to MS-275. The levels of HMD2 and WIP1 were repressed after a 
treatment period of 24 hours, if HU was added in combination with the HDACi. In case of 
p21, MS-275 alone showed a strong induction of the protein. This effect has been described 
before 173. Nevertheless, joint application with HU impaired the MS-275-supported p21 
expression.   
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Figure 7.4:  Expression of p53 target genes in HCT116 cells. 
Cells were incubated with 1 mM HU and/or 2 µM MS-275 for 6 and 24 h. Western blots show detection of the 
p53 target genes HDM2, p21, and WIP1 from two membranes. In both cases, Tubulin was used as loading 
control.  
 
7.2 Class I HDACs affect cellular physiology and the sensitivity towards DNA 
damage 
7.2.1 Loss of HDAC activity amplifies hydroxyurea-induced DNA damage 
A very rapid event after the occurrence of genomic lesions is phosphorylation of the histone 
variant H2A.X on serine 139, commonly referred to as H2A.X 174. Both, ATR and ATM are 
among the reported kinases for H2A.X 34,46. In a cellular context, the formation of H2A.X foci 
can be used as a marker for DNA damage 175. 
In a first approach, the amount of H2A.X in cells was analyzed by western blot 
(Figure 7.5 A). Treatment with HU for 24 hours showed an accumulation of H2A.X, whereas 
no phosphorylation of H2A.X could be found in cells incubated with MS-275 alone. If HCT 
cells were incubated with HU and the HDAC inhibitor together, an even stronger H2A.X 
signal was detectable compared to single HU treatment.  To further analyze whether the 
increased amount of H2A.X was only randomly distributed in the genome or localized in 
defined foci, confocal fluorescence microscopy was performed. As shown in Figure 7.5 B, 
control cells incubated with DMSO as solvent control and MS-275 treated cells generated no 
foci. In contrast, incubation with HU resulted in the formation of H2A.X. This amount of 
H2A.X within the nucleus varied among single cells and a range from less to more damaged 
cells was visible. When MS-275 was applied together with HU, the same variability occurred. 
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Additionally, some cells with an extremely high amount of H2A.X appeared. Single HU 




Figure 7.5:  Incidence of H2A.X in HCT116 cells. 
(A) Cells were treated with 1 mM HU, 2 µM MS-275 or both for 24 h, whereas control cells were incubated only 
with DMSO. Whole cell lysates were analyzed for H2A.X phosphorylation (H2A.X) by western blot. Some lines 
of the blot were cut out, which is denoted by a vertical line. (B) Treatment of HCT cells was carried out as in (A). 
After 24 h, cells were fixed and stained for H2A.X (green). Corresponding DAPI (blue) and DIC (Differential 
interference contrast) images are shown, too. Scale bar = 10 µm.  
 
7.2.2 Hydroxyurea-induced S phase arrest is counteracted by MS-275 
In order to repair damaged DNA and to prevent new lesions, the cell cycle becomes arrested 
by a variety of pathways during replication stress 70,176.  Hydroxyurea has been shown to halt 
the cell cycle in S phase 177,178. After 24 hours of treatment with HU, cell cycle analysis indeed 
showed an arrest of cells in S phase and therefore a reduced percentage of cells in G2 phase 
and mitosis (G2/M) compared to the control (Figure 7.6 A). The HDAC inhibitor MS-275 
generated an arrest in G1 with depletion of the S phase (Figure 7.6 A lower part). Combined 
application of HU and MS-275 resulted in a cell cycle profile that also showed an 
accumulation of cells in S phase. However, unlike with HU treatment, far more cells have 
progressed towards and in G2/M. The bar diagram in Figure 7.6 A shows that the relative 
amount of cells in G2/M after this treatment is nearly equal to that of untreated cells.  
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Figure 7.6:  MS-275 abbreviates the HU-induced S phase arrest. 
(A) Upper part: Cells were incubated with DMSO as solvent control, 1 mM HU and/or 2 µM MS-275 for 24 h, 
and subsequently fixed for PI staining. Cell cycle distribution was analyzed by flow cytometry. Amount of cells 
in G2/M is depicted in the diagram and is represented as fold of control. Results show the mean of three 
independent experiments. Error bars indicate s.d. values. Lower part:  Cell cycle profile of one representative 
experiment used for generation of the bar diagram above. Profiles display cell cycle distribution of 10,000 cells 
each. Color coding for treatments: see upper bar diagram. DNA content 2n = G1 phase; DNA content 
4n = G2/M phase; DNA content in between = S phase (B) Treatment with 1 mM HU alone or in combination 
with 2 µM MS-275 was carried out for the indicated time periods (16-28 h). Cell cycle analysis revealed the 
progression of cells through the cell cycle. Profiles display cell cycle distribution of 10,000 cells each. Image 
shows one representative out of three independent experiments. 
In a next step, cell cycle progression should be investigated in greater detail, to gain more 
information about the differences between HU and HU+MS-275 treatment on cell 
replication. HCT116 cells were incubated with the respective drugs for a period of 16 to 
28 hours and cell cycle profiles were determined every two hours (Figure 7.6 B). After 
16 hours, cell cycle profiles for both treatments were still very similar and displayed an 
accumulation of cells at the transition from G1 to S phase. From a period of 18 hours, cell 
cycle progression through S phase remained strongly decelerated in cells incubated with HU. 
In contrast, cells treated with HU and MS-275 overcame HU-induced S phase arrest much 
faster. This is demonstrated by a more rapid increase of DNA content during S phase and the 
increasing amount of cells in G2/M (DNA content 4n) compared to single HU application. 
Therefore, HDAC inhibition seems to counteract the HU-induced retention of cells in S phase 
and promotes their progression towards G2 phase and mitosis. 
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7.2.3 MS-275 increases the cytotoxicity of hydroxyurea 
Hydroxyurea as a chemotherapeutic substance induces apoptosis in cancer cells 156,179,180. 
Since it has been reported that HDACi are able to increase this effect 156,157, initiation of 
apoptotic cell death was examined. Initial western blot experiments were performed with an 
antibody that specifically recognizes the 89kDa cleavage product of poly(ADP-ribose)-
polymerase-1 (PARP-1). This fragment results from site-specific cleavage of full-length PARP-
1 protein by Caspase 3 181,182. The presence of cleaved PARP is considered as a marker of 
apoptosis 183. Only long-time exposure to HU for 24 hours resulted in a signal for cleaved 
PARP protein by western blot analysis (Figure 7.7 A). The same time-period of incubation 
with MS-275, on the other hand, only showed a very faint band for PARP cleavage. Of note, 




Figure 7.7:  MS-275 enhances apoptosis in cells with HU-induced replicative stress. 
(A) HCT116 cells were treated with 1 mM HU and 2 µM MS-275 for 6 and 24 h. Whole cell lysates were 
analyzed for PARP-1 cleavage (cl. PARP) and mSIN3A by western blot. (B)  FACS analysis of HCT116 cells with 
Annexin V. Bars indicate the amount of apoptotic cells within a sample. Cells remained untreated or were 
treated with 1 mM HU, 2 µM MS-275 or both for 24 and 48 hours. Error bars represent the s.d. of three 
independent experiments (** P<0.01) (C) Fraction of HCT116 cells in subG1 was determined by FACS analysis 
after PI staining. Cells were treated as in (B). Error bars represent the s.d. of three independent experiments 
(* P<0.05). 
Early apoptotic cell death was further quantified by staining cells with Annexin V and 
subsequent flow cytometry analysis (FACS). Annexin V exclusively binds to 
phosphatidylserine, which becomes exposed on the cell surface due to loss of membrane 
asymmetry after induction of apoptosis 184. After 48 hours of incubation with HU, about 20% 
of cells had become apoptotic. If HU-stressed cells were co-stimulated with MS-275, the rate 
of apoptosis significantly increased and approximately doubled (Figure 7.7 B). The same 
results were obtained with subG1 fractions after cell cycle analysis (Figure 7.7 C). Samples 
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treated with both agents, HU and MS-275, showed a significantly increased amount of cells 
in subG1 compared to the single treatment schedules. For single MS-275 treatment nearly 
the same percentage of subG1 fraction was determined as for HU incubation. Taken 
together, additional application of the HDACi MS-275 sensitized HCT116 cells for the 
cytotoxic effect of HU.  
  
7.3 Mimicking the effects of MS-275 through inhibition of individual DDR 
kinases  
7.3.1 Depletion of checkpoint kinase activity during S phase stress 
Stalled replication forks, like induced by HU, primarily cause activation of ATR and 
subsequently of the whole DDR 185. ATR not only activates its direct downstream target 
CHK1, but also cross-activates the ATM-CHK2 axis and thereby lays the foundation for a 
global cellular reaction to stress 9,17. To decipher the DDR after HU+MS-275 treatment, it was 
tested how inhibition of individual DDR kinases affects the signaling outcome. First, the 
putative role of checkpoint kinases CHK1 and CHK2 was evaluated. The inhibitor UCN-01 
shows a much higher specificity for CHK1 than for CHK2 and was chosen to abrogate CHK1 
activity 186. In combination with HU, UCN-01 enhanced cleavage of the repair protein PARP-1 
after 24 hours (Figure 7.8 A). Cells also showed increased levels of p53 phosphorylation at 
Ser15 and a little less at Ser20, which consequently stabilized p53 protein. These results do 
not completely match with the effects of MS-275 on HU-induced DDR signaling and 
suggested that CHK1 function is not the essential target of MS-275.  
The role of CHK2 was examined in CHK2-negative HCT116 cells, which were compared to 
their wild-type counterparts (Figure 7.8 B). The induction of apoptosis during HU treatment 
was monitored by PARP cleavage and revealed that induction of apoptotic cell death after 
24 hours was much stronger in wild-type cells than in cells lacking CHK2. Also, p53 
accumulated to the same extent in both cell lines after application of 1 mM HU, whereas the 
basal level of p53 protein in CHK2-/- cells was a little higher. Both events are in contrast to 
the MS-275-dependent increase of apoptosis and downregulation of p53 (Figure 7.3 
and 7.7). Taken together, neither CHK1 nor CHK2 depletion shows the same consequences 
for cells like adding MS-275 during exposure to HU.  
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Figure 7.8:  Effects of absent checkpoint kinase activity during HU treatment. 
(A) HCT116 cells were pre-incubated with 100 nM UCN-01 for 1 h and subsequently treated with 1 mM HU for 
24 h. The same whole cell lysate was blotted to two membranes for detection of PARP-1 cleavage as well as 
total p53 and p53 phosphorylation by western blot. mSIN3A and HSP90 were used as independent loading 
controls. (B) HCT116 cells and their comparative CHK2
-/-
 cell line were treated with 1 mM HU for 6 and 24 h. 
PARP-1 cleavage, p53, CHK2, and Actin were detected.  
 
7.3.2 Selective inhibition of ATR and ATM during S phase stress 
On the next step, the apical kinases ATR and ATM were selectively inhibited to investigate 
whether repression of their catalytic activity during replication stress is determining for the 
effects observed with MS-275. Inhibition of ATR was achieved by means of the novel and 
highly ATR-selective compound ETP-46464 187. ETP-46464 was administered alone for 
24 hours or combined with HU for six and 24 hours to HCT116 cells. The ATR inhibitor 
efficiently abrogated CHK1 phosphorylation after treatment with HU thus abolished ATR 
kinase activity for up to 24 hours (Figure 7.9 A). Western blot analysis indicated that basal 
amounts of cleaved PARP fragment were comparable in control cells cultured with and 
without ETP-46464. However, HCT116 cells had already triggered PARP cleavage after six 
hours if ETP-46464 was applied together with HU. Additionally, longer co-administration 
with the ATR inhibitor for 24 hours generated a much higher level of the apoptotic PARP 
fragment than single HU application. This was accompanied by a strongly enhanced Ser1981 
phosphorylation of ATM at both time points, which did not occur in cells treated with ETP-
46464 alone. The ATR inhibitor further on decreased the HU-induced phosphorylation of p53 
at Ser15, but increased phospho-Ser46 resulting in an overall lower amount of total p53 
protein compared to single exposure to HU.  
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For depletion of ATM activity, the ATP-competitive inhibitor KU-55933 was employed. KU-
55933 is able to inhibit all PIKK family members, but shows the highest specificity for 
ATM 188. In the experimental setup, HCT116 cells were exposed to HU and KU-55933 either 
alone or together for 24 hours. KU-55933 was administered at previously described 
concentrations 189,190. When phospho-Ser1981 ATM signals were detected by western blot, 
addition of the ATM inhibitor to HU did not show suppressed ATM auto-phosphorylation 
(Figure 7.9 B). However, Ser15 phosphorylation of p53 was impaired and also total p53 
protein was less present if KU-55933 was applied together with HU. Rather unexpected, also 
HU-induced CHK1 activation was diminished by KU-55933. Phosphorylation of CHK2 after 
replication stress though was intensified if ATM was inhibited, which is contrary to CHK2 as 
an important downstream target of the ATM kinase. Finally, a stronger signal for apoptotic 
PARP conversion was observed when HU was jointly applied with KU-55933. 
 
 
Figure 7.9:  Effects of exogenous inhibitors for ATR and ATM during hydroxyurea treatment. 
(A) HCT116 cells were pre-incubated with the specific ATR inhibitor ETP-46464 (3 µM) for 1 h and subsequently 
treated with 1 mM HU for additional 6 and 24 h. Control cells incubated with solvent or ETP-46464 alone were 
harvested after 24 h. Whole cell lysates were analyzed with specific antibodies by western blot. Actin was used 
as loading control (C) Cells were pre-incubated with 10 µM KU-55933 for 1 h and treated with 1 mM HU for 
additional 24 h. Total and phosphorylated proteins were detected on three different membranes from the 
same whole cell lysate with mSIN3A as loading control in each case. 
The results obtained with both, ATM and ATR kinase inhibitors resemble the effects of MS-
275 on HU-induced signaling to a large extent. Since ATR is the initial kinase of replication 
stress signaling, its role in apoptosis induction and cell cycle control was more closely 
investigated by PI and Annexin V staining for treatment with HU, ETP-46464, or both 
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compounds (Figure 7.10 A). Single application of ETP-46464 only marginally increased the 
relatively low basal level of apoptosis. HU alone evoked apoptosis in only 15% of cells after 
48 hours whereas simultaneous loss of ATR activity resulted in a significantly higher rate with 
50% Annexin V-positive cells (Figure 7.10 A).  
 
 
Figure 7.10:  Effect of the ATR inhibitor ETP-46464 on apoptosis and cell cycle progression. 
(A) Apoptotic cell death was determined by staining with Annexin V and subsequent measurement by flow 
cytometry. 3 µM ETP-46464 (3 µM) or DMSO as solvent control were pre-incubated for 1 h, then 1 mM HU was 
added for further 48 h. Diagram shows the mean ± s.d. of three independent experiments (*** P<0.001). 
(B) Pre-treatment with 3 µM ETP-46464 or DMSO as solvent control for 1 h was followed by incubation with 
1 mM HU for the indicated time periods (16-26 h). FACS analysis with PI staining revealed the progression of 
cells through the cell cycle. Profiles display cell cycle distribution of 10,000 cells each. The shown experiment 
was only conducted once. (C) Diagram depicts the amount of subG1 cells after the indicated treatments. 
Results were obtained during the experiment shown in (B). 
Cell cycle progression of HCT116 cells was analyzed for three time points in a period of 18 to 
26 hours. The respective cell cycle profiles for HU treated cells with active (HU) and inhibited 
ATR kinase (HU + ETP) are shown in Figure 7.10 B. Exposure to HU for 16 hours caused 
accumulation of cells in G1 and S phase and such cells slowly migrated towards and through 
S phase in the following eight hours. In contrast, HCT cells with ETP-46464-inactived ATR did 
not develop this typical S phase arrest in presence of HU. The majority of these cells stayed 
in G1 phase over the entire treatment period. Yet, with time, an increasing amount of subG1 
was detected indicating ongoing cell death (Figure 7.10 C). Incubation with HU or ETP-46464 
alone caused amounts of subG1 fraction comparable to control samples and varying from 1 
to 3%. When HCT cells were exposed to both substances at the same time, though, the 
percentage of subG1 considerably increased. About 5% of cells were present in subG1 after 
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16 hours of co-treatment and this rate further increased to 9% after 22 hours and almost 
12% subG1 fraction after 26 hours. The results can be considered as a hint for the time-
dependent increase of dead cells during the respective treatments.  
Thus, inhibition of ATR kinase activity by ETP-46464 disrupted the usual S phase arrest in 
cells suffering from replicative stress and in the same context potentiated the induction of 
apoptosis. Both processes were similarly evoked in HU-treated HCT116 cells by addition of 
MS-275 (see Figures 7.6 and 7.7). 
 
7.4 A link between HDAC1/2 and PP2A phosphatase activity 
7.4.1 Time-dependent inactivation of the DNA damage response by MS-275  
At the beginning it was shown that HU-induced phosphorylation of DDR kinases and 
downstream p53 was diminished or even lost after 24 hours, but not after six hours of co-
treatment with MS-275 (Figures 7.1 A, Figure 7.3). This suggested a time-dependent 
disabling effect of the applied HDACi on replication stress signaling.  
Based on this finding, MS-275 pre-treatment for 16 hours was included in a next experiment. 
After MS-275 incubation overnight, HU was added for six, ten and 14 hours. Whole cell 
lysates were compared to those with simultaneous HU+MS-275 and single HU application 
for the same time periods (see treatment regimen in Figure 7.11). Stimulation with HU 
resulted in a stable activation of ATM, CHK1 and p53 (Figure 7.11). Additional treatment with 
MS-275, however, strongly decreased the phosphorylation of ATM over time, which was 
nearly gone after 14 hours. Also, activation of CHK1 and downstream generation of Ser15-
phosphorylated p53 was reduced. Strikingly, pre-treatment with MS-275 prior to HU 
application almost completely blunted activation of the DDR. This is illustrated by the very 
low levels of phosphorylated ATM and CHK1, which were detected by western blot. 
Furthermore, stabilizing Ser15 phosphorylation of p53 was strongly inhibited.  
These data strongly suggested that MS-275 modifies the cellular gene expression pattern, 
which could be causal for downregulation of the DDR in cells exposed to HU. Thus, HDAC 
activity is necessary to maintain replication stress signaling.  
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Figure 7.11:  Loss of HDAC activity diminishes hydroxyurea-induced DDR signaling in a time-dependent 
manner. 
Upper part illustrates the applied treatment regimen. HCT116 cells were stimulated with 1 mM HU alone or 
together with 2 µM MS-275. Wedges indicate increasing incubation periods of 6, 10 and 14 h, respectively. 
Asterisks mark pre-incubation with MS-275 for 16 h. Whole cell lysates were analyzed for phosphorylation of 
shown proteins by western blot, with Vinculin used as loading control. 
 
7.4.2 HDACs suppress expression of the PP2A regulatory subunit B´´ PR130  
HDAC inhibitors are able to activate or repress the transcription of various genes by direct 
and indirect mechanisms 113,120. In order to investigate the potential impact of MS-275 on 
the proteome of HCT116 cells, microarray analysis was performed at the European 
Molecular Biology Laboratory (EMBL, Heidelberg). The dataset obtained was searched for 
genes whose transcription was altered by the HDACi and which could possibly be involved in 
S Phase signaling pathways. One of the genes that were identified to be affected by MS-275 
was PPP2R3A. PPP2R3A encodes for specific regulatory subunits of the serine/threonine 
protein phosphatase 2A (PP2A). Since all of the phosphorylation sites of checkpoint kinases 
and p53 detected in this study are phosphorylated serine or threonine residues, PP2A was 
considered as a potential regulator of their phosphorylation level.  
In a first approach, the general impact of this phosphatase on DDR kinase phosphorylation 
was assessed by using specific PP2A inhibitors. One inhibitor with high selectivity for PP2A is 
Cantharidin 191. HCT cells were treated with HU alone or in combination with MS-275. After 
24 hours, Cantharidin was added in two concentrations for the following four hours. Analysis 
of whole cell extracts by western blot revealed that Cantharidin had almost no impact on the 
activity of DDR kinases in control cells (Figure 7.12 A). Induction of the DDR by HU was 
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shown by the phosphorylation of ATM and CHK1. Additional exposure to Cantharidin further 
boosted these phosphorylation levels and also enhanced the signal for pCHK2. As shown 
before, the addition of MS-275 reduced the basal amount of phosphorylated ATM and CHK1 
during simultaneous incubation with HU. Intriguingly, Cantharidin was able to reverse this 
effect within four hours. It counteracted the effect of MS-275 and elevated the 
phosphorylation of all three shown kinases to levels comparable with those of HU-treated 
cells.  
A second highly specific PP2A inhibitor, Okadaic acid (OA), was applied in a similar 
experimental setup 192. Cells were left untreated or were incubated with HU and MS-275, 
either alone or in combination, for 24 hours. Then, OA was applied only to co-treated cells 
and incubation was continued for further four hours. Western blots revealed that OA almost 
completely abrogated the negative effect of MS-275 on DDR signaling (Figure 7.12 B). 
Phosphorylation of ATM and also CHK1 was restored in presence of the PP2A inhibitor. The 
total amount of ATM protein remained the same throughout all treatment regimens.  
 
 
Figure 7.12:  Inhibitors of PP2A restore DNA damage and checkpoint signaling. 
(A) HCT116 cells were cultured without treatment for control, with 1 mM HU alone or in combination with 
2 µM MS-275 for 24 h. Afterwards, cells were incubated with the PP2A inhibitor Cantharidin (20; 40 µM) for 
additional 4 h. Phosphorylated ATM, CHK1, CHK2, and mSIN3A as loading control were detected with specific 
antibodies by western blot. (B) Cells were left untreated as control or were incubated with 1 mM HU and/or 
2 µM MS-275 for 24 h. PP2A inhibitor Okadaic acid (OA; 25 nM) was added for further 4 h. Proteins were 
detected by western blot. 
The results obtained with both phosphatase inhibitors, Cantharidin and OA, pointed to a role 
of PP2A in the orchestration of the replication stress response. Therefore, the contribution 
of PPP2R3A to DDR signaling and its putative control by HDACs was investigated in greater 
detail. Since microarray analysis showed an induction of PPP2R3A by MS-275, this should be 
validated by quantitative RT-PCR. After six and 24 hours, mRNA levels of HU, MS-275 and co-
treated cells were analyzed and compared to that of untreated control cells (Figure 7.13 A). 
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Hydroxyurea did not alter the mRNA amount of PPP2R3A. Also additional application of MS-
275 and single exposure to the HDACi for six hours had not affected mean PPP2R3A mRNA 
levels. Administration of MS-275 for 24 h, on the other hand, led to a significant 2.5-fold 
increase of PPP2R3A transcript level. This effect was even more pronounced and highly 
significant for cells co-treated with HU.  
 
 
Figure 7.13:  PP2A regulatory subunit PR130 is upregulated by MS-275. 
(A) Mean relative mRNA expression levels of PPP2R3A in HCT116 cells evaluated by quantitative RT-PCR. Cells 
were treated with 1 mM HU and 2 µM MS-275 for 6 and 24 h. Error bars represent the s.d. of three 
independent experiments. (** P<0.01; *** P<0.001). (B) HCT116 cells were cultured without treatment or with 
increasing amounts of MS-275 (0.5; 1; 2; 5 µM) alone or in combination with 1 mM HU for 24 h. Respective 
proteins were detected by western blot. 
Whether elevated mRNA levels of PPP2R3A also increased the amount of encoded protein 
was analyzed by western blot. A total of three transcript variants have been reported for 
PPP2R3A, which are generated by alternative splicing or alternative initiation of 
translation 193. Only two of them though, PR72 and PR130, were studied so far. PR72 is 
present exclusively in heart and skeletal muscle, while PR130 is expressed ubiquitously in all 
tissues 101,194 (see also Figure 3.7). Thus, HCT116 cells were probed for PR130 protein. 
Western blot analysis showed that PR130 levels were elevated by MS-275, which is 
consistent with the increase of PPP2R3A mRNA (Figure 7.13 B). Moreover, this effect was 
concentration-dependent. PR130 progressively accumulated with rising doses of MS-275 and 
this increase was also detected together with HU treatment. Intriguingly, HU-induced 
phosphorylation of ATM diminished as PR130 protein accelerated. ATM kinase is located and 
acts predominantly in the nucleus of a cell 195,196. To be directly connected with ATM 
phosphorylation levels, PR130 would have to be present in the nucleus as well. Therefore, 
cytosolic and nuclear extracts of HCT cells were analyzed for PR130 distribution. Figure 7.14 
reveals that the regulatory subunit was mainly located in the cytosol. Only 5 to 10% of total 
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PR130 protein appeared in the nuclear fraction. Yet, its protein level was increased by MS-
275 in both compartments to the same extent. Phosphorylated ATM was detected almost 
exclusively in the nucleus and the inhibitory effect of MS-275 on HU-induced ATM activation 
was observed again. mSIN3A as nuclear and α-Tubulin as cytosolic loading control remained 
equal. 
Taken together, MS-275 elevates expression of the PP2A regulatory subunit PR130 on both 
mRNA and protein level. Upregulation of PR130 correlated with the loss of HU-induced ATM 
phosphorylation on Ser1981, while addition of specific inhibitors for PP2A was able to 
restore this phosphorylation.  
 
 
Figure 7.14:  PR130 protein is mainly located in the cytoplasm. 
HCT116 cells were left untreated for control or were incubated with 1 mM HU and 2 µM MS-275 alone or in 
combination for 24 h. Nuclear and cytosolic extracts were analyzed for the shown proteins by western blot. 
Tubulin was used as cytosolic and mSIN3A as nuclear loading control. (* a band which reflects remaining PR130 
antibody on the membrane) 
 
7.4.3 Simultaneous knockdown of HDAC1 and HDAC2 is sufficient to mimic the effects 
of MS-275  
The histone deacetylase inhibitor MS-275 specifically impedes the activity of HDAC1, HDAC2 
and HDAC3 120. Since replication stress signaling induced by HU is attenuated by MS-275, 
either the activity of a single or more than one of these HDACs is necessary to maintain the 
DDR cascade. Hence, it was studied which HDACs mediate the effects observed with MS-275. 
In a first attempt, transfection protocols for the knockdown of these HDACs by siRNAs were 
established. Simultaneous double and triple knockdowns were performed in all possible 
combinations of HDAC1, HDAC2 and HDAC3 in HCT116 cells. The final protocols for siRNAs 
RESULTS  HDACs regulate phosphatase activity  
page | 53 
  
application resulted in high knockdown efficiencies of at least 70 to 90% for HDAC2 and 
almost 100% for HDACs 1 and 3 (Figure 7.15 A). These efficiencies were stable in all setups. 
Also, treatment with HU for 24 hours did not affect the knockdown of HDACs.  
 
 
Figure 7.15:  Simultaneous knockdown of HDAC1 and HDAC2 is necessary to attenuate HU-induced DDR 
signaling. 
(A)  Efficiencies for double and triple knockdown with siRNAs against HDAC1, 2 and/or 3. HCT116 cells were 
transiently transfected with siRNA against HDACs 1-3. After 48 h of incubation, 1 mM HU was added for further 
24 h.  (B) Whole cell lysates were used for evaluation of the shown proteins and their phosphorylation by 
western blot. Time schedule of transfection and treatment was the same as in (A). Both experiments were 
carried out by Maria Schreiber, former Master student of AG Krämer, FSU Jena. 
With the established protocols for siRNAs, the putative role of HDACs1-3 in the modulation 
of DDR signaling was tested. Therefore, activation of ATM-CHK2 and ATR-CHK1 pathways 
was evaluated by the detection of pATM, pCHK1 and pSer15 p53 via western blot 
(Figure 7.15 B). Transfection of cells with scrambled siRNA and knockdown of HDACs itself 
did not cause activation of DDR signaling. No signals for phosphorylated ATM, CHK1 or p53 
were obtained. Replication stress triggered by HU resulted in regular phosphorylation of all 
three proteins in control cells. Double knockdown of HDAC1 and 3 (siHDAC1/3) even slightly 
increased the level of pATM, but did not affect pCHK1 or pSer15 p53. The same was true for 
cells transfected with HDAC2/3 targeting siRNAs. Loss of these HDACs showed unchanged 
phosphorylation of DDR kinases and p53 during HU treatment compared to control cells. 
Interestingly, phosphorylation of ATM, CHK1 and p53 by HU was diminished in cells lacking 
HDAC1 and 2 (siHDAC1/2). Additional depletion of HDAC3 (siHDAC1/2/3) likewise showed 
reduced activation of these DDR proteins. However, simultaneous knockout of HDAC3 did 
not further reduce phosphorylation of ATM, CHK1 or p53 in comparison to HDAC1/2 
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depleted cells. Unequal amounts of total ATM and CHK1 could not account for their reduced 
phosphorylation level as their constant expression was verified by respective western blots 
(Figure 7.15 B). Further detection of PARP protein showed that knockdown of HDAC1/2 and 
HDAC1/2/3 created a distinct second signal at a lower molecular weight in the context of HU 
treatment. This signal represents the 89kDa fragment of PARP cleavage and indicates 
apoptotic cell death. While this fragment was also observed in control cells incubated with 
HU, it was even more abundant in cells transfected with siHDAC1/2 and siHDAC1/2/3. Again, 
depletion of HDAC3 showed no additional effect.  
Since knockdown of HDAC1/2 and HDAC1/2/3 successfully mimicked the effects of MS-275 
on HU-induced DDR signaling and apoptosis, their putative role on PR130 expression was 
tested next. Simultaneous transfection of siRNAs for HDAC1 and HDAC2 elevated PR130 
protein as shown by western blot (Figure 7.16). This induction was independent of HU. 
Furthermore, the intensity of PR130 signals after HDAC1-3 triple knockdown was the same 
as for HDAC1/2 depletion.  
In summary, simultaneous knockdown of HDAC1 and HDAC2 was sufficient to modulate the 
cellular response to HU. It increased PR130 protein (Figure 7.16), attenuated 
phosphorylation of important DDR mediators and finally sensitized cells for apoptotic PARP-
1 cleavage (Figure 7.15). Further depletion of HDAC3 showed no additional impact on the 
examined processes.  
 
 
Figure 7.16:  Simultaneous knockdown of HDAC1 and HDAC2 increases PR130 protein. 
Knockdown of HDAC1/2 and HDAC1/2/3 was performed with respective siRNAs by transient transfection. After 
48 h of incubation, 1 mM HU was added for further 24 h. PR130 expression was analyzed by western blot. 
mSIN3A was used as loading control. The experiment was carried out by Maria Schreiber, former Master 
student of AG Krämer, FSU Jena. 
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7.5 PP2A-PR130 as a potential phosphatase of ATM 
7.5.1 Elimination of PR130 restores ATM phosphorylation 
The experiments described so far revealed, among other things, that MS-275 interferes with 
replication stress-driven signaling (Figure 7.1) and increases expression of the PP2A 
regulatory subunit PR130 in HCT116 cells (Figure 7.13). It was also shown that PP2A 
inhibitors are able to counteract the effect of MS-275 on DDR signaling (Figure 7.12). 
However, a direct link between the upregulation of a phosphatase subunit and potentially 
increased dephosphorylation of DDR kinases was still missing.  
 
 
Figure 7.17:  Knockdown of PR130 restores ATM phosphorylation. 
HCT116 cells were transfected with control siRNA or the indicated amounts of PPP2R3A-specific siRNA. After 
24 h of incubation, 1 mM HU and 2 µM MS-275 were added and incubation was extended for additional 24 h. 
Whole cell lysates were used for protein detection by western blot. 
For this reason, a specific siRNA for PPP2R3A was employed. Different concentrations of the 
siRNA were used to knock down PR130 protein. As a control, scrambled siRNA was 
transfected to HCT116 cells and after 24 hours of incubation cells were either left untreated, 
were exposed to HU or HU+MS-275 for a total of 48 hours. The same time schedule was 
used for the transfection of siPPP2R3A. Only these cells were solely exposed to the 
combination treatment of HU and MS-275 or remained untreated. Western blot analysis of 
PR130 protein showed its induction by MS-275 in control cells (Figure 7.17). Also, 
transfection with scrambled control siRNA did not affect HU-induced ATM phosphorylation 
or its loss during co-administration with the HDACi. The specific siRNA for PPP2R3A was able 
to reduce the basal level of PR130 by at least 90%. Application of the siRNA showed a dose-
dependent knockdown of the PP2A subunit. An amount of 40 pmol PPP2R3A siRNA was 
sufficient to completely block the induction of PR130 by MS-275. More importantly, 
PPP2R3A siRNA dose-dependently restored ATM phosphorylation in cells exposed to HU and 
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MS-275. The less PR130 was present, the more ATM molecules were phosphorylated. This 
fact points to a direct connection of ATM phosphorylation and PR130 protein level. 
 
7.5.2 PR130 physically interacts with ATM  
A necessity for the involvement of PR130 in dephosphorylation of ATM is direct interaction 
of the phosphatase with the targeted kinase. Since regulatory subunits mediate PP2A target 
specificity 97 PR130 should be present in the complex of phospho-protein and phosphatase. 
Therefore, pATM antibody was used for co-immunoprecipitation experiments. HCT116 cells 
were treated with HU and MS-275 for 24 hours to induce PR130. The resulting low level of 
pATM was restored by further incubation with OA for four hours (see Figure 7.12 B) to 
provide enough potential interaction partners. Those enzyme-substrate complexes would be 
very transient. Therefore, they were stabilized prior to lysis by fixation with 1% 
formaldehyde. This method would also prevent detachment of the proteins during 
purification of precipitates. As negative controls, normal IgG of pre-immune serum or no 
antibody were used for immunoprecipitation. Both controls showed no signals for pATM or 
PR130 in western blot (Figure 7.18). By using pATM antibody, phosphorylated ATM was 
successfully precipitated from whole cell lysates. Finally, detection for co-
immunoprecipitated PR130 resulted in a distinct signal at the same molecular weight as for 
PR130 in the input control. 
 
 
Figure 7.18:  Endogenous PR130 physically interacts with phosphorylated ATM in vivo. 
After 20 h of treatment with 1 mM HU and 2 µM MS-275, Okadaic acid (OA, 25 nM) was added for further 4 h. 
Co-immunoprecipitations (IP) with anti-pSer1981-ATM antibody, rabbit pre-immune serum (Pre) or no 
antibody (no AB) were analyzed for ATM phosphorylation (Ser1981) and PR130 protein by western blot with 
specific antibodies. Right panel shows anti-pATM and anti-PR130 immunoblots of the initial lysate (6% Input, 
IN).  
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The experiment showed that PR130 physically interacts with phosphorylated ATM in HCT116 
cells. Of note, neither of the proteins was artificially expressed and precipitation was 
performed with endogenous protein levels.  
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8 DISCUSSION 
 The use of anti-metabolites in cancer therapy has become a standard chemotherapeutic 
approach for a variety of malignancies 197. Among them are hydroxyurea (HU) and 5-
Fluorouracil (5-FU), which are established drugs for leukemia and various solid tumors 154,162. 
Both compounds act in a similar manner as they interfere with the de novo synthesis of 
deoxynucleotide triphosphates (dNTPs) – the building blocks of DNA 162,198. Consequently, a 
shortage of dNTPs during replication of the genome impedes the complete duplication of 
chromosomes, which is a prerequisite for cell division. Thus, it provokes activation of the 
replication checkpoint that functions to stabilize stalled replication forks until the stress is 
relieved and replication can continue 199. If the onset of this checkpoint was defective, 
delayed, or to weak, cellular survival would be endangered. Several in vitro studies showed 
that the desired cytotoxic effect of HU and 5-FU on cancer cells could be increased when 
histone deacetylase inhibitors (HDACi) were applied simultaneously with the anti-
metabolites 156,157,200.  
8.1 Inhibition of HDACs interferes with DDR signaling and cell replication  
The first line mediator of DNA damage response signaling upon replication stress is the ATR-
CHK1 pathway 17,71,201. Incubation with HU obstructs replication fork progression and in turn 
creates long stretches of RPA-coated ssDNA, which are the ultimate trigger for activation of 
ATR 19. The phosphorylation of its downstream target CHK1 at Ser317 was used as readout 
for the catalytic activity of ATR in the present study 63 (Figure 7.1 A). Besides activation of 
CHK1, also ATM and CHK2 phosphorylation were detected in response to HU 9. These should 
be considered as secondary downstream effects and this is also illustrated by the increase of 
pATM levels from six to 24 hours of treatment. The agent 5-FU was used as reference 
compound and similarly induced DDR signaling in HCT116 cells (Figure 7.1 B). ATM kinase 
was described as a direct target of active ATR after UV radiation and replication stress 9. It 
was shown that ATM is phosphorylated at Ser1981 in an ATR-dependent manner, which in 
turn promoted ATM activity and CHK2 phosphorylation. Additionally, ATM activation could 
be a cause of occurring DNA double-strand breaks (DSBs). After prolonged exposure to 
replication stressors like HU, blocked replication forks progressively collapse and generate 
fork-associated DSBs that thereupon mediate ATM signaling 36,202. Resolution of these DSBs 
by homologous recombination (HR) in return triggers ATR activity 18,203. Both paths leading 
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to ATM phosphorylation do not exclude each other and are likely to run in parallel. DSB-
associated ATM activation though should be induced at a later time.  
Figure 7.1 further shows that even long-time exposure of HCT cells to the HDACi MS-275 
does not induce DDR signaling, although HDACi alone can cause damage to DNA 113. 
However, MS-275 did affect HU- and 5-FU-induced DNA damage signaling in a way that 
reduced DDR kinase phosphorylation after long periods of co-treatment with the HDACi 
(Figure 7.1). Especially the experiment performed with HU showed a clear time-dependent 
loss of kinase activation in presence of MS-275. Phosphorylation of ATM, CHK1, and CHK2 is 
still comparable to the HU-induced DDR after six, but diminished after 24 hours. Increased 
modification by acetylation often alters mRNA or protein stability and can favor stabilization 
as well as (proteasomal) degradation depending on the modified mRNA/protein 111. 
Inhibition of HDACs by MS-275 showed no impact on the protein level of ATM and 
checkpoint kinases. Consequently, a reduced amount of kinase molecules in the cell as cause 
for their attenuated phosphorylation after 24 hours of co-treatment with HU and MS-275 
can be excluded for the shown experimental setups. The kinase ATM of the DDR cascade is a 
reported target for acetylation by the HAT TIP60 41. The associated deacetylase for ATM is 
unfortunately unknown until today, although it was shown that the kinase is localized in a 
complex with catalytically active HDAC1 204. So MS-275 would (if at all) increase acetylation 
of ATM. Sun et al. also delineated in their work that acetylation is necessary for activation of 
ATM. This way, HDAC inhibition would rather increase activity or phosphorylation of ATM, 
but not account for suppressed pATM levels. 
To investigate whether the obtained effects corresponded to a general mechanism, other 
cell lines were examined for ATM phosphorylation (Figure 7.2). For this, the p53 negative 
counterpart to HCT116 wild-type cells as well as MEF cells, both harboring and lacking p53 
wild-type protein, were chosen. RKO cells were additionally tested as a second cell line 
originating from human colon carcinoma. In each case, HDAC inhibition by MS-275 reduced 
the amount of phosphorylated ATM after 24 hours of co-incubation with HU. In RKO cells, 
the depletion of DDR signaling already occurred after a short period of six hours. Thus, they 
appear more sensitive to MS-275 compared to HCT116 cells. The results demonstrate that 
sustained replication stress signaling requires class I HDAC activity and that this seems to be 
a universal regulatory mechanism (at least for ATM). The MS-275-dependent loss of ATM 
activity affected murine cells in the same way as human cells and is independent of p53.  
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The tumor suppressor p53 is an important downstream effector of the DDR and direct 
substrate for ATM/ATR and CHK1/CHK2 83. Treatment with HU triggered phosphorylation at 
Ser15 by apical and at Ser20 by checkpoint kinases (Figure 7.3 A). Modification of these 
serine residues in the N-terminal transactivation domain is generally considered to stabilize 
p53 protein by preventing interaction with the E3 ubiquitin ligase MDM2 (also ‘HDM2’ in 
humans) 83. Consistent with this, the total amount of p53 protein increased after incubation 
with HU (Figure 7.3 A). The MS-275-dependent reduction in ATM, CHK1, and CHK2 activity 
also reflected on the p53 phosphorylation status. Phosphorylation at Ser15 and Ser20 of p53 
after S phase stress was reduced by the HDACi after 24 hours. Also, total p53 levels were 
lower if HDAC activity was suppressed. The serine residue 46, in contrast, is substrate to the 
kinases HIPK2 and DYRK2 166,167. Both are activated upon DNA damage and modified p53 
Ser46 even stronger in presence of MS-275, which might also indicate increased activity of 
these kinases (Figure 7.3 A). Densitometric analysis of western blots revealed that the 
residual accumulation of p53 after long-time exposure to HU+MS-275 cannot only be 
explained by residual Ser15 phosphorylation (Figure 7.3 B). This is supported by the findings 
of several studies. They indicate that phosphorylated Ser15 is rather important to stimulate 
transactivation of target genes whereas Ser20 phosphorylation primarily interferes with 
HDM2 interaction 87. Additionally, acetylation of several lysine residues in the C-terminal 
domain contributes to p53 stabilization. This prevents HDM2-mediated ubiquitination at the 
same residues 84,205,206. HDAC1 and SIRT1 are known deacetylases for several of these 
sites 206,207. HDAC inhibition would therefore preserve p53 acetylation and increase half-life 
of p53 protein. This fact also explains slightly increased amounts of the tumor suppressor 
after single application of MS-275 in HCT116 cells (Figure 7.3).  
The amount of activated p53 protein in cells correlated well with p53 target gene 
expression. When HU was applied, the expression of early response p53 target genes like 
HDM2 and WIP1 was induced. On the other hand, decreased accumulation of p53 during 
24 hours of co-treatment with MS-275 resulted in diminished expression of these proteins 
(Figure 7.4). As described previously, the cell cycle regulator p21 cannot and was not 
induced by HU-activated p53 208 (Figure 7.4). Long-time incubation with MS-275 though 
promoted p21 expression and this effect was already demonstrated for several HDACi in 
various cell lines 209,210. However, additional exposure to HU decreased p21 levels at both 
indicated time points. The underlying cause is probably the same mechanism that prevents 
p53-dependent induction of p21 during S phase stress in the first place. Beckermann et al. 
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found that CHK1 activated by the replication checkpoint mediates a blockage of p21 
transcriptional elongation and thereby prevents increase of p21 mRNA 211.  
In summary, cells suffering from S phase stress induce proper DDR signaling, whereas 
simultaneous inhibition of HDAC1-3 activity by MS-275 attenuates DDR kinase 
phosphorylation and thereby also lowers the HU-triggered increase in p53 protein and target 
gene expression in a time-delayed manner. A recent publication from Thurn et al. 
demonstrated a diminished phosphorylation of ATM and p53 after combined treatment of 
cell lines with the DSB-inducing cytostatic Epirubicin and different HDACi 212. Accordingly, 
also DDR signaling after DSBs is modified by deacetylases. The group states that HDAC 
inhibition perturbs ATM expression. They specify that a maximal reduction of 20 to 40% ATM 
mRNA accounts for an almost complete loss of ATM phosphorylation observed by western 
blot analysis. This explanation cannot be transferred to the results obtained during this 
study, since ATM protein levels were not altered by HU and MS-275 treatments (Figure 7.1).  
An early marker for the occurrence of DNA damage is phosphorylation of the histone variant 
H2A.X, commonly referred to as H2A.X 34,175. When HCT116 cells were incubated with MS-
275 for 24 hours, there were no H2A.X signals detected (Figure 7.5). Yet, HDACi like TSA, 
SAHA, or depsipeptide were described to cause DNA damage in malignant cells during single 
administration 213-215. It cannot be excluded that MS-275 is also capable to evoke damage in 
HCT116 cells, but it did not do so in the monitored time frame and with the used 
concentration. This is also in line with the absence of DDR kinase activation after MS-275 
treatment (Figure 7.1). HU triggered H2A.X phosphorylation by activation of ATR kinase and 
the S phase checkpoint 34 (Figure 7.5). Also phosphorylated ATM could have contributed to 
the generation of observed H2A.X foci. They were distributed across the cellular chromatin 
indicating sites of DNA damage (Figure 7.1 and Figure 7.5 B). Immunofluorescence staining 
for H2A.X revealed a variable number of foci in different cells, which could be connected to 
their respective position within the cell cycle. While healthy cells in G1 should not harbor 
foci, an increasing amount of H2A.X in S phase could correlate with the cell´s remaining rate 
of DNA synthesis or collapsing replication forks. A concurrent exposure of stressed HCT116 
cells to MS-275 caused a similar variability in H2A.X foci. It additionally created cells with a 
massive amount of the same (Figure 7.5 B). So MS-275 strongly elevated DNA damage 
induction in individual cells, which could again be correlated to a cell´s position within the 
cell cycle. Western blot analysis revealed that also the overall amount of H2A.X 
DISCUSSION  HDACs regulate phosphatase activity  
page | 62 
  
phosphorylation after application of HU+MS-275 was higher than in HU-treated cells 
(Figure 7.5 A). At first sight, this is a contradiction to the MS-275-dependent attenuation of 
DDR kinase activity since ATM and ATR phosphorylate H2A.X. An intramolecular interplay of 
phosphorylation and acetylation on H2A.X could be a possible explanation and the histone is 
indeed targeted by acetylation. However, this modification was reported to be independent 
of phosphorylation and rather serves to mediate H2A.X ubiquitination 216. WIP1 was 
described as phosphatase for H2A.X and also targets many other substrates of ATM and 
ATR like p53 217-219. The reduced p53-dependent expression of WIP1 in HU+MS-275-treated 
HCT116 cells could account for increased H2A.X phosphorylation, since dephosphorylation of 
the histone is hindered (Figure 7.4). It was also shown that CHK1 activation during HU 
treatment is indispensable to impart repair of occurring DNA damage by HR 201. HR is the 
predominantly triggered repair pathway after replication arrest and collapsing 
forks 203,220,221. So, reduced checkpoint signaling by CHK1 as a result of HDAC inhibition 
would consequently restrict the repair capacity of HR and maintain damage (Figure 7.1 and 
Figure 7.5). The well-defined feature of HDACi to alter gene expression might also negatively 
affect DNA damage repair pathways. There are several reports about downregulation of 
repair genes, such as RAD51, by inhibitors of HDACs 113,222. The protein RAD51 is required to 
rescue stalled replication forks and for repair by HR and its expression was suppressed by 
the broad-spectrum HDACi PCI-24781 in HCT116 cells 221,223. 
Any repair of the DNA will only be effective if the cell cycle is arrested first. The regular cell 
cycle profile of HCT116 cells is presented in the lower part of Figure 7.6 A. After 24 hours of 
incubation with MS-275, the S and G2/M phase are depleted and cells gathered in G1 stage. 
This effect of HDACi is attributed to their induction of the CDK inhibitor p21 141 (Figure 7.4). 
P21 mainly inhibits CDK2 and prevents binding of the cell cycle-regulating kinase to cyclin E 
and A required for transition into S phase. Consequently, these cells arrest in G1 224. In 
contrast, the compound HU primarily induces the S phase checkpoint as it obstructs 
replication fork progression. Before discussing the consequences of HU for HCT116 cells, a 
closer look should be taken on the process of DNA replication itself. Multiple so called 
‘origins of replication’ are distributed along the chromosomes and they are initiated in a 
time-ordered manner (origin firing). Several of them are active at the same time to allow 
successful DNA duplication within only six hours 225,226. The replication checkpoint governs 
the stability of the generated replication forks as well as origin firing during the undisturbed 
and disturbed cell cycle 227,228. An essential function of activated CHK1 during replication 
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checkpoint is to modify CDC25 phosphatases and thereby target them for proteasomal 
degradation or sequestration in the cytosol 66,67,70 (see also Figure 3.5). These phosphatases 
are crucial cell cycle regulators and facilitate the binding of cyclins to CDKs by activating 
dephosphorylation of the latter. If CDK2-cyclinA dimers cannot be established owing to the 
absence of CDC25A, the cell cycle will arrest in S phase 67. This is why treatment with HU for 
24 hours accumulated cells at the stage of DNA synthesis and the amount of cells in G2 and 
mitosis is decreased compared to the undisturbed cell cycle (Figure 7.6 A). When the cell 
cycle progression of HU-treated HCT116 cells was monitored over 12 hours, a considerably 
decelerated course through S phase was visible (Figure 7.6 B). Most of the cells were located 
in the early S phase after 16 hours of incubation, but they slowly continued to progress 
during the next hours. This indicates that the cell cycle arrest was not stable. Indeed, HU 
reversibly inhibits the enzyme RNR, which is why its catalytic activity might be restored at 
later time points 229. It has also been shown in a system with budding yeast that HU only 
delays fork progression and origin firing, thus does not complete block cell cycle 
progression 178. The active ATR-CHK1-mediated replication checkpoint is crucial to stabilize 
stalled replication forks. It furthermore mediates restart of obstructed forks or repair of 
collapsed forks by HR 201, which would also encourage transition through the S phase.  
After simultaneous administration of HU and MS-275 for 24 hours, cell cycle profiling 
showed a decreased amount of cells in S phase and a higher percentage in G2/M compared 
to single HU treatment (Figure 7.6 A). Also, the progression of cells through S phase was 
accelerated and indicates declining replication checkpoint activity with time (Figure 7.6 B). 
This correlates well with the phosphorylation status of DDR kinases (Figure 7.1). Inhibition of 
HDACs did not affect HU-induced DDR signaling after six hours and had just as little effect on 
S phase arrest after 16 hours. Longer incubation with the HDACi diminished replication 
stress signaling by ATM, CHK1, and CHK2 and thus abolished cell cycle arrest. The reduced 
activity of CHK1 in stressed cells would allow new origin firing but also destabilize and restart 
breakage-prone replication forks. This might subsequently lead to the generation of more 
severe DSB lesions 185. Moreover, it would limit repair of these lesions since CHK1 is 
necessary for induction of HR 201. That could also contribute to the massive accumulation of 
H2A.X in co-treated HCT116 cells (Figure 7.5). 
The mediator kinase CHK1 not only critically regulates the intra-S phase checkpoint but also 
the transition of cells into mitosis at the G2/M checkpoint by targeting CDC25C 67. A study 
from Lossaint et al. showed that efficient induction of p21 after DSBs was able to 
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compensate a loss of CHK1 activity and arrested cells in G2 230. However, p21 protein was 
not induced in HU+MS-275-treated cells after 24 hours (Figure 7.4) and hence could not 
contribute to cell cycle blockage. But how can accelerated completion of DNA replication in 
presence of MS-275 be explained, considering the depleted synthesis of dNTPs by HU? It is 
unclear how effective RNR was inhibited by 1 mM HU in HCT116 cells, but most commonly 
the enzyme is only partially inhibited by HU 177. So some enzymatic activity remained to 
supply the pool of dNTPs. Furthermore, it is an acknowledged fact these days that also 
ribonucleotides can be and are occasionally incorporated in newly synthesized DNA 231,232. In 
normal cells, they are far more abundant than deoxyribonucleotides and inhibition of the 
RNR by HU further increases the imbalance. This would make misincorporation of 
ribonucleotides even more likely.  
How single and combined application of HU and MS-275 affected the induction of 
(apoptotic) cell death was investigated with western blot and FACS assays (Figure 7.7). 
Apoptosis was evaluated in western blot with a specific antibody for a caspase 3-dependent 
PARP cleavage fragment. Incubation of HCT116 cells with MS-275 for 24 hours created no 
pronounced signal for PARP cleavage. Also Annexin V staining revealed only minor apoptosis 
with about 8% apoptotic cells after 24 and 48 hours. Long-time exposure for 48 hours 
though showed 20% of cells in subG1 fraction indicating DNA fragmentation. One 
explanation would be that, apart from the intrinsic and extrinsic apoptotic pathway, HDACi 
in general were also shown to eliminate tumor cells via induction of reactive oxygen species 
(ROS), mitotic cell death, or autophagy 233. When the lethal capability of HU was quantified, 
the percentage of apoptotic cells (Annexin V) was a little higher than that of the subG1 
fraction. This is because PI staining only reveals the late, but not early apoptotic stage 
(Figure 7.7 B-C). Cell death of HCT116 cells could be further increased by simultaneous HDAC 
inhibition. First, western blot analysis indicated higher caspase-dependent turnover of 
PARP (Figure 7.7 A). Additional FACS analysis confirmed that cytotoxicity after 48 hours was 
significantly enhanced if HU and MS-275 were applied together instead of alone 
(Figure 7.7 B-C). These data are in line with earlier publications showing that disturbed HDAC 
activity contributes to a more efficient induction of apoptosis in HU-stressed cells 156,157. 
Moreover, enhanced tumor cell toxicity was also reported for co-administration of 5-FU with 
MS-275 200. It was described above that the HDACi MS-275 disrupts HU-induces cell cycle 
arrest. This would also impair repair and cause an accumulation of damage. If those cells 
pre-maturely entered mitosis with damaged DNA, cell death would be certain. 
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Taken together, inhibition of HDACs reduced checkpoint kinase signaling and consequently 
disturbed cell cycle checkpoints set on by HU. This was accompanied by increased DNA 
damage and apoptotic cell death. Replication stress-induced S phase arrest was canceled in 
presence of MS-275 in a time-dependent fashion and facilitated the progression of cells 
harboring unrepaired DNA towards mitosis.  
8.2 Deactivation of apical kinases during DNA damage conveys the effects of 
MS-275  
The primary ATM-CHK1 and secondary ATM-CHK2 DDR kinase cascades were induced after 
treatment with HU but were attenuated upon HDAC inhibition by MS-275 (Figure 7.1 and 
Figure 7.3). Therefore, it was investigated whether impaired activity of only one of these 
kinases could account for the MS-275-dependent effects on cell signaling and viability. The 
kinase CHK1 is required for faithful DNA replication during unperturbed S phase and 
depletion of CHK1 is lethal for every proliferating cell 71,227,234,235. In the experiments of this 
study, CHK1 activity was blocked with UCN-01 186. Application of the inhibitor increased p53 
phosphorylation at Ser15 in HU-treated cells, indicating that ATR and/or ATM activation was 
elevated (Figure 7.8 A) 75,80. These data match previous studies, which showed that CHK1 is 
indispensable to trigger the S phase checkpoint and to avoid replication initiation after 
occurrence of stalled replication forks 11,236. So, loss of CHK1 activity must have augmented 
the formation of DSB after replication inhibition with HU. It additionally must have reduced 
repair of the damage by HR 201,236. As a consequence, caspase 3-dependent PARP cleavage 
was markedly increased in HCT116 cells incubated with UCN-01 (Figure 7.8 A) 237. In contrast 
to p53 Ser15, checkpoint kinase-dependent phosphorylation of Ser20 remained unchanged 
with addition of UCN-01 proving efficient inhibition of CHK1 81,82. Despite their partially 
overlapping substrates, the second checkpoint kinase CHK2 is not crucial for the survival of 
normal cells 238,239. This is also demonstrated by the availability of the CHK2-deficient cell line 
HCT116 CHK2-/-. These cells were used to address the role of CHK2 in HU-induced signaling. 
Wild type and CHK2-negative HCT116 cells show the same accumulation of p53 upon 
exposure to HU (Figure 7.8 B). Yet, apoptosis was decreased if CHK2 was missing. The data 
speak against a role of CHK2 as coordinator of replication stress signaling. Hence, increased 
apoptosis after HU+MS-275 treatment is not reliant on this checkpoint kinase. Reduced 
CHK1 activity neither completely displays the effects of MS-275 (Figure  7.8 A). UCN-01 
clearly accentuated apoptotic death of cells with replicative stress, like MS-275 did. 
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However, CHK1 inhibition did not cause reduced downstream phosphorylation of p53 after 
HU and therefore is not the sole mediator for the effects of MS-275. 
The apical kinase ATM was selectively inhibited using KU-55933 188. This compound was 
unable to prevent auto-phosphorylation of ATM molecules in trans, since HU generated the 
same amount of Ser1981-phosphorylated ATM irrespective of the inhibitor (Figure 7.9 B). 
The inhibitory capacity of KU-55933 is demonstrated by the reduction of p53 
phosphorylation at Ser15 during simultaneous incubation with HU. This in turn impeded the 
accumulation of p53 protein. Surprisingly, KU-55933 also diminished HU-induced CHK1 
phosphorylation at Ser317. It has been published before that ATM inhibition by KU-55933 
reduced phosphorylation of CHK1 following IR or ICRF-193 (an inhibitor of DNA 
topoisomerase II) 33,230. KU-55933 did not affect ATR, since work from Liu et al. showed that 
ATR activation is not disturbed in HCT116 cells incubated with 10 µM KU-55933 22. This 
reflects the set-up used in the present study. In contrast to reduced CHK1 phosphorylation, 
the ATM inhibitor paradoxically increased the amount of Thr68-phosphorylated CHK2 after 
HU (Figure 7.9 B). This effect of KU-55933 has also been published and the authors state that 
ATM could be dispensable for phosphorylation of CHK2 at Thr68 230. The experiment in 
Figure 7.9 B furthermore shows that the ATM inhibitor supported induction of apoptosis 
after replication stress, which is indicated by increased apoptotic PARP cleavage. 
Addition of the ATR inhibitor ETP-46464 similarly increased PARP cleavage after 24 hours of 
HU treatment (Figure 7.9 A). Annexin V staining revealed a highly significant increase in 
apoptosis after 48 hours, if ATR activity was impaired during replication stress 
(Figure 7.10 A) 237. Moreover, ETP-46464 caused massive phosphorylation of ATM in 
presence of HU (Figure 7.9 A). The induction of cell cycle arrest following perturbations of 
DNA synthesis is critically dependent on ATR and its downstream kinase CHK1. Both proteins 
are crucial for cell survival. When replication forks become stalled, ATR signaling mediates 
fork stabilization and blocks new origin firing 71,185,240. ETP-46464 suspends this mechanism 
and leaves S phase uncontrolled, which would result in DSB formation or even chromosomal 
breakage and explains the high degree of ATM phosphorylation 241 (Figure 7.9 A). In line with 
this, DNA damage-inducible phosphorylation at Ser46 of p53 was increased when the 
S phase checkpoint was abrogated by ETP-46464. In contrast, Ser15 of p53 was less 
phosphorylated in HU-treated HCT116 cells if ATR was inhibited - despite the high levels of 
activated ATM. This demonstrates the primary role of ATR in p53 phosphorylation after 
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replication stress. An additional proof for the efficacy of ETP-46464 is the complete loss of 
CHK1 phosphorylation following HU (Figure 7.9 A). How this loss of CHK1 activity affected 
cell cycle progression was investigated by PI staining after 18, 22, and 26 hours of treatment. 
Incubation of HCT116 cells with HU alone activated the replication checkpoint so cells 
accumulated in early S phase and progressed only very slowly towards G2 (Figure 7.10 B, see 
also section 8.1 and Figure 7.6 B). Simultaneous inhibition of ATR by ETP-46464 disturbed 
the onset of both an S phase and G2/M arrest. HCT116 cells instead gathered at the G1/S 
transition. It is known that the kinase ATR can only be activated in the S and G2 phase of the 
cell cycle 18,187 which also restricts CHK1-dependent DNA repair via HR to these cell cycle 
stages 201,242. If ATR activity is blocked right from the beginning of a HU-induced stress 
response, only G1 arrest can be initiated. This checkpoint is, unlike the replication and G2 
checkpoint, independent of ATR 243,244. Cells that escape from G1 and re-enter the cell cycle 
would face an unchecked process of DNA synthesis which is moreover disturbed by HU and 
lacks DNA repair by HR. As a consequence, these cells would be eliminated. The depiction of 
subG1 fraction for the treatment of HCT116 cells with HU and ETP-46464 indeed shows an 
increasing amount of dead cells with time (Figure 7.10 C). After 26 hours of co-incubation, 
about 12% of cells had died. The effectively established S phase arrest in cells exposed to HU 
prevented cell death, so the respective proportion of subG1 (3%) is comparable to the 
control treatments used (1-2%).  
The targeted inhibition of the apical kinases ATM and ATR during HU-induced replication 
stress showed that repression of not only one but rather both kinases conveys the effects of 
MS-275 on DDR signaling and cell fate. The ATR inhibitor ETP-46464 nicely reproduced the 
attenuated downstream signaling though CHK1, p53 phosphorylation and accumulation, 
disturbed cell cycle arrest and also elevated the cytotoxicity of HU in HCT116 cells (Figure 7.9 
and 7.10). Nevertheless, it also strongly increased the level of ATM phosphorylation which is 
why ATM activity has to be counteracted by MS-275 as well.  
8.3 HDAC1/2 are important players in the orchestration of DDR signaling 
The synthetic benzamide derivate MS-275 was identified as a potent HDAC inhibitor in 1999 
and selectively targets HDAC1, HDAC2 and HDAC3 148,245. It was therefore tested which of 
these three HDACs mediate(s) the negative effect of MS-275 on HU-induced DDR signaling. 
Single HDACs were eliminated by siRNA-mediated knockdown with high efficiency 
(Figure 7.15 A). Interestingly, application of siRNA against either HDAC1 or HDAC2 (each in 
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combination with HDAC3) upregulated the endogenous amount of the other HDAC variant. 
This indicates a mutual compensation of HDAC1 and HDAC2 (Figure 7.15 A) 246. The 
combined knockdown of HDAC1/3 and HDAC2/3 still showed a proper induction of the DDR 
after 24 hours of HU treatment. Phosphorylation of ATM, CHK1, and p53 was induced as in 
control cells transfected with scrambled siRNA (Figure 7.15 B). That HDAC2 is not necessarily 
required for ATM activation in response to HU is also demonstrated by the regularly induced 
phosphorylation of ATM in HCT116 p53-/- cells lacking the deacetylase 247 (Figure 7.2 A). Joint 
depletion of HDAC1 and HDAC2 in HCT wild-type cells, however, diminished activation of 
ATM and CHK1 upon exposure to HU whereas the total amount of these proteins was not 
affected. Furthermore, the p53 residue Ser15 was less phosphorylated and apoptotic PARP 
cleavage was markedly induced in HU-treated cells depleted of HDAC1 and HDAC2. Hence, a 
loss of HDAC1/2 protein imitated the effects of their catalytic inhibition by MS-
275 (Figure 7.1 and  7.7 A). The additional transfection of siHDAC3 in triple knockdown 
experiments yielded the same results without additional effects (Figure 7.15 B). This 
excludes an essential function of HDAC3 in the maintenance of replication stress signaling. 
Instead, activity of both HDAC1 and HDAC2 is required for the onset of a cellular response 
after disturbed DNA synthesis. These results are in agreement with a recent publication of 
Thurn et al., which demonstrated that HDAC1 and HDAC2 hold important function in the 
DDR after DSBs 212.  
8.4 PR130 as a new regulator of ATM phosphorylation 
What was still missing was a molecular mechanism for the modulation of apical DDR kinases 
by HDAC1 and HDAC2. Pre-incubation of HCT116 cells with MS-275 was used to gain more 
insight in its time-dependent regulation of the DDR (Figure 7.11). Simultaneous treatment 
with HU and MS-275 revealed decreasing phosphorylation of ATM, CHK1, and p53 after 
more than six hours of exposure. Pre-incubation with MS-275 over-night blunted the 
induction of HU-induced replication stress signaling via ATR and ATM right from the 
beginning. These results suggested that MS-275 altered expression of (an) unknown gene(s) 
which afterward antagonized DDR signaling. A delayed increase in phosphatase activity by 
MS-275 was a suitable, direct explanation for the observed sensitivity of kinase 
phosphorylation to HDAC inhibition.  
WIP1 acts as an important serine/threonine phosphatase in the DDR and was also reported 
as a possible negative regulator of ATM and ATR 218,219,248,249. However, long-time exposure 
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to HU showed a reduced expression of the p53 target WIP1 in the presence of the HDACi 
(Figure 7.4). This makes WIP1 an unlikely candidate for ATM/ATR dephosphorylation in cells 
treated with HU and MS-275. Other researchers also reported additional phosphatases. 
These might either prevent basal ATM phosphorylation and thereby keep the kinase in an 
inactive state or facilitate ATM activation and downstream signaling following DNA damage. 
They include PP1 250, PP5 251, and PP2A 252, which are all serine/threonine phosphatases of 
the PPP family (see also section 3.2). Since PP2A is a key phosphatase in mammalian cells 100, 
it was investigated whether inhibition of HDACs by MS-275 increased the general catalytic 
activity of PP2A. The inhibitors Cantharidin and Okadaic acid (OA) were applied to block 
dephosphorylation by PP2A. Cantharidin increasingly rescued the MS-275-mediated 
repression of HU-induced DDR signaling with rising concentration (Figure 7.12 A). 
Phosphorylation of ATM, CHK1, and CHK2 was restored by Cantharidin within four hours, 
which was reproducible with the PP2A inhibitor Okadaic acid (Figure 7.12). Moreover, 
Cantharidin accentuated phosphorylation of the mentioned kinases in cells treated with HU 
alone, but did not do so in untreated HCT116 cells (Figure 7.12 A).  These data argue that 
PP2A rather controls the intensity of DDR kinase activity than their basal phosphorylation. 
They could further mean that (i) PP2A counteracts phosphorylation of apical as well as 
checkpoint kinases or (ii) PP2A regulates phosphorylation of apical kinases and restored 
activity of ATM/ATR by Cantharidin (or OA) in turn increases downstream target 
phosphorylation. In fact, PP2A was shown to also control phosphorylation of CHK1 (Ser317, 
Ser345) 253 and CHK2 (Thr68) 254 of the S phase signaling cascade. Albeit many proteins have 
been described as targets of PP2A, very few publications identified the critical regulatory 
subunit, which facilitates specificity of the phosphatase for the respective substrate. For 
example, it was found that the PP2A B’α subunit binds to CHK2 and thereby marks it for 
dephosphorylation 255.  
When the microarray data obtained during this study was searched for genes that were 
apparently controlled by HDAC activity, one gene encoding for regulatory subunits of PP2A 
appeared. Expression of the gene PPP2R3A yields two protein isoforms called PR72 and 
PR130 and a third transcript variant that has not been further described 193. Since PR72 is 
exclusively found in heart and skeletal muscle tissue, only the level of PR130 was examined 
in HCT116 cells 101,194. Quantitative RT-PCR revealed that PPP2R3A expression was not 
affected by HU over 24 hours of incubation (Figure 7.13 A). Also western blot analysis 
showed comparable signals for PR130 in HU-treated and control samples (Figure 7.13 B). If 
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MS-275 was applied, mRNA levels of PPP2R3A were significantly increased independent of 
the presence of HU (Figure 7.13 A). More than six hours of HDAC inhibition were necessary 
to elevate the mRNA amount. Western blot analysis showed that PR130 protein nicely 
increased with rising concentrations of MS-275 (Figure 7.13 B) and knockdown of HDAC1 
and HDAC2 was sufficient to show a strong induction of PR130 (Figure 7.16). These results 
point to a role of solely HDAC1 and HDAC2 in suppressing expression of the PP2A regulatory 
subunit PR130 under normal cellular conditions. It is still unclear how both HDACs repress 
PPP2R3A. Either, epigenetic gene regulation by histone deacetylation or direct 
transcriptional repression is possible. The need to eliminate both, HDAC1 and HDAC2, for the 
induction of PR130 seems plausible for the latter scenario, because they share overlapping 
functions and are part of the same transcriptional co-repressor complexes, e.g. 
mSIN3A 116,123. Interestingly, the more PR130 was accumulated by MS-275 the stronger HU-
induced ATM phosphorylation was lost. This suggested a link between PR130 and ATM 
activity (Figure 7.13 B). 
Until today, PR130 was shown to modulate Wnt signaling 256 and to affect epidermal growth 
factor (EGF)-mediated signaling by the EGF receptor (EGFR) 257. PR130 is also associated with 
the huge scaffolding protein CG-NAP, although the function of the PP2A subunit in this 
complex remains to be defined 258. Within cells, PR130 localizes in the cytosol as well as in 
the nucleus 259-261. Cellular fractionation of HCT116 cells revealed that the regulatory subunit 
mainly localized in the cytoplasm and only resided to a small extent in the nucleus 
(Figure 7.14). MS-275 did not visibly change the balance of this distribution and only 
elevated the amount of PR130 protein in both compartments. In the same experiment, 
pATM appeared exclusively in the nucleus.  So, if ATM would actually serve as a substrate for 
PP2A-PR130, just a minor proportion of all PR130 detected in whole cell lysates would be 
capable to target phosphorylated ATM molecules. 
The potential role of PR130 in particular and not PP2A in general in the regulation of ATM 
Ser1981 phosphorylation was investigated by transfecting PR130-targeted siRNA. The MS-
275-induced upregulation of the phosphatase subunit could be efficiently blocked by the 
specific siRNA. PR130 levels could be reduced to below the basal value in the control sample 
(Figure 7.17).  The elimination of PR130 in HCT116 cells treated with HU and MS-275 had the 
same effect like inhibition of PP2A as it rescued phosphorylation of ATM (Figure 7.17 
and  7.12). To further study the interaction of the phosphatase with its suggested substrate, 
pSer1981 ATM was precipitated from whole cell lysates of previously fixed cells. To enhance 
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the usually low amount of phosphorylated ATM molecules after treatment with HU and MS-
275 and thereby increase the number of possible PP2A interaction partners, OA was applied 
(Figure 7.18). Western blots of immunoprecipitates indeed displayed a clear signal for PR130 
in pATM-precipitates, which was not the result of unspecific binding of PR130 to sepharose 
beads (“no AB”) or IgG antibody (“Pre”). In addition, the detected signals only reflect 
complexes that must have existed in the nucleus prior to lysis. Fixation of the cells at the end 
of the treatment period should have prevented the artefact of an interaction between 
cytosolic PR130 and nuclear pATM after dissolution of the compartments. Hence, PR130 and 
pATM can physically interact with each other, whereby both might be part of a larger 
protein complex. 
The results obtained in this study create reasonable evidence that PR130 is part of a 
phosphatase complex, which mediates deactivation of at least ATM kinase (Figure 7.13 B, 
7.17, and 7.18). The degree of ATM dephosphorylation after replication stress is determined 
by the abundance of PR130, since regulatory subunits are the limiting factor for the 
assembly of active PP2A holoenzymes 259. Interestingly, PR130 was identified as a potential 
target of CHK1 and CHK2 phosphorylation by using in vitro kinase assays 262. This could 
enable a feedback regulation in cells. Under normal cellular conditions, specifically HDAC1 
and HDAC2 mediate transcriptional repression of PPP2R3A. Thereby, they facilitate a 
sustained response of a cell to occurring lesions in the DNA (Figure 7.16 and 7.15 A). 
Suppression of HDAC1 and HDAC2 activity by MS-275 triggered a delayed expression of 
PR130 (Figure 7.13). This correlates with the proper activation of replication stress signaling 
in the beginning as well as its subsequent decline (Figure 7.1 A and 7.11). Perspectively, it 
would be of great interest to find out how HDAC1 and HDAC2 repress PPP2R3A. A regulation 
via epigenetic modification or modulation of the respective transcription factor(s) is 
possible.  
To draw more general conclusions about the functions of PP2A-PR130 in mediation of the 
cellular replication stress response, additional experiments need to be carried out. For 
example, the impact of ectopic PR130 overexpression on HU-induced ATM phosphorylation 
should be monitored or in vitro dephosphorylation assays could be performed. 
Immunofluorescence studies should reveal whether the phosphatase subunit co-localizes at 
DNA damage foci with H2A.X and ATM. It is also of high importance to find out whether 
ATR phosphorylation is also counteracted by PP2A-PR130 holoenzymes, since ATR is the 
main DDR kinase activated by stalled replication forks during HU treatment. There is 
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evidence that also phosphorylated ATR is a substrate of PP2A 263, although ATR activity was 
induced with IR in the respective experiments. Considering the close relation to ATM 264, it 
seems conceivable that also ATR is regulated by PR130. Thus, knockdown experiments as 
shown in Figure 7.17 need to be performed with respect to phosphorylated ATR and DDR 
downstream signaling. Also co-localization of phosphorylated ATR with PR130 should be 
tested and an antibody for Thr1989 would be most appropriate 22,23. Last but not least, the 
biological roles of PR130 should be addressed in greater detail. One approach would be to 
compare the cell cycle profiles of HU+MS-275-treated cells with high (siCtrl) and repressed 
(siPR130) PR130 levels. If the PP2A subunit was involved in the positive control of cell cycle 
progression, a knockdown of PR130 should restore a sustained HU-mediated cell cycle arrest 
in S phase. In an opposing approach, cell cycle profiles of HU-treated cells with elevated 
PR130 by MS-275 and transient overexpression could be compared.  
8.5 Summarizing model and conclusions  
In summary, this study revealed that HDACs modulate the DNA damage response after 
replication stress and it also provides a possible mechanistic link for this interference. The 
following model is proposed: 
Replication forks that became stalled during treatment of cancer cells with hydroxyurea 
trigger a DDR encompassing the apical kinases ATR and ATM, the mediator kinases CHK1 and 
CHK2, and the effector p53 (Figure 8.1). The cascade-like phosphorylation of these proteins 
facilitates the cell´s response to inhibited DNA synthesis. It includes p53 target gene 
expression, activation of cell cycle checkpoints to arrest cells with perturbed S phase, and 
apoptosis as a last resort to eliminate severely damaged cells. A simultaneous inhibition of 
HDAC1 and HDAC2 activity in HU-treated cells, however, suppresses DNA damage signaling. 
The loss of HDAC1/2 activity abolishes the transcriptional repression of the gene PPP2R3A 
which encodes the PP2A B subunit PR130. As a regulatory subunit of PP2A, PR130 
specifically mediates substrate specificity for apical DDR kinases. Accumulation of PR130 
through MS-275 increases dephosphorylation and therefore deactivation of ATM and ATR. 
Consequently, the entire DDR downstream signaling pathway is diminished, which also 
impairs transcriptional activity of p53. All this contributes to insufficient cell cycle checkpoint 
activation, subsequent reentry of unrepaired cells with impaired DNA synthesis capacity into 
the cell cycle, replication fork collapse, and accumulation of DNA damage. On the biological 
level, cells show a higher susceptibility for apoptotic cell death. It was not directly 
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demonstrated that ATR phosphorylation is counteracted by PP2A-PR130. Yet, experiments 
with specific kinase inhibitors revealed that deprivation of neither ATR nor ATM activity 
alone accounts for all effects obtained with MS-275. This is why both apical kinases have to 
be negatively regulated by the HDAC inhibitor. Furthermore, the amount of phosphorylated 
CHK1 protein, which is a common readout for catalytically active ATR 63, was decreased by 
MS-275 and restored with PP2A inhibitors. This supports the idea of MS-275-mediated ATR 
dephosphorylation by PP2A phosphatase complexes though it cannot be completely ruled 
out that CHK1 phosphorylation is also modulated by MS-275-induced PP2A activity.  
 
 
Figure 8.1:  Summarizing model for the modulation of the DDR by histone deacetylases 1 and 2. 
The image shows a schematic summary of the project´s most important discoveries. Herein, the cell´s condition 
after hydroxyurea treatment is directly compared to that with additional inhibition of HDAC1 and HDAC2. 
Further descriptions can be found in the text below. Filled red bullets indicate phosphorylation. Framed red 
bullets indicate low rates of phosphorylation. p53 RE: p53 response element. 
Overexpression of HDAC1 and HDAC2 is found in a variety of tumors and correlates with 
poor patient prognosis 120,123,124. According to the results of this study, these cancer entities 
should show strong repression of PR130 expression and thus little PP2A-PR130 activity. The 
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phosphatase PP2A is generally considered as tumor suppressor and its functions are often 
repressed or abolished in solid tumors and leukemia 102. Experiments in immortalized, non-
tumorigenic HEK TER cells also revealed that a loss of PR130 was associated with cell 
transformation. In this system, the shRNA-mediated suppression of PR130 increased the 
expression and activity of the proto-oncogene cMyc 265. The administration of HDAC 
inhibitors would cancel transcriptional repression and elevate PR130 levels in HDAC1/2 
overexpressing tumors and probably also normal cells. Rapidly dividing, cancerous cells are 
by nature prone to intrinsic replicational stress 187,241. An exposure to replication inhibitors 
or genotoxic compounds therefore causes stronger damage in tumorigenic cells. The 
increase in PR130 protein by simultaneous exposure to HDACi like MS-275 would interfere 
with the subsequent onset of sustained DDR signaling via ATM/ATR and cell cycle arrest in S 
or G2 phase. The resulting lack of time for proper repair of damaged DNA would especially 
trouble tumor cells. Most cancers are moreover p53-deficient, which abrogates induction of 
the G1 checkpoint 266 – the only remaining cell cycle checkpoint of the interphase if ATR and 
CHK1 signaling is disturbed 243,244. All these mechanisms might contribute to the 
understanding, why HDAC inhibitors are highly tumor cell specific compounds and positively 






LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 75 
  
9 LIST OF REFERENCES  
 
1 Smith J., Tho L.M., Xu N. & Gillespie D.A. (2010) 
The ATM-Chk2 and ATR-Chk1 pathways in DNA 
damage signaling and cancer. Advances in cancer 
research 108: 73-112 
2 Shiloh Y. (2003) ATM and related protein kinases: 
safeguarding genome integrity. Nature reviews. 
Cancer 3: 155-168 
3 Matsuoka S., Ballif B.A., Smogorzewska A. et al. 
(2007) ATM and ATR substrate analysis reveals 
extensive protein networks responsive to DNA 
damage. Science 316: 1160-1166 
4 Linding R., Jensen L.J., Ostheimer G.J. et al. (2007) 
Systematic discovery of in vivo phosphorylation 
networks. Cell 129: 1415-1426 
5 Harper J.W. & Elledge S.J. (2007) The DNA 
damage response: ten years after. Mol Cell 28: 
739-745 
6 Dai Y. & Grant S. (2010) New insights into 
checkpoint kinase 1 in the DNA damage response 
signaling network. Clinical cancer research : an 
official journal of the American Association for 
Cancer Research 16: 376-383 
7 Shiloh Y. & Ziv Y. (2013) The ATM protein kinase: 
regulating the cellular response to genotoxic 
stress, and more. Nature reviews. Molecular cell 
biology 14: 197-210 
8 Gatei M., Sloper K., Sorensen C. et al. (2003) 
Ataxia-telangiectasia-mutated (ATM) and NBS1-
dependent phosphorylation of Chk1 on Ser-317 in 
response to ionizing radiation. The Journal of 
biological chemistry 278: 14806-14811 
9 Stiff T., Walker S.A., Cerosaletti K. et al. (2006) 
ATR-dependent phosphorylation and activation of 
ATM in response to UV treatment or replication 
fork stalling. The EMBO journal 25: 5775-5782 
10 d'Adda di Fagagna F. (2008) Living on a break: 
cellular senescence as a DNA-damage response. 
Nature reviews. Cancer 8: 512-522 
11 Patil M., Pabla N. & Dong Z. (2013) Checkpoint 
kinase 1 in DNA damage response and cell cycle 
regulation. Cellular and molecular life sciences : 
CMLS 70: 4009-4021 
12 Durocher D. & Jackson S.P. (2001) DNA-PK, ATM 
and ATR as sensors of DNA damage: variations on 
a theme? Current opinion in cell biology 13: 225-
231 
13 Savitsky K., Bar-Shira A., Gilad S. et al. (1995) A 
single ataxia telangiectasia gene with a product 
similar to PI-3 kinase. Science 268: 1749-1753 
14 Alderton G.K., Joenje H., Varon R. et al. (2004) 
Seckel syndrome exhibits cellular features 
demonstrating defects in the ATR-signalling 
pathway. Human molecular genetics 13: 3127-
3138 
15 Brown E.J. & Baltimore D. (2000) ATR disruption 
leads to chromosomal fragmentation and early 
embryonic lethality. Genes & development 14: 
397-402 
16 Cortez D., Guntuku S., Qin J. & Elledge S.J. (2001) 
ATR and ATRIP: partners in checkpoint signaling. 
Science 294: 1713-1716 
17 Nyberg K.A., Michelson R.J., Putnam C.W. & 
Weinert T.A. (2002) Toward maintaining the 
genome: DNA damage and replication 
checkpoints. Annual review of genetics 36: 617-
656 
18 Jazayeri A., Falck J., Lukas C. et al. (2006) ATM- 
and cell cycle-dependent regulation of ATR in 
response to DNA double-strand breaks. Nature 
cell biology 8: 37-45 
19 Zou L. & Elledge S.J. (2003) Sensing DNA damage 
through ATRIP recognition of RPA-ssDNA 
complexes. Science 300: 1542-1548 
20 Fanning E., Klimovich V. & Nager A.R. (2006) A 
dynamic model for replication protein A (RPA) 
function in DNA processing pathways. Nucleic 
acids research 34: 4126-4137 
21 Ball H.L., Ehrhardt M.R., Mordes D.A. et al. (2007) 
Function of a conserved checkpoint recruitment 
domain in ATRIP proteins. Molecular and cellular 
biology 27: 3367-3377 
22 Liu S., Shiotani B., Lahiri M. et al. (2011) ATR 
autophosphorylation as a molecular switch for 
checkpoint activation. Mol Cell 43: 192-202 
23 Nam E.A., Zhao R., Glick G.G. et al. (2011) Thr-
1989 phosphorylation is a marker of active ataxia 
telangiectasia-mutated and Rad3-related (ATR) 
kinase. The Journal of biological chemistry 286: 
28707-28714 
24 Bermudez V.P., Lindsey-Boltz L.A., Cesare A.J. et 
al. (2003) Loading of the human 9-1-1 checkpoint 
complex onto DNA by the checkpoint clamp 
loader hRad17-replication factor C complex in 
vitro. Proceedings of the National Academy of 
Sciences of the United States of America 100: 
1633-1638 
25 Parrilla-Castellar E.R., Arlander S.J. & Karnitz L. 
(2004) Dial 9-1-1 for DNA damage: the Rad9-
Hus1-Rad1 (9-1-1) clamp complex. DNA repair 3: 
1009-1014 
26 St Onge R.P., Besley B.D., Pelley J.L. & Davey S. 
(2003) A role for the phosphorylation of hRad9 in 
checkpoint signaling. The Journal of biological 
chemistry 278: 26620-26628 
27 Delacroix S., Wagner J.M., Kobayashi M., 
Yamamoto K. & Karnitz L.M. (2007) The Rad9-
Hus1-Rad1 (9-1-1) clamp activates checkpoint 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 76 
  
signaling via TopBP1. Genes & development 21: 
1472-1477 
28 Takeishi Y., Ohashi E., Ogawa K. et al. (2010) 
Casein kinase 2-dependent phosphorylation of 
human Rad9 mediates the interaction between 
human Rad9-Hus1-Rad1 complex and TopBP1. 
Genes to cells : devoted to molecular & cellular 
mechanisms 15: 761-771 
29 Kumagai A., Lee J., Yoo H.Y. & Dunphy W.G. 
(2006) TopBP1 activates the ATR-ATRIP complex. 
Cell 124: 943-955 
30 Lee J., Kumagai A. & Dunphy W.G. (2007) The 
Rad9-Hus1-Rad1 checkpoint clamp regulates 
interaction of TopBP1 with ATR. The Journal of 
biological chemistry 282: 28036-28044 
31 Bao S., Tibbetts R.S., Brumbaugh K.M. et al. (2001) 
ATR/ATM-mediated phosphorylation of human 
Rad17 is required for genotoxic stress responses. 
Nature 411: 969-974 
32 Wang X., Zou L., Lu T. et al. (2006) Rad17 
phosphorylation is required for claspin 
recruitment and Chk1 activation in response to 
replication stress. Mol Cell 23: 331-341 
33 Smits V.A., Reaper P.M. & Jackson S.P. (2006) 
Rapid PIKK-dependent release of Chk1 from 
chromatin promotes the DNA-damage checkpoint 
response. Current biology : CB 16: 150-159 
34 Ward I.M. & Chen J. (2001) Histone H2AX is 
phosphorylated in an ATR-dependent manner in 
response to replicational stress. The Journal of 
biological chemistry 276: 47759-47762 
35 Cimprich K.A. & Cortez D. (2008) ATR: an essential 
regulator of genome integrity. Nature reviews. 
Molecular cell biology 9: 616-627 
36 Shiloh Y. (2006) The ATM-mediated DNA-damage 
response: taking shape. Trends in biochemical 
sciences 31: 402-410 
37 Bakkenist C.J. & Kastan M.B. (2003) DNA damage 
activates ATM through intermolecular 
autophosphorylation and dimer dissociation. 
Nature 421: 499-506 
38 Lee J.H. & Paull T.T. (2007) Activation and 
regulation of ATM kinase activity in response to 
DNA double-strand breaks. Oncogene 26: 7741-
7748 
39 Kozlov S.V., Graham M.E., Peng C. et al. (2006) 
Involvement of novel autophosphorylation sites in 
ATM activation. The EMBO journal 25: 3504-3514 
40 Kozlov S.V., Graham M.E., Jakob B. et al. (2011) 
Autophosphorylation and ATM activation: 
additional sites add to the complexity. The Journal 
of biological chemistry 286: 9107-9119 
41 Sun Y., Jiang X., Chen S., Fernandes N. & Price B.D. 
(2005) A role for the Tip60 histone 
acetyltransferase in the acetylation and activation 
of ATM. Proceedings of the National Academy of 
Sciences of the United States of America 102: 
13182-13187 
42 You Z., Bailis J.M., Johnson S.A., Dilworth S.M. & 
Hunter T. (2007) Rapid activation of ATM on DNA 
flanking double-strand breaks. Nature cell biology 
9: 1311-1318 
43 Soutoglou E. & Misteli T. (2008) Activation of the 
cellular DNA damage response in the absence of 
DNA lesions. Science 320: 1507-1510 
44 Lee J.H. & Paull T.T. (2005) ATM activation by DNA 
double-strand breaks through the Mre11-Rad50-
Nbs1 complex. Science 308: 551-554 
45 Bhatti S., Kozlov S., Farooqi A.A. et al. (2011) ATM 
protein kinase: the linchpin of cellular defenses to 
stress. Cellular and molecular life sciences : CMLS 
68: 2977-3006 
46 Burma S., Chen B.P., Murphy M., Kurimasa A. & 
Chen D.J. (2001) ATM phosphorylates histone 
H2AX in response to DNA double-strand breaks. 
The Journal of biological chemistry 276: 42462-
42467 
47 Stewart G.S., Wang B., Bignell C.R., Taylor A.M. & 
Elledge S.J. (2003) MDC1 is a mediator of the 
mammalian DNA damage checkpoint. Nature 421: 
961-966 
48 Stucki M., Clapperton J.A., Mohammad D. et al. 
(2005) MDC1 directly binds phosphorylated 
histone H2AX to regulate cellular responses to 
DNA double-strand breaks. Cell 123: 1213-1226 
49 Lukas C., Melander F., Stucki M. et al. (2004) 
Mdc1 couples DNA double-strand break 
recognition by Nbs1 with its H2AX-dependent 
chromatin retention. The EMBO journal 23: 2674-
2683 
50 Lou Z., Minter-Dykhouse K., Franco S. et al. (2006) 
MDC1 maintains genomic stability by participating 
in the amplification of ATM-dependent DNA 
damage signals. Mol Cell 21: 187-200 
51 Lavin M.F. (2008) Ataxia-telangiectasia: from a 
rare disorder to a paradigm for cell signalling and 
cancer. Nature reviews. Molecular cell biology 9: 
759-769 
52 Lee J.H., Goodarzi A.A., Jeggo P.A. & Paull T.T. 
(2010) 53BP1 promotes ATM activity through 
direct interactions with the MRN complex. The 
EMBO journal 29: 574-585 
53 Gatei M., Jakob B., Chen P. et al. (2011) ATM 
protein-dependent phosphorylation of Rad50 
protein regulates DNA repair and cell cycle 
control. The Journal of biological chemistry 286: 
31542-31556 
54 Rahal E.A., Henricksen L.A., Li Y. et al. (2010) ATM 
regulates Mre11-dependent DNA end-
degradation and microhomology-mediated end 
joining. Cell cycle 9: 2866-2877 
55 Buscemi G., Savio C., Zannini L. et al. (2001) Chk2 
activation dependence on Nbs1 after DNA 
damage. Molecular and cellular biology 21: 5214-
5222 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 77 
  
56 Girard P.M., Riballo E., Begg A.C., Waugh A. & 
Jeggo P.A. (2002) Nbs1 promotes ATM dependent 
phosphorylation events including those required 
for G1/S arrest. Oncogene 21: 4191-4199 
57 Matsuoka S., Rotman G., Ogawa A. et al. (2000) 
Ataxia telangiectasia-mutated phosphorylates 
Chk2 in vivo and in vitro. Proceedings of the 
National Academy of Sciences of the United States 
of America 97: 10389-10394 
58 Ahn J.Y., Schwarz J.K., Piwnica-Worms H. & 
Canman C.E. (2000) Threonine 68 
phosphorylation by ataxia telangiectasia mutated 
is required for efficient activation of Chk2 in 
response to ionizing radiation. Cancer research 
60: 5934-5936 
59 Ahn J.Y., Li X., Davis H.L. & Canman C.E. (2002) 
Phosphorylation of threonine 68 promotes 
oligomerization and autophosphorylation of the 
Chk2 protein kinase via the forkhead-associated 
domain. The Journal of biological chemistry 277: 
19389-19395 
60 Bartek J., Falck J. & Lukas J. (2001) CHK2 kinase--a 
busy messenger. Nature reviews. Molecular cell 
biology 2: 877-886 
61 Ward I.M., Wu X. & Chen J. (2001) Threonine 68 
of Chk2 is phosphorylated at sites of DNA strand 
breaks. The Journal of biological chemistry 276: 
47755-47758 
62 Lee C.H. & Chung J.H. (2001) The hCds1 (Chk2)-
FHA domain is essential for a chain of 
phosphorylation events on hCds1 that is induced 
by ionizing radiation. The Journal of biological 
chemistry 276: 30537-30541 
63 Zhao H. & Piwnica-Worms H. (2001) ATR-
mediated checkpoint pathways regulate 
phosphorylation and activation of human Chk1. 
Molecular and cellular biology 21: 4129-4139 
64 Capasso H., Palermo C., Wan S. et al. (2002) 
Phosphorylation activates Chk1 and is required 
for checkpoint-mediated cell cycle arrest. Journal 
of cell science 115: 4555-4564 
65 Tapia-Alveal C., Calonge T.M. & O'Connell M.J. 
(2009) Regulation of chk1. Cell division 4: 8 
66 Bartek J. & Lukas J. (2003) Chk1 and Chk2 kinases 
in checkpoint control and cancer. Cancer cell 3: 
421-429 
67 Boutros R., Lobjois V. & Ducommun B. (2007) 
CDC25 phosphatases in cancer cells: key players? 
Good targets? Nature reviews. Cancer 7: 495-507 
68 Shen T. & Huang S. (2012) The role of Cdc25A in 
the regulation of cell proliferation and apoptosis. 
Anti-cancer agents in medicinal chemistry 12: 631-
639 
69 Moore J.D. (2013) In the wrong place at the 
wrong time: does cyclin mislocalization drive 
oncogenic transformation? Nature reviews. 
Cancer 13: 201-208 
70 Medema R.H. & Macurek L. (2012) Checkpoint 
control and cancer. Oncogene 31: 2601-2613 
71 Sorensen C.S. & Syljuasen R.G. (2012) 
Safeguarding genome integrity: the checkpoint 
kinases ATR, CHK1 and WEE1 restrain CDK activity 
during normal DNA replication. Nucleic acids 
research 40: 477-486 
72 Liu P., Barkley L.R., Day T. et al. (2006) The Chk1-
mediated S-phase checkpoint targets initiation 
factor Cdc45 via a Cdc25A/Cdk2-independent 
mechanism. The Journal of biological chemistry 
281: 30631-30644 
73 Heffernan T.P., Unsal-Kacmaz K., Heinloth A.N. et 
al. (2007) Cdc7-Dbf4 and the human S checkpoint 
response to UVC. The Journal of biological 
chemistry 282: 9458-9468 
74 Shimada M., Niida H., Zineldeen D.H. et al. (2008) 
Chk1 is a histone H3 threonine 11 kinase that 
regulates DNA damage-induced transcriptional 
repression. Cell 132: 221-232 
75 Banin S., Moyal L., Shieh S. et al. (1998) Enhanced 
phosphorylation of p53 by ATM in response to 
DNA damage. Science 281: 1674-1677 
76 Canman C.E., Lim D.S., Cimprich K.A. et al. (1998) 
Activation of the ATM kinase by ionizing radiation 
and phosphorylation of p53. Science 281: 1677-
1679 
77 Khanna K.K., Keating K.E., Kozlov S. et al. (1998) 
ATM associates with and phosphorylates p53: 
mapping the region of interaction. Nature 
genetics 20: 398-400 
78 Haupt Y., Maya R., Kazaz A. & Oren M. (1997) 
Mdm2 promotes the rapid degradation of p53. 
Nature 387: 296-299 
79 Oren M., Damalas A., Gottlieb T. et al. (2002) 
Regulation of p53: intricate loops and delicate 
balances. Biochemical pharmacology 64: 865-871 
80 Tibbetts R.S., Brumbaugh K.M., Williams J.M. et 
al. (1999) A role for ATR in the DNA damage-
induced phosphorylation of p53. Genes & 
development 13: 152-157 
81 Shieh S.Y., Ahn J., Tamai K., Taya Y. & Prives C. 
(2000) The human homologs of checkpoint 
kinases Chk1 and Cds1 (Chk2) phosphorylate p53 
at multiple DNA damage-inducible sites. Genes & 
development 14: 289-300 
82 Hirao A., Kong Y.Y., Matsuoka S. et al. (2000) DNA 
damage-induced activation of p53 by the 
checkpoint kinase Chk2. Science 287: 1824-1827 
83 Kruse J.P. & Gu W. (2009) Modes of p53 
regulation. Cell 137: 609-622 
84 Gu B. & Zhu W.G. (2012) Surf the post-
translational modification network of p53 
regulation. International journal of biological 
sciences 8: 672-684 
85 Khosravi R., Maya R., Gottlieb T. et al. (1999) 
Rapid ATM-dependent phosphorylation of MDM2 
precedes p53 accumulation in response to DNA 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 78 
  
damage. Proceedings of the National Academy of 
Sciences of the United States of America 96: 
14973-14977 
86 Wade M., Li Y.C. & Wahl G.M. (2013) MDM2, 
MDMX and p53 in oncogenesis and cancer 
therapy. Nature reviews. Cancer 13: 83-96 
87 Olsson A., Manzl C., Strasser A. & Villunger A. 
(2007) How important are post-translational 
modifications in p53 for selectivity in target-gene 
transcription and tumour suppression? Cell death 
and differentiation 14: 1561-1575 
88 Riley T., Sontag E., Chen P. & Levine A. (2008) 
Transcriptional control of human p53-regulated 
genes. Nature reviews. Molecular cell biology 9: 
402-412 
89 Sullivan K.D., Gallant-Behm C.L., Henry R.E., 
Fraikin J.L. & Espinosa J.M. (2012) The p53 circuit 
board. Biochimica et biophysica acta 1825: 229-
244 
90 Brugarolas J., Moberg K., Boyd S.D. et al. (1999) 
Inhibition of cyclin-dependent kinase 2 by p21 is 
necessary for retinoblastoma protein-mediated 
G1 arrest after gamma-irradiation. Proceedings of 
the National Academy of Sciences of the United 
States of America 96: 1002-1007 
91 Tan T. & Chu G. (2002) p53 Binds and activates 
the xeroderma pigmentosum DDB2 gene in 
humans but not mice. Molecular and cellular 
biology 22: 3247-3254 
92 Batchelor E., Loewer A. & Lahav G. (2009) The ups 
and downs of p53: understanding protein 
dynamics in single cells. Nature reviews. Cancer 9: 
371-377 
93 Nakano K. & Vousden K.H. (2001) PUMA, a novel 
proapoptotic gene, is induced by p53. Mol Cell 7: 
683-694 
94 Youle R.J. & Strasser A. (2008) The BCL-2 protein 
family: opposing activities that mediate cell 
death. Nature reviews. Molecular cell biology 9: 
47-59 
95 Green D.R. & Kroemer G. (2009) Cytoplasmic 
functions of the tumour suppressor p53. Nature 
458: 1127-1130 
96 Cohen P. (2001) The role of protein 
phosphorylation in human health and disease. 
The Sir Hans Krebs Medal Lecture. European 
journal of biochemistry / FEBS 268: 5001-5010 
97 Moorhead G.B., Trinkle-Mulcahy L. & Ulke-Lemee 
A. (2007) Emerging roles of nuclear protein 
phosphatases. Nature reviews. Molecular cell 
biology 8: 234-244 
98 Fellner T., Lackner D.H., Hombauer H. et al. (2003) 
A novel and essential mechanism determining 
specificity and activity of protein phosphatase 2A 
(PP2A) in vivo. Genes & development 17: 2138-
2150 
99 Hombauer H., Weismann D., Mudrak I. et al. 
(2007) Generation of active protein phosphatase 
2A is coupled to holoenzyme assembly. PLoS 
biology 5: e155 
100 Seshacharyulu P., Pandey P., Datta K. & Batra S.K. 
(2013) Phosphatase: PP2A structural importance, 
regulation and its aberrant expression in cancer. 
Cancer letters 335: 9-18 
101 Janssens V. & Goris J. (2001) Protein phosphatase 
2A: a highly regulated family of serine/threonine 
phosphatases implicated in cell growth and 
signalling. The Biochemical journal 353: 417-439 
102 Perrotti D. & Neviani P. (2013) Protein 
phosphatase 2A: a target for anticancer therapy. 
The lancet oncology 14: e229-238 
103 Eichhorn P.J., Creyghton M.P. & Bernards R. 
(2009) Protein phosphatase 2A regulatory 
subunits and cancer. Biochimica et biophysica 
acta 1795: 1-15 
104 Bononi A., Agnoletto C., De Marchi E. et al. (2011) 
Protein kinases and phosphatases in the control 
of cell fate. Enzyme research 2011: 329098 
105 Brautigan D.L. (1995) Flicking the switches: 
phosphorylation of serine/threonine protein 
phosphatases. Seminars in cancer biology 6: 211-
217 
106 Tolstykh T., Lee J., Vafai S. & Stock J.B. (2000) 
Carboxyl methylation regulates phosphoprotein 
phosphatase 2A by controlling the association of 
regulatory B subunits. The EMBO journal 19: 
5682-5691 
107 Shouse G.P., Nobumori Y., Panowicz M.J. & Liu X. 
(2011) ATM-mediated phosphorylation activates 
the tumor-suppressive function of B56gamma-
PP2A. Oncogene 30: 3755-3765 
108 Muller S. & Kramer O.H. (2010) Inhibitors of 
HDACs--effective drugs against cancer? Current 
cancer drug targets 10: 210-228 
109 Durrin L.K., Mann R.K., Kayne P.S. & Grunstein M. 
(1991) Yeast histone H4 N-terminal sequence is 
required for promoter activation in vivo. Cell 65: 
1023-1031 
110 Thiagalingam S., Cheng K.H., Lee H.J. et al. (2003) 
Histone deacetylases: unique players in shaping 
the epigenetic histone code. Annals of the New 
York Academy of Sciences 983: 84-100 
111 Spange S., Wagner T., Heinzel T. & Kramer O.H. 
(2009) Acetylation of non-histone proteins 
modulates cellular signalling at multiple levels. 
The international journal of biochemistry & cell 
biology 41: 185-198 
112 Ocker M. (2010) Deacetylase inhibitors - focus on 
non-histone targets and effects. World journal of 
biological chemistry 1: 55-61 
113 Ververis K., Hiong A., Karagiannis T.C. & Licciardi 
P.V. (2013) Histone deacetylase inhibitors 
(HDACIs): multitargeted anticancer agents. 
Biologics : targets & therapy 7: 47-60 
114 de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp 
S. & van Kuilenburg A.B. (2003) Histone 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 79 
  
deacetylases (HDACs): characterization of the 
classical HDAC family. The Biochemical journal 
370: 737-749 
115 Buck S.W., Gallo C.M. & Smith J.S. (2004) Diversity 
in the Sir2 family of protein deacetylases. Journal 
of leukocyte biology 75: 939-950 
116 Yang X.J. & Seto E. (2008) The Rpd3/Hda1 family 
of lysine deacetylases: from bacteria and yeast to 
mice and men. Nature reviews. Molecular cell 
biology 9: 206-218 
117 Martin M., Kettmann R. & Dequiedt F. (2007) 
Class IIa histone deacetylases: regulating the 
regulators. Oncogene 26: 5450-5467 
118 Gregoretti I.V., Lee Y.M. & Goodson H.V. (2004) 
Molecular evolution of the histone deacetylase 
family: functional implications of phylogenetic 
analysis. Journal of molecular biology 338: 17-31 
119 Denu J.M. (2005) The Sir 2 family of protein 
deacetylases. Current opinion in chemical biology 
9: 431-440 
120 Bolden J.E., Peart M.J. & Johnstone R.W. (2006) 
Anticancer activities of histone deacetylase 
inhibitors. Nature reviews. Drug discovery 5: 769-
784 
121 Bernstein B.E., Meissner A. & Lander E.S. (2007) 
The mammalian epigenome. Cell 128: 669-681 
122 Wang Z., Zang C., Cui K. et al. (2009) Genome-
wide mapping of HATs and HDACs reveals distinct 
functions in active and inactive genes. Cell 138: 
1019-1031 
123 Spiegel S., Milstien S. & Grant S. (2012) 
Endogenous modulators and pharmacological 
inhibitors of histone deacetylases in cancer 
therapy. Oncogene 31: 537-551 
124 Weichert W., Roske A., Niesporek S. et al. (2008) 
Class I histone deacetylase expression has 
independent prognostic impact in human 
colorectal cancer: specific role of class I histone 
deacetylases in vitro and in vivo. Clinical cancer 
research : an official journal of the American 
Association for Cancer Research 14: 1669-1677 
125 Montgomery R.L., Davis C.A., Potthoff M.J. et al. 
(2007) Histone deacetylases 1 and 2 redundantly 
regulate cardiac morphogenesis, growth, and 
contractility. Genes & development 21: 1790-1802 
126 Montgomery R.L., Hsieh J., Barbosa A.C., 
Richardson J.A. & Olson E.N. (2009) Histone 
deacetylases 1 and 2 control the progression of 
neural precursors to neurons during brain 
development. Proceedings of the National 
Academy of Sciences of the United States of 
America 106: 7876-7881 
127 Wilting R.H., Yanover E., Heideman M.R. et al. 
(2010) Overlapping functions of Hdac1 and Hdac2 
in cell cycle regulation and haematopoiesis. The 
EMBO journal 29: 2586-2597 
128 Lagger G., O'Carroll D., Rembold M. et al. (2002) 
Essential function of histone deacetylase 1 in 
proliferation control and CDK inhibitor repression. 
The EMBO journal 21: 2672-2681 
129 Huang B.H., Laban M., Leung C.H. et al. (2005) 
Inhibition of histone deacetylase 2 increases 
apoptosis and p21Cip1/WAF1 expression, 
independent of histone deacetylase 1. Cell death 
and differentiation 12: 395-404 
130 Miller K.M., Tjeertes J.V., Coates J. et al. (2010) 
Human HDAC1 and HDAC2 function in the DNA-
damage response to promote DNA 
nonhomologous end-joining. Nature structural & 
molecular biology 17: 1144-1151 
131 Wen Y.D., Perissi V., Staszewski L.M. et al. (2000) 
The histone deacetylase-3 complex contains 
nuclear receptor corepressors. Proceedings of the 
National Academy of Sciences of the United States 
of America 97: 7202-7207 
132 Guenther M.G., Lane W.S., Fischle W. et al. (2000) 
A core SMRT corepressor complex containing 
HDAC3 and TBL1, a WD40-repeat protein linked 
to deafness. Genes & development 14: 1048-1057 
133 Ishii S., Kurasawa Y., Wong J. & Yu-Lee L.Y. (2008) 
Histone deacetylase 3 localizes to the mitotic 
spindle and is required for kinetochore-
microtubule attachment. Proceedings of the 
National Academy of Sciences of the United States 
of America 105: 4179-4184 
134 Eot-Houllier G., Fulcrand G., Watanabe Y., 
Magnaghi-Jaulin L. & Jaulin C. (2008) Histone 
deacetylase 3 is required for centromeric H3K4 
deacetylation and sister chromatid cohesion. 
Genes & development 22: 2639-2644 
135 Li Y., Kao G.D., Garcia B.A. et al. (2006) A novel 
histone deacetylase pathway regulates mitosis by 
modulating Aurora B kinase activity. Genes & 
development 20: 2566-2579 
136 Bhaskara S., Chyla B.J., Amann J.M. et al. (2008) 
Deletion of histone deacetylase 3 reveals critical 
roles in S phase progression and DNA damage 
control. Mol Cell 30: 61-72 
137 Bhaskara S., Knutson S.K., Jiang G. et al. (2010) 
Hdac3 is essential for the maintenance of 
chromatin structure and genome stability. Cancer 
cell 18: 436-447 
138 Montgomery R.L., Potthoff M.J., Haberland M. et 
al. (2008) Maintenance of cardiac energy 
metabolism by histone deacetylase 3 in mice. The 
Journal of clinical investigation 118: 3588-3597 
139 Miller T.A., Witter D.J. & Belvedere S. (2003) 
Histone deacetylase inhibitors. Journal of 
medicinal chemistry 46: 5097-5116 
140 Minucci S. & Pelicci P.G. (2006) Histone 
deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. 
Nature reviews. Cancer 6: 38-51 
141 Marks P.A. (2010) Histone deacetylase inhibitors: 
a chemical genetics approach to understanding 
cellular functions. Biochimica et biophysica acta 
1799: 717-725 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 80 
  
142 Burgess A., Ruefli A., Beamish H. et al. (2004) 
Histone deacetylase inhibitors specifically kill 
nonproliferating tumour cells. Oncogene 23: 
6693-6701 




144 Dokmanovic M. & Marks P.A. (2005) Prospects: 
histone deacetylase inhibitors. Journal of cellular 
biochemistry 96: 293-304 
145 Ma X., Ezzeldin H.H. & Diasio R.B. (2009) Histone 
deacetylase inhibitors: current status and 
overview of recent clinical trials. Drugs 69: 1911-
1934 
146 Marks P.A. & Breslow R. (2007) Dimethyl sulfoxide 
to vorinostat: development of this histone 
deacetylase inhibitor as an anticancer drug. 
Nature biotechnology 25: 84-90 
147 Campas-Moya C. (2009) Romidepsin for the 
treatment of cutaneous T-cell lymphoma. Drugs 
of today 45: 787-795 
148 Bradner J.E., Mak R., Tanguturi S.K. et al. (2010) 
Chemical genetic strategy identifies histone 
deacetylase 1 (HDAC1) and HDAC2 as therapeutic 
targets in sickle cell disease. Proceedings of the 
National Academy of Sciences of the United States 
of America 107: 12617-12622 
149 National-Institutes-of-Health. clinical trials on MS-
275, 
<http://clinicaltrials.gov/ct2/results?term=Entinos
tat&pg=1 > (03-19-2014). 
150 Laemmli U.K. (1970) Cleavage of structural 
proteins during the assembly of the head of 
bacteriophage T4. Nature 227: 680-685 
151 Hehlmann R., Heimpel H., Hasford J. et al. (1993) 
Randomized comparison of busulfan and 
hydroxyurea in chronic myelogenous leukemia: 
prolongation of survival by hydroxyurea. The 
German CML Study Group. Blood 82: 398-407 
152 Harousseau J.L., Martinelli G., Jedrzejczak W.W. et 
al. (2009) A randomized phase 3 study of 
tipifarnib compared with best supportive care, 
including hydroxyurea, in the treatment of newly 
diagnosed acute myeloid leukemia in patients 70 
years or older. Blood 114: 1166-1173 
153 Vokes E.E., Haraf D.J., Brockstein B.E. & 
Weichselbaum R.R. (1999) Paclitaxel, 5-
fluorouracil, hydroxyurea, and concomitant 
radiation therapy for poor-prognosis head and 
neck cancer. Semin Radiat Oncol 9: 70-76 
154 Saban N. & Bujak M. (2009) Hydroxyurea and 
hydroxamic acid derivatives as antitumor drugs. 
Cancer Chemother Pharmacol 64: 213-221 
155 Elford H.L. (1968) Effect of hydroxyurea on 
ribonucleotide reductase. Biochem Biophys Res 
Commun 33: 129-135 
156 Kramer O.H., Knauer S.K., Zimmermann D., 
Stauber R.H. & Heinzel T. (2008) Histone 
deacetylase inhibitors and hydroxyurea modulate 
the cell cycle and cooperatively induce apoptosis. 
Oncogene 27: 732-740 
157 Stauber R.H., Knauer S.K., Habtemichael N. et al. 
(2012) A combination of a ribonucleotide 
reductase inhibitor and histone deacetylase 
inhibitors downregulates EGFR and triggers BIM-
dependent apoptosis in head and neck cancer. 
Oncotarget 3: 31-43 
158 Waldman T., Kinzler K.W. & Vogelstein B. (1995) 
p21 is necessary for the p53-mediated G1 arrest 
in human cancer cells. Cancer research 55: 5187-
5190 
159 Waldman T., Lengauer C., Kinzler K.W. & 
Vogelstein B. (1996) Uncoupling of S phase and 
mitosis induced by anticancer agents in cells 
lacking p21. Nature 381: 713-716 
160 Bunz F., Dutriaux A., Lengauer C. et al. (1998) 
Requirement for p53 and p21 to sustain G2 arrest 
after DNA damage. Science 282: 1497-1501 
161 Grem J.L. (2000) 5-Fluorouracil: forty-plus and still 
ticking. A review of its preclinical and clinical 
development. Investigational new drugs 18: 299-
313 
162 Longley D.B., Harkin D.P. & Johnston P.G. (2003) 
5-fluorouracil: mechanisms of action and clinical 
strategies. Nature reviews. Cancer 3: 330-338 
163 Zhang N., Yin Y., Xu S.J. & Chen W.S. (2008) 5-
Fluorouracil: mechanisms of resistance and 
reversal strategies. Molecules 13: 1551-1569 
164 Liu Y. & Kulesz-Martin M. (2001) p53 protein at 
the hub of cellular DNA damage response 
pathways through sequence-specific and non-
sequence-specific DNA binding. Carcinogenesis 
22: 851-860 
165 Lavin M.F. & Gueven N. (2006) The complexity of 
p53 stabilization and activation. Cell death and 
differentiation 13: 941-950 
166 D'Orazi G., Cecchinelli B., Bruno T. et al. (2002) 
Homeodomain-interacting protein kinase-2 
phosphorylates p53 at Ser 46 and mediates 
apoptosis. Nature cell biology 4: 11-19 
167 Taira N., Nihira K., Yamaguchi T., Miki Y. & Yoshida 
K. (2007) DYRK2 is targeted to the nucleus and 
controls p53 via Ser46 phosphorylation in the 
apoptotic response to DNA damage. Mol Cell 25: 
725-738 
168 Woo G.H., Bak E.J., Nakayama H. & Doi K. (2006) 
Molecular mechanisms of hydroxyurea(HU)-
induced apoptosis in the mouse fetal brain. 
Neurotoxicology and teratology 28: 125-134 
169 Schneider G., Henrich A., Greiner G. et al. (2010) 
Cross talk between stimulated NF-kappaB and the 
tumor suppressor p53. Oncogene 29: 2795-2806 
170 Gartel A.L., Serfas M.S. & Tyner A.L. (1996) p21--
negative regulator of the cell cycle. Proceedings of 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 81 
  
the Society for Experimental Biology and 
Medicine. Society for Experimental Biology and 
Medicine 213: 138-149 
171 Wu X., Bayle J.H., Olson D. & Levine A.J. (1993) 
The p53-mdm-2 autoregulatory feedback loop. 
Genes & development 7: 1126-1132 
172 Lu X., Ma O., Nguyen T.A. et al. (2007) The Wip1 
Phosphatase acts as a gatekeeper in the p53-
Mdm2 autoregulatory loop. Cancer cell 12: 342-
354 
173 Sowa Y., Orita T., Minamikawa S. et al. (1997) 
Histone deacetylase inhibitor activates the 
WAF1/Cip1 gene promoter through the Sp1 sites. 
Biochem Biophys Res Commun 241: 142-150 
174 Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S. & 
Bonner W.M. (1998) DNA double-stranded breaks 
induce histone H2AX phosphorylation on serine 
139. The Journal of biological chemistry 273: 
5858-5868 
175 Pilch D.R., Sedelnikova O.A., Redon C. et al. (2003) 
Characteristics of gamma-H2AX foci at DNA 
double-strand breaks sites. Biochemistry and cell 
biology = Biochimie et biologie cellulaire 81: 123-
129 
176 Errico A. & Costanzo V. (2012) Mechanisms of 
replication fork protection: a safeguard for 
genome stability. Critical reviews in biochemistry 
and molecular biology 47: 222-235 
177 Koc A., Wheeler L.J., Mathews C.K. & Merrill G.F. 
(2004) Hydroxyurea arrests DNA replication by a 
mechanism that preserves basal dNTP pools. The 
Journal of biological chemistry 279: 223-230 
178 Alvino G.M., Collingwood D., Murphy J.M. et al. 
(2007) Replication in hydroxyurea: it's a matter of 
time. Molecular and cellular biology 27: 6396-
6406 
179 Johnson C.A., Forster T.H., Winterford C.M. & 
Allan D.J. (1992) Hydroxyurea induces apoptosis 
and regular DNA fragmentation in a Burkitt's 
lymphoma cell line. Biochimica et biophysica acta 
1136: 1-4 
180 Gui C.Y., Jiang C., Xie H.Y. & Qian R.L. (1997) The 
apoptosis of HEL cells induced by hydroxyurea. 
Cell research 7: 91-97 
181 Tewari M., Quan L.T., O'Rourke K. et al. (1995) 
Yama/CPP32 beta, a mammalian homolog of CED-
3, is a CrmA-inhibitable protease that cleaves the 
death substrate poly(ADP-ribose) polymerase. Cell 
81: 801-809 
182 Patel T., Gores G.J. & Kaufmann S.H. (1996) The 
role of proteases during apoptosis. FASEB journal 
: official publication of the Federation of American 
Societies for Experimental Biology 10: 587-597 
183 Kaufmann S.H., Desnoyers S., Ottaviano Y., 
Davidson N.E. & Poirier G.G. (1993) Specific 
proteolytic cleavage of poly(ADP-ribose) 
polymerase: an early marker of chemotherapy-
induced apoptosis. Cancer research 53: 3976-
3985 
184 Vermes I., Haanen C., Steffens-Nakken H. & 
Reutelingsperger C. (1995) A novel assay for 
apoptosis. Flow cytometric detection of 
phosphatidylserine expression on early apoptotic 
cells using fluorescein labelled Annexin V. Journal 
of immunological methods 184: 39-51 
185 Lopez-Contreras A.J. & Fernandez-Capetillo O. 
(2010) The ATR barrier to replication-born DNA 
damage. DNA repair 9: 1249-1255 
186 Busby E.C., Leistritz D.F., Abraham R.T., Karnitz 
L.M. & Sarkaria J.N. (2000) The radiosensitizing 
agent 7-hydroxystaurosporine (UCN-01) inhibits 
the DNA damage checkpoint kinase hChk1. Cancer 
research 60: 2108-2112 
187 Toledo L.I., Murga M., Zur R. et al. (2011) A cell-
based screen identifies ATR inhibitors with 
synthetic lethal properties for cancer-associated 
mutations. Nature structural & molecular biology 
18: 721-727 
188 Hickson I., Zhao Y., Richardson C.J. et al. (2004) 
Identification and characterization of a novel and 
specific inhibitor of the ataxia-telangiectasia 
mutated kinase ATM. Cancer research 64: 9152-
9159 
189 Qi Y., Schoene N.W., Lartey F.M. & Cheng W.H. 
(2010) Selenium compounds activate ATM-
dependent DNA damage response via the 
mismatch repair protein hMLH1 in colorectal 
cancer cells. The Journal of biological chemistry 
285: 33010-33017 
190 Zakikhani M., Bazile M., Hashemi S. et al. (2012) 
Alterations in cellular energy metabolism 
associated with the antiproliferative effects of the 
ATM inhibitor KU-55933 and with metformin. PloS 
one 7: e49513 
191 Honkanen R.E. (1993) Cantharidin, another 
natural toxin that inhibits the activity of 
serine/threonine protein phosphatases types 1 
and 2A. FEBS letters 330: 283-286 
192 Bialojan C. & Takai A. (1988) Inhibitory effect of a 
marine-sponge toxin, okadaic acid, on protein 
phosphatases. Specificity and kinetics. The 
Biochemical journal 256: 283-290 




194 Hendrix P., Mayer-Jackel R.E., Cron P. et al. (1993) 
Structure and expression of a 72-kDa regulatory 
subunit of protein phosphatase 2A. Evidence for 
different size forms produced by alternative 
splicing. The Journal of biological chemistry 268: 
15267-15276 
195 Brown K.D., Ziv Y., Sadanandan S.N. et al. (1997) 
The ataxia-telangiectasia gene product, a 
constitutively expressed nuclear protein that is 
not up-regulated following genome damage. 
Proceedings of the National Academy of Sciences 
of the United States of America 94: 1840-1845 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 82 
  
196 Watters D., Khanna K.K., Beamish H. et al. (1997) 
Cellular localisation of the ataxia-telangiectasia 
(ATM) gene product and discrimination between 
mutated and normal forms. Oncogene 14: 1911-
1921 
197 Parker W.B. (2009) Enzymology of purine and 
pyrimidine antimetabolites used in the treatment 
of cancer. Chemical reviews 109: 2880-2893 
198 Szekeres T., Fritzer-Szekeres M. & Elford H. (1997) 
The enzyme ribonucleotide reductase: target for 
antitumor and anti-HIV therapy. Critical reviews in 
clinical laboratory sciences 34: 503-528 
199 Branzei D. & Foiani M. (2005) The DNA damage 
response during DNA replication. Current opinion 
in cell biology 17: 568-575 
200 Flis S., Gnyszka A., Flis K. & Splawinski J. (2010) 
MS275 enhances cytotoxicity induced by 5-
fluorouracil in the colorectal cancer cells. 
European journal of pharmacology 627: 26-32 
201 Sorensen C.S., Hansen L.T., Dziegielewski J. et al. 
(2005) The cell-cycle checkpoint kinase Chk1 is 
required for mammalian homologous 
recombination repair. Nature cell biology 7: 195-
201 
202 Saintigny Y., Delacote F., Vares G. et al. (2001) 
Characterization of homologous recombination 
induced by replication inhibition in mammalian 
cells. The EMBO journal 20: 3861-3870 
203 Lundin C., Erixon K., Arnaudeau C. et al. (2002) 
Different roles for nonhomologous end joining 
and homologous recombination following 
replication arrest in mammalian cells. Molecular 
and cellular biology 22: 5869-5878 
204 Kim G.D., Choi Y.H., Dimtchev A. et al. (1999) 
Sensing of ionizing radiation-induced DNA 
damage by ATM through interaction with histone 
deacetylase. The Journal of biological chemistry 
274: 31127-31130 
205 Tang Y., Zhao W., Chen Y., Zhao Y. & Gu W. (2008) 
Acetylation is indispensable for p53 activation. 
Cell 133: 612-626 
206 Ito A., Kawaguchi Y., Lai C.H. et al. (2002) MDM2-
HDAC1-mediated deacetylation of p53 is required 
for its degradation. The EMBO journal 21: 6236-
6245 
207 Brooks C. & Gu W. (2011) The impact of 
acetylation and deacetylation on the p53 
pathway. Protein & cell 2: 456-462 
208 Gottifredi V., Shieh S., Taya Y. & Prives C. (2001) 
p53 accumulates but is functionally impaired 
when DNA synthesis is blocked. Proceedings of 
the National Academy of Sciences of the United 
States of America 98: 1036-1041 
209 Sambucetti L.C., Fischer D.D., Zabludoff S. et al. 
(1999) Histone deacetylase inhibition selectively 
alters the activity and expression of cell cycle 
proteins leading to specific chromatin acetylation 
and antiproliferative effects. The Journal of 
biological chemistry 274: 34940-34947 
210 Richon V.M., Sandhoff T.W., Rifkind R.A. & Marks 
P.A. (2000) Histone deacetylase inhibitor 
selectively induces p21WAF1 expression and 
gene-associated histone acetylation. Proceedings 
of the National Academy of Sciences of the United 
States of America 97: 10014-10019 
211 Beckerman R., Donner A.J., Mattia M. et al. (2009) 
A role for Chk1 in blocking transcriptional 
elongation of p21 RNA during the S-phase 
checkpoint. Genes & development 23: 1364-1377 
212 Thurn K.T., Thomas S., Raha P., Qureshi I. & 
Munster P.N. (2013) Histone deacetylase 
regulation of ATM-mediated DNA damage 
signaling. Molecular cancer therapeutics 12: 2078-
2087 
213 Lee J.H., Choy M.L., Ngo L., Foster S.S. & Marks 
P.A. (2010) Histone deacetylase inhibitor induces 
DNA damage, which normal but not transformed 
cells can repair. Proceedings of the National 
Academy of Sciences of the United States of 
America 107: 14639-14644 
214 Gaymes T.J., Padua R.A., Pla M. et al. (2006) 
Histone deacetylase inhibitors (HDI) cause DNA 
damage in leukemia cells: a mechanism for 
leukemia-specific HDI-dependent apoptosis? 
Molecular cancer research : MCR 4: 563-573 
215 Wang H., Zhou W., Zheng Z. et al. (2012) The 
HDAC inhibitor depsipeptide transactivates the 
p53/p21 pathway by inducing DNA damage. DNA 
repair 11: 146-156 
216 Ikura T., Tashiro S., Kakino A. et al. (2007) DNA 
damage-dependent acetylation and 
ubiquitination of H2AX enhances chromatin 
dynamics. Molecular and cellular biology 27: 
7028-7040 
217 Macurek L., Lindqvist A., Voets O. et al. (2010) 
Wip1 phosphatase is associated with chromatin 
and dephosphorylates gammaH2AX to promote 
checkpoint inhibition. Oncogene 29: 2281-2291 
218 Cha H., Lowe J.M., Li H. et al. (2010) Wip1 directly 
dephosphorylates gamma-H2AX and attenuates 
the DNA damage response. Cancer research 70: 
4112-4122 
219 Lu X., Nguyen T.A., Moon S.H. et al. (2008) The 
type 2C phosphatase Wip1: an oncogenic 
regulator of tumor suppressor and DNA damage 
response pathways. Cancer metastasis reviews 
27: 123-135 
220 Arnaudeau C., Tenorio Miranda E., Jenssen D. & 
Helleday T. (2000) Inhibition of DNA synthesis is a 
potent mechanism by which cytostatic drugs 
induce homologous recombination in mammalian 
cells. Mutation research 461: 221-228 
221 Petermann E., Orta M.L., Issaeva N., Schultz N. & 
Helleday T. (2010) Hydroxyurea-stalled replication 
forks become progressively inactivated and 
require two different RAD51-mediated pathways 
for restart and repair. Mol Cell 37: 492-502 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 83 
  
222 Kachhap S.K., Rosmus N., Collis S.J. et al. (2010) 
Downregulation of homologous recombination 
DNA repair genes by HDAC inhibition in prostate 
cancer is mediated through the E2F1 transcription 
factor. PloS one 5: e11208 
223 Adimoolam S., Sirisawad M., Chen J. et al. (2007) 
HDAC inhibitor PCI-24781 decreases RAD51 
expression and inhibits homologous 
recombination. Proceedings of the National 
Academy of Sciences of the United States of 
America 104: 19482-19487 
224 Cazzalini O., Scovassi A.I., Savio M., Stivala L.A. & 
Prosperi E. (2010) Multiple roles of the cell cycle 
inhibitor p21(CDKN1A) in the DNA damage 
response. Mutation research 704: 12-20 
225 Symeonidou I.E., Taraviras S. & Lygerou Z. (2012) 
Control over DNA replication in time and space. 
FEBS letters 586: 2803-2812 
226 Painter R.B., Drew R.M. & Giauque B.G. (1960) 
Further studies on deoxyribonucleic acid 
metabolism in mammalian cell cultures. 
Experimental cell research 21: 98-105 
227 Petermann E. & Caldecott K.W. (2006) Evidence 
that the ATR/Chk1 pathway maintains normal 
replication fork progression during unperturbed S 
phase. Cell cycle 5: 2203-2209 
228 Nam E.A. & Cortez D. (2011) ATR signalling: more 
than meeting at the fork. The Biochemical journal 
436: 527-536 
229 Bundy R., Marczin N., Chester A.H. & Yacoub M. 
(1999) Differential regulation of DNA synthesis by 
nitric oxide and hydroxyurea in vascular smooth 
muscle cells. The American journal of physiology 
277: H1799-1807 
230 Lossaint G., Besnard E., Fisher D., Piette J. & Dulic 
V. (2011) Chk1 is dispensable for G2 arrest in 
response to sustained DNA damage when the 
ATM/p53/p21 pathway is functional. Oncogene 
30: 4261-4274 
231 Dalgaard J.Z. (2012) Causes and consequences of 
ribonucleotide incorporation into nuclear DNA. 
Trends in genetics : TIG 28: 592-597 
232 Goksenin A.Y., Zahurancik W., LeCompte K.G. et 
al. (2012) Human DNA polymerase epsilon is able 
to efficiently extend from multiple consecutive 
ribonucleotides. The Journal of biological 
chemistry 287: 42675-42684 
233 Xu W., Parmigiani R. & Marks P. (2007) Histone 
deacetylase inhibitors: molecular mechanisms of 
action. Oncogene 26: 5541-5552 
234 Liu Q., Guntuku S., Cui X.S. et al. (2000) Chk1 is an 
essential kinase that is regulated by Atr and 
required for the G(2)/M DNA damage checkpoint. 
Genes & development 14: 1448-1459 
235 Takai H., Tominaga K., Motoyama N. et al. (2000) 
Aberrant cell cycle checkpoint function and early 
embryonic death in Chk1(-/-) mice. Genes & 
development 14: 1439-1447 
236 Syljuasen R.G., Sorensen C.S., Hansen L.T. et al. 
(2005) Inhibition of human Chk1 causes increased 
initiation of DNA replication, phosphorylation of 
ATR targets, and DNA breakage. Molecular and 
cellular biology 25: 3553-3562 
237 Myers K., Gagou M.E., Zuazua-Villar P., Rodriguez 
R. & Meuth M. (2009) ATR and Chk1 suppress a 
caspase-3-dependent apoptotic response 
following DNA replication stress. PLoS genetics 5: 
e1000324 
238 Takai H., Naka K., Okada Y. et al. (2002) Chk2-
deficient mice exhibit radioresistance and 
defective p53-mediated transcription. The EMBO 
journal 21: 5195-5205 
239 Hirao A., Cheung A., Duncan G. et al. (2002) Chk2 
is a tumor suppressor that regulates apoptosis in 
both an ataxia telangiectasia mutated (ATM)-
dependent and an ATM-independent manner. 
Molecular and cellular biology 22: 6521-6532 
240 Casper A.M., Nghiem P., Arlt M.F. & Glover T.W. 
(2002) ATR regulates fragile site stability. Cell 111: 
779-789 
241 Toledo L., Altmeyer M., Rask M.-B. et al. (2013) 
ATR prohibits replication catastrophe by 
preventing global exhaustion of RPA. Cell 155: 
1088-1103 
242 Branzei D. & Foiani M. (2008) Regulation of DNA 
repair throughout the cell cycle. Nature reviews. 
Molecular cell biology 9: 297-308 
243 Nghiem P., Park P., Kim Y., Vaziri C. & Schreiber S. 
(2001) ATR inhibition selectively sensitizes G1 
checkpoint-deficient cells to lethal premature 
chromatin condensation. Proceedings of the 
National Academy of Sciences of the United States 
of America 98: 9092-9097 
244 Deckbar D., Stiff T., Koch B. et al. (2010) The 
limitations of the G1-S checkpoint. Cancer 
research 70: 4412-4421 
245 Saito A., Yamashita T., Mariko Y. et al. (1999) A 
synthetic inhibitor of histone deacetylase, MS-27-
275, with marked in vivo antitumor activity 
against human tumors. Proceedings of the 
National Academy of Sciences of the United States 
of America 96: 4592-4597 
246 Senese S., Zaragoza K., Minardi S. et al. (2007) 
Role for histone deacetylase 1 in human tumor 
cell proliferation. Molecular and cellular biology 
27: 4784-4795 
247 Brandl A., Wagner T., Uhlig K.M. et al. (2012) 
Dynamically regulated sumoylation of HDAC2 
controls p53 deacetylation and restricts apoptosis 
following genotoxic stress. Journal of molecular 
cell biology 4: 284-293 
248 Lu X., Nguyen T.A. & Donehower L.A. (2005) 
Reversal of the ATM/ATR-mediated DNA damage 
response by the oncogenic phosphatase PPM1D. 
Cell cycle 4: 1060-1064 
LIST OF REFERENCES  HDACs regulate phosphatase activity  
page | 84 
  
249 Shreeram S., Demidov O.N., Hee W.K. et al. (2006) 
Wip1 phosphatase modulates ATM-dependent 
signaling pathways. Mol Cell 23: 757-764 
250 Peng A., Lewellyn A.L., Schiemann W.P. & Maller 
J.L. (2010) Repo-man controls a protein 
phosphatase 1-dependent threshold for DNA 
damage checkpoint activation. Current biology : 
CB 20: 387-396 
251 Ali A., Zhang J., Bao S. et al. (2004) Requirement 
of protein phosphatase 5 in DNA-damage-induced 
ATM activation. Genes & development 18: 249-
254 
252 Goodarzi A.A., Jonnalagadda J.C., Douglas P. et al. 
(2004) Autophosphorylation of ataxia-
telangiectasia mutated is regulated by protein 
phosphatase 2A. The EMBO journal 23: 4451-4461 
253 Leung-Pineda V., Ryan C.E. & Piwnica-Worms H. 
(2006) Phosphorylation of Chk1 by ATR is 
antagonized by a Chk1-regulated protein 
phosphatase 2A circuit. Molecular and cellular 
biology 26: 7529-7538 
254 Carlessi L., Buscemi G., Fontanella E. & Delia D. 
(2010) A protein phosphatase feedback 
mechanism regulates the basal phosphorylation 
of Chk2 kinase in the absence of DNA damage. 
Biochimica et biophysica acta 1803: 1213-1223 
255 Freeman A.K., Dapic V. & Monteiro A.N. (2010) 
Negative regulation of CHK2 activity by protein 
phosphatase 2A is modulated by DNA damage. 
Cell cycle 9: 736-747 
256 Creyghton M.P., Roel G., Eichhorn P.J. et al. (2006) 
PR130 is a modulator of the Wnt-signaling 
cascade that counters repression of the 
antagonist Naked cuticle. Proceedings of the 
National Academy of Sciences of the United States 
of America 103: 5397-5402 
257 Zwaenepoel K., Goris J., Erneux C., Parker P.J. & 
Janssens V. (2010) Protein phosphatase 2A 
PR130/B''alpha1 subunit binds to the SH2 
domain-containing inositol polyphosphate 5-
phosphatase 2 and prevents epidermal growth 
factor (EGF)-induced EGF receptor degradation 
sustaining EGF-mediated signaling. FASEB journal : 
official publication of the Federation of American 
Societies for Experimental Biology 24: 538-547 
258 Takahashi M., Shibata H., Shimakawa M. et al. 
(1999) Characterization of a novel giant 
scaffolding protein, CG-NAP, that anchors 
multiple signaling enzymes to centrosome and the 
golgi apparatus. The Journal of biological 
chemistry 274: 17267-17274 
259 Janssens V., Longin S. & Goris J. (2008) PP2A 
holoenzyme assembly: in cauda venenum (the 
sting is in the tail). Trends in biochemical sciences 
33: 113-121 
260 Zwaenepoel K., Louis J.V., Goris J. & Janssens V. 
(2008) Diversity in genomic organisation, 
developmental regulation and distribution of the 
murine PR72/B" subunits of protein phosphatase 
2A. BMC genomics 9: 393 
261 Elong Edimo W., Derua R., Janssens V. et al. 
(2011) Evidence of SHIP2 Ser132 phosphorylation, 
its nuclear localization and stability. The 
Biochemical journal 439: 391-401 
262 Kim M.-A., Kim H.-J., Brown A. et al. (2007) 
Identification of novel substrates for human 
checkpoint kinase Chk1 and Chk2 through 
genome-wide screening using a consensus Chk 
phosphorylation motif. Experimental & molecular 
medicine 39: 205-212 
263 Yan Y., Cao P., Greer P. et al. (2010) Protein 
phosphatase 2A has an essential role in the 
activation of gamma-irradiation-induced G2/M 
checkpoint response. Oncogene 29: 4317-4329 
264 Mordes D.A. & Cortez D. (2008) Activation of ATR 
and related PIKKs. Cell cycle 7: 2809-2812 
265 Sablina A.A., Hector M., Colpaert N. & Hahn W.C. 
(2010) Identification of PP2A complexes and 
pathways involved in cell transformation. Cancer 
research 70: 10474-10484 
266 Dixon H. & Norbury C.J. (2002) Therapeutic 
exploitation of checkpoint defects in cancer cells 
lacking p53 function. Cell cycle 1: 362-368 
CURRICULUM VITAE  HDACs regulate phosphatase activity  





Name: Claudia Schäfer 
Date of birth: 13.11.1985 
Place of birth: Arnstadt 
 
EDUCATION 
05/2010 – 03/2014 PhD student 
 Institute for Biochemistry and Biophysics 
 Center for Molecular Biomedicine (CMB) 
 Friedrich-Schiller-University Jena 
 PhD thesis:  ‘Modulation of the Replication Stress Response by 
Histone Deacetylases is connected to Suppression of the PP2A 
regulatory Subunit PR130’ 
 
04/2009 – 04/2010 Diploma thesis 
 ‘Untersuchungen zur allosterischen Modulation des EGFR durch 
Assoziation von PKC in Bustkarzinomzelllinien’  
 Institute for Biochemistry and Biophysics 
 Center for Molecular Biomedicine (CMB) 
 Friedrich-Schiller-University Jena 
 
09/2004 – 03/2009 Studies of Biology 
 Friedrich-Schiller-University Jena 
 
07/1996 – 05/2004 Abitur 






_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
   Claudia Schäfer 
 
PUBLICATIONS  HDACs regulate phosphatase activity  




Schäfer C., Schreiber M., Wang Z.-Q., Heinzel T., Schneider G. & Krämer O.H. HDAC1 and 
HDAC2 Integrate Checkpoint Kinase Signaling Through Induction of the Phosphatase PR130.  
(was submitted to Genes & Development; manuscript is currently edited) 
 
Rauch A.*, Hennig D.*, Schäfer C.*, Wirth M., Marx C., Schneider G. & Krämer O.H. (2014) 
Survivin and YM155: How faithful is the liaison? Biochim Biophys Acta 1845: 202-220 
(* equal contribution) 
 
Dietrich S., Krämer O.H., Hahn E., Schäfer C., Giese T., Hess M., Tretter T., Rieger M., Hüllein 
J., Zenz T., Ho A.D., Dreger P. & Luft T. (2012) Leflunomide induces apoptosis in fludarabine-




  HDACs regulate phosphatase activity 
page | 87 
  
ACKNOWLEDGEMENTS  - Danksagung 
 
In diesem vorletzten Abschnitt meiner Dissertation möchte ich die Gelegenheit wahrnehmen, all den 
Leuten zu danken, die jeweils ihren ganz eigenen Beitrag zum Gelingen dieser Arbeit hatten.  
Zu Beginn wäre dies Prof. Oliver Krämer, der mir dieses interessante Thema zur Verfügung stellte und 
mir damit auch gewissermaßen dessen Schicksal in die Hände legte. Ich danke ihm für die vielen und 
ausdauernden Diskussionsrunden sowie für sein Engagement und Motivation bei der Betreuung 
dieser Doktorarbeit. Im gleichen Atemzug möchte ich mich auch bei Prof. Thorsten Heinzel für seine 
Unterstützung und den durch ihn erhaltenen Input bedanken. Weiterhin danke ich PD Dr. Günter 
Schneider vom Klinikum rechts der Isar der TU München und Prof. Zhao-Qi Wang vom Leibniz-Institut 
für Altersforschung (FLI) für den regen wissenschaftlichen Austausch. 
In jedem Fall ist es auch das Wesen der Arbeitsgruppe selbst, das den Alltag im Labor entscheidend 
beeinflusst. Daher möchte ich allen derzeitigen und auch früheren Mitgliedern des Instituts für 
Biochemie für die freundschaftliche, wunderbare Arbeitsatmosphäre in den letzten Jahren danken! 
Exemplarisch möchte ich dabei Georg, Sigrid, Anke, Ulli und Sabine nennen, mit denen ich viele 
unterhaltsame und durchaus auch sehr informative und lehrreiche Stunden hatte, nicht nur zur 
Mittagszeit. Ein besonderer Dank geht auch an Maria Schreiber, die mit ihrer Masterarbeit und ihrem 
Enthusiasmus zur Bearbeitung dieses Projekts beigetragen hat. Peter danke ich außerdem für 
helfende(n) Rat und Tat bei Mikroskopie-Experimenten, sowie der Arbeitsgruppe Hemmerich vom FLI 
für die ermöglichte Mitbenutzung des konfokalen Mikroskops.  
Ich möchte zudem meinen Freunden und lieben Bekannten einen großen Dank sagen für die schöne 
Zeit, die einem Auftrieb gibt.  
Und dann ist da meine Familie. Ihr habt immer an mich geglaubt und mich meinen Weg jederzeit 
selbst wählen lassen, ohne belehrende Worte. Dafür bin ich euch unendlich dankbar.  
Zum Schluss gilt ein inniger Dank meinem Freund, der mir stets auf nah und fern eine Stütze war. Du 
hast mich motiviert, auch aufgebaut, wenn es nötig war, und mir das Ziel immer vor Augen gehalten. 
  
Euch allen mein Dank! 
 
  HDACs regulate phosphatase activity 
page | 88 
  
DECLARATION OF INDEPENDENT ASSIGNMENT  - Eigenständigkeitserklärung  
 
Die vorliegende Arbeit habe ich mit den angegebenen Hilfsmitteln selbst angefertigt, keine 
Textabschnitte Dritter ohne Kennzeichnung übernommen, sowie meine Quellen und 
Hilfsmittel aufgeführt. Ein Promotionsberater wurde nicht in Anspruch genommen und 
Dritte bekamen von mir keine Gelder oder geldwerten Leistungen die im Zusammenhang mit 
der Dissertation stehen. 
Die Dissertationsschrift wurde in vorliegender oder ähnlicher Form nicht als Dissertation, 
Prüfungsarbeit oder anderweitige wissenschaftliche Prüfung bei einer Hochschule 
eingereicht. 
Die geltende Promotionsordnung der Biologisch-Pharmazeutischen Fakultät der Friedrich 
Schiller Universität ist mir bekannt. 
 
 
Jena, den 24. November 2014 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
   Claudia Schäfer 
 
